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Abstract  
ANCA-associated vasculitis (AAV) is characterised by macrophage and neutrophil 
infiltration at the site of injury. Animal models have been used to study the disease and to try 
different treatment approaches. The aim of this study was to investigate the involvement of 
the innate immune system in AAV. This was done by looking at different innate immune 
system components such as macrophages and neutrophils.  
    There were a large number of CD68+ cells in the crescent region of the kidney following 
treatment with anti-MPO antibodies and LPS. Serial section staining has shown that these 
cells are more likely to be classically activated macrophages. Furthermore, gene expression 
studies have confirmed the up regulation of genes associated with classically activated 
macrophages such as calprotectin. In addition, there was an up regulation of genes 
associated with macrophages accumulation such as CCR2 and CX3CR1. These 
macrophages could be involved in secreting TGF-β, which was up regulated, which can lead 
to an increase in extracellular matrix such as collagen. Blocking macrophage accumulation 
was evaluated using anti-mouse CCR2 which was effective in depleting GR1+ blood 
monocytes. However, there was no significant difference on the disease outcome following 
treatment with anti-mouse CCR2. This suggests a lesser role of macrophages in the 
development of vasculitis or that disease was mild and so an effect could not be identified. 
In addition, I investigated the variability in ANCA-induced neutrophil degranulation from 
healthy donors. I purified human neutrophils from healthy donors and treated them with 
different ANCA IgG samples. I found that these neutrophils responded differently to the 
same ANCA IgG as measured by neutrophil degranulation using ELISA. I tried to study the 
resulting metabolites using mass spectrometry but there was a considerable degree of 
technical variation which prevented making final conclusions. However, this was a novel 
approach and provided me with good ideas on how to take it further. I also looked at the 
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effect of pre-treating neutrophils with simvastatin. I found a significant reduction in ANCA-
induced neutrophil degranulation following treatment with a statin.  
In conclusion, preventing macrophage infiltration did not have an effect on the 
development of the disease in mice. This could be because the disease was mild or because 
resident macrophages are more important than infiltrating ones. In addition, the microarray 
experiment has provided interesting results that could be used to find common pathways in 
mouse, rat and human. It also provided more information on genes that are upregulated in 
the kidney following AAV induction. This could be used to arrange the genes into pathways 
and biological processes to study the involvement of macrophages and other components of 
the innate immune system. Finally, simvastatin significantly reduced ANCA-induced 
neutrophil degranulation.  
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1. Introduction 
1.1. Autoimmunity 
The immune system plays an essential role in providing protection from invading micro-
organisms. The ability of the immune system to recognise and kill these micro-organisms 
while preventing harm to body elements (self-antigens) is called self-tolerance. Deficiency in 
this mechanism can lead to autoimmunity. Autoimmune diseases are characterised by 
chronic inflammation that can effect specific or multiple organs such as systemic lupus 
erythematosus (SLE) and systemic vasculitis (Thomas 2010). Furthermore, these systemic 
autoimmune diseases have vascular involvement with or without immune complex 
deposition and autoantibodies directed against self autoantigens. The development of such 
diseases could be the result of different factors, including genetic factors. Different animal 
studies have described a genetic defect in negative selection which results in the presence 
of autoreactive T cells (Liston, Lesage et al. 2004; Jiang, Anderson et al. 2005). 
Autoantibodies are considered to have significant value in the clinical field because they are 
used as a biomarkers for classification, diagnosis and disease progression (von Muhlen and 
Tan 1995). Systemic vasculitis is one of these autoimmune disorders and I will discuss small 
vessel vasculitis in this report.    
1.2. The glomerulus 
The kidneys are important organs in the human body and have several functions which 
include regulation of electrolytes, regulation of blood pressure, and maintenance of acid-
base balance. The kidneys receive about 20% of the cardiac output via the renal artery 
which enters the kidney at the renal hilus (figure 1.1). The blood goes through the glomerular 
capillaries where it gets filtered. Furthermore, the glomerulus consists of the capillary 
endothelium, the glomerular basement membrane, and podocytes. The endothelial cells of 
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the capillary prevent blood cells and platelets from coming into contact with the basement 
membrane which allows filtration of molecules depending on their molecular size, charge, 
and shape. The glomerular filtration rate is around 125 ml/min, and molecules with a 
molecular weight less than 7,000 pass freely through the filters. Furthermore, some of the 
solutes that get filtered in the kidneys are reabsorbed in the proximal tubules, such as 
protein (Lote 2000). In anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, the 
glomerulus is affected which results in its loss of function as a filtering unit.  
 
Figure 1.1: Kidney anatomy. This figure shows a cross section of the kidney (A). The functional unit 
of the kidney which is the nephron (B). Blood is filtered in the nephrons which are very important in 
regulating blood pressure, blood volume, and acid-base balance. (A) obtained from 
http://www.childrenshospital.org/az/Site1318/mainpageS1318P0.html and (B) obtained from 
http://biology-forums.com/index.php?topic=2926.0.  
 
1.2.1. The glomerular endothelium 
The endothelial cells of the glomerulus are involved in permeability and regulate the 
transport of fluid and solutes from the blood. In addition, they form the initial barrier to 
filtration. The glomerular capillaries are involved in the filtering of fluid and solutes, but not 
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oxygen and nutrient exchange like in other vascular beds. In addition, these glomerular 
endothelial cells contain small pores called fenestrae that are 60 to 80 nm in diameter which 
are involved in the filtration process. The glomerular capillary consists of a fenestrated 
endothelium, along with podocytes and the basal lamina or glomerular basement membrane; 
these structures form a filtration slit that filters the blood (Aird 2007) (figure 1.2 B). We are 
interested in the glomerulus because it is the most affected part of the kidney in ANCA-
associated crescentic glomerulonephritis.  
 
Figure 1.2: Structure of the glomerulus. (A) the filtering unit of the kidney is the glomerulus. The 
blood enters the glomerular capillaries through the afferent arteriole where it gets filtered and then 
leaves the glomerulus via the efferent arteriole. (B) Cross section of the glomerular capillary showing 
the filtration unit which consists of fenestrated endothelial cells, the basal lamina, and podocytes 
which form the filtration slit. (A) Adapted from http://www.siumed.edu/~dking2/crr/rnguide.htm. (B) 
Adapted from Aird et al., Circ Res. 2007;100;174-90. 
1.3. Primary vasculitis 
1.3.1 Types of primary systemic vasculitis 
Inflammation of blood vessel walls is a feature of a disease known as vasculitis, which is 
classified according to the size of blood vessels affected (figure 1.3). Giant cell arteritis and 
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Takayasu’s arteritis are both examples of large vessel vasculitis. Medium vessel vasculitis 
includes polyarteritis nodosa and Kawasaki disease. Finally, small vessel vasculitis is usually 
tightly associated with the presence of antineutrophil cytoplasm antibodies (ANCA). This 
type of systemic vasculitis is the focus of this research project.  
 
Figure 1.3: Types of systemic vasculitis. The different types of systemic vasculitis are divided 
according to the size of blood vessels affected. Adapted from Jennette et al. Arthritis Rheum 
1994;37:187-92. 
Wegener’s granulomatosis (WG) is the most common type of small vessel vasculitis in 
the UK; the upper respiratory tract and lungs are usually affected in these patients. A high 
percentage of these patients also suffer from kidney disease, which can lead to renal failure. 
Necrotising and crescentic glomerulonephritis can often be seen in Wegener’s 
granulomatosis. In addition, some patients with this disease develop alveolar necrotising 
capillaritis in the lung. Other parts of the body, such as the gut, skin, peripheral nervous 
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system, and eye can also be affected in this disease. Anti-neutrophil cytoplasm antibodies 
against proteinase 3 (PR3) are found in about 95% of patients with Wegener’s 
granulomatosis, although it can be hard to detect ANCA if the disease is limited to the upper 
respiratory tract. 
Microscopic polyangiitis and Churg-Strauss syndrome are also examples of small vessel 
vasculitis (Savage, Harper et al. 2000). Microscopic polyangiitis is similar to Wegener’s 
granulomatosis, but upper respiratory tract disease is rare in microscopic polyangiitis. 
Glomerulonephritis is common in people suffering from this type of small vessel vasculitis, 
which is indistinguishable from that observed in Wegener’s granulomatosis. ANCA are 
present in this type of small vessel vasculitis and are usually directed against 
myeloperoxidase (MPO). Churg-Strauss syndrome is usually associated with asthma and 
renal failure is relatively uncommon. ANCA directed against MPO are found in 50% of these 
patients. Approximately 20% of the patients with this disease have ANCA against PR3.  
1.4. Anti-neutrophil cytoplasm antibody-associated vasculitis: 
understanding the causes of the disease and current therapy 
Anti-neutrophil cytoplasmic antibodies (ANCA) are autoantibodies directed, in small 
vessel vasculitis, against the constituents of neutrophils and the lysosomes of monocytes 
(Chen and Kallenberg 2010). Anti-neutrophil cytoplasm antibodies were first described in 
1982 (Davies, Moran et al. 1982) and they have proven to be invaluable for the diagnosis 
and monitoring of disease activity (van der Woude, Rasmussen et al. 1985). These 
autoantibodies are classified as cANCA or pANCA depending on the pattern of staining by 
indirect immunofluorescence on ethanol-fixed neutrophils (figure 1.4). For example, cANCA 
show a cytoplasmic staining pattern and most patients with cANCA have ANCA directed 
against PR3. On the other hand, pANCA show a perinuclear staining pattern and patients 
with pANCA have antibodies directed against MPO in small vessel vasculitis (Miller, Basu et 
al. 2008). A lot of work has gone into investigating what triggers the immune system to 
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produce these autoantibodies. There are several hypotheses about what causes the 
production of these antibodies, including a possible role of environmental factors, bacterial 
infection, and genetic factors in initiating the disease. 
 
Figure 1.4: Binding of ANCA to neutrophils. Immunostaining of human neutrophils with plasma 
from vasculitis patients and IgG from a disease control. Neutrophils were isolated from human blood 
and then cytospins were made. Then, PR3-ANCA, MPO-ANCA, or normal IgG were added to each 
cytospin. This was followed by adding anti human IgG (red) and DAPI to stain the nucleus (blue). 
Perinuclear staining (A) and cytoplasmic staining (B) represent the interaction of MPO-ANCA and 
PR3-ANCA with human neutrophils. Adapted from (Al-Ani 2010). 
1.4.1. Potential factors that could cause ANCA-associated vasculitis 
1.4.1.1. Environmental factors: silica   
Silica exposure has been associated with some autoimmune diseases such as systemic 
lupus erythematosus, rheumatoid arthritis, scleroderma, and ANCA-associated vasculitis 
(Hogan, Satterly et al. 2001). In addition, silica has been associated with rapidly progressive 
glomerulonephritis, and silica exposure in ANCA-associated vasculitis was first reported in 
the 1990s. It has been found that MPO is the predominant targeted antigen by ANCA in 
patients with ANCA-associated vasculitis following the exposure to silica. Furthermore, most 
of these patients were clinically diagnosed as having microscopic polyangiitis. In addition, it 
has been reported in several case-control studies that 22 to 46% of patients with ANCA-
associated vasculitis were previously exposed to silica (de Lind van Wijngaarden, van Rijn et 
al. 2008). It is not completely understood how silica exposure may be involved in the 
development of ANCA-associated vasculitis, but several in vitro studies have suggested that 
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silica exposure could trigger the immune response and cause inflammatory reactions. For 
example, Leigh et al. have shown that intratracheal instillation of silica results in accelerated 
apoptosis of neutrophils in a dose-dependent manner (Leigh, Wang et al. 1997).  
1.4.1.2. Bacterial infections  
Bacterial infection is thought to play a role in stimulating the production of ANCA and the 
development of ANCA-associated vasculitis (figure 1.5). For example, the initiation and 
relapse of WG has been associated with bacterial infection, in particular with Staphylococcus 
aureus (S. aureus) (Holle and Gross 2009). In addition, there was an increase in the relapse 
rate in association with chronic nasal carriage of S. aureus in patients with WG (Stegeman, 
Tervaert et al. 1994). There are several hypotheses related to the mechanism underlying the 
increased risk of relapse by S. aureus in patients with WG. One of these theories is that T 
and/or B cells may be activated by superantigens from S. aureus (Popa, Stegeman et al. 
2002). In addition, B cells may be activated polyclonally by the bacterium cell-wall 
components of S. aureus which could lead to the persistence of ANCA. Furthermore, direct 
stimulation of neutrophils by S. aureus is another possibility which could result in increased 
expression of PR3 on the surface of neutrophils (Kallenberg and Tadema 2008). Recently, a 
study described the presence of complementary proteins to PR3 which could, possibly, be 
related to S. aureus. In this study, Pendergraft et al. were able to identify a complementary 
protein to PR3, which is translated from the antisense DNA strand encoding for PR3. They 
suggested that the complementary peptides initiate the production of antibodies which 
results in producing antibodies called anti-idiotypic antibodies. As a result, these antibodies 
will react with the original antigen, which is PR3 in this case. In addition, the authors showed 
that immunising mice with complementary PR3 resulted in the production of antibodies to 
cPR3 and to PR3 itself. They also showed strong homology between peptides from cPR3 
and peptides from S. aureus which could mean that an infection resulted in molecular 
mimicry and initiation of the disease (Pendergraft, Preston et al. 2004).  
8 
 
Molecular mimicry has been investigated in other types of ANCA-associated diseases 
such as pauci-immune focal necrotising glomerulonephritis (FNGN) which typically occurs in 
the context of a systemic small vessel vasculitis. Kain et al. found that patients with FNGN 
have ANCA directed against lysosomal membrane protein-2 (LAMP-2). In addition, they also 
found that 93% of 84 individuals had autoantibodies to human LAMP-2. Furthermore, rats 
that were injected with antibodies to human LAMP-2 developed FNGN. In addition, they 
found that these autoantibodies recognised two major human LAMP-2 epitopes, P41-49 and 
P331-341. They showed that one of these epitopes had 100% homology to bacterial FimH. In 
addition, immunising rats with a recombinant FimH fusion protein resulted in the induction 
FNGN and the production of autoantibodies to rat and human LAMP-2. Also, they showed 
that most patients with FNGN in their study had a FimH-expressing bacterial infection. These 
studies have shown the possible relationship between bacterial infection and the 
development of autoimmune diseases (Kain, Exner et al. 2008).   
1.4.1.3. Genetic factors 
Genetic factors have been suggested to have an effect on the susceptibility of 
autoimmune diseases and ANCA-associated vasculitis (figure 1.5). Different studies have 
identified some genes that could be associated with an increased incidence of AAV. For 
example, some studies have suggested associations between MHC loci and WG; these 
include HLA-B50, HLA-DR9, HLA-DQw7, HLA-DR3, and HLA-DR1 (Papiha, Murty et al. 
1992; Spencer, Burns et al. 1992; Cotch, Fauci et al. 1995). Furthermore, the activity of PR3 
is inhibited by α1-antitrypsin, and it is thought to limit the damage done to local tissues. 
Polymorphisms in the gene encoding for α1-antitrypsin, including the Z and S alleles, reduce 
the function of this protein. Griffith et al. has shown an association between the presence of 
the Z and S alleles with cANCA and pANCA-positive vasculitis, respectively (Griffith, 
Lovegrove et al. 1996). Recently, Aitman et al. screened for susceptibility loci in a 
nephrotoxic nephritis (NTN) rat model and they were able to identify two major trait loci on 
chromosomes 13 and 16 (known as crescentic glomerulonephritis 1 and 2, Crgn 1, and Crgn 
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2). Furthermore, these two loci were associated with crescent formation and proteinuria. One 
of the genes found in the Crgn1 region is the gene encoding the Fc receptor (Fcgr3), which 
is also known as FcyRIII. In humans, a copy number polymorphism in Fcgr3 is associated 
with glomerulonephritis (Aitman, Dong et al. 2006). This finding has been linked recently to 
ANCA-associated vasculitis. Little et al. have shown resistance in non-WKY rats in 
developing vasculitis following immunisation with human MPO (Little, Smyth et al. 2009). 
They showed that these different rat strains developed a high titre of anti-MPO antibodies 
but they did not develop the disease. This further demonstrates the role of genetic variation 
in susceptibility to ANCA-associated vasculitis.     
 
Figure 1.5: Potential aetiologic factors in AAV. Genetic factors, environmental factors, and 
bacterial infection are thought to be involved in triggering ANCA-associated vasculitis.  
1.4.2. Epidemiology of vasculitis 
The incidence of vasculitis varies in different parts of the world and according to the age 
group studied. For example, Kawasaki disease is most common in Asia in children under 
five with an incidence rate of 90/100,000. On the other hand, giant cell arteritis is more 
common in elderly Caucasians with an incidence rate of 53/100,000. Wegener’s 
granulomatosis is more common than Churg-Strauss syndrome and microscopic polyangiitis 
in Europe, except for Spain which has a higher incidence of microscopic polyangiitis. These 
data were obtained from studies done in Norway, UK, Germany, and Spain (Koldingsnes 
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and Nossent 2000; Watts, Lane et al. 2001). The annual incidence of ANCA-associated 
vasculitis (AAV) in Europe is 10-20/million/year (Watts and Scott 2003). Furthermore, AAV 
can affect individuals from different age groups, but older people are more susceptible. 
1.4.3. Current therapeutics of ANCA-associated vasculitis (AAV) 
Considerable morbidity and mortality can be caused by AAV, with 20% of patients at five 
years developing end-stage renal failure (Booth, Almond et al. 2003). The chance for 
survival was very slim before introduction of cyclophosphamide (CYP) and steroid treatment 
in the early 1970s. As a result, remission can be achieved now in over 90% of patients with 
generalised WG by six months, and the survival rates at five years are around 75% 
(Matteson, Gold et al. 1996; Jayne, Rasmussen et al. 2003). However, the relapse rates are 
still high and up to 50% over five years (Westman, Bygren et al. 1998). Treatment of AAV 
can be divided into the initial immunosuppression stage to induce remission and follow-up 
treatment to prevent relapse. For example, CYP and steroids are used to induce remission 
in severe disease. However, these treatments are associated with increased risk of 
treatment-related morbidity and mortality. Other treatments include glucocorticoids, plasma 
exchange, methotrexate (MTX), mycophenolate mofetil (MMF), and rituximab (RTX) used as 
induction therapy. In addition, long-term immunosuppression treatment is usually required 
for the maintenance of remission in ANCA-associated vasculitis. These treatments include a 
low dose of glucocorticoids together with a second agent such as azathioprine, 
methotrexate, or mycophenolate mofetil. Finally, biological therapies such as TNF-α 
blockade using infliximab and B-cell depletion using RTX have been successful in some 
cases (Hamour, Salama et al. 2010).    
In this chapter, I will give an introduction to ANCA-associated vasculitis and the 
involvement of the innate immune system in the development of this disease. In addition, I 
will mention animal models of ANCA-associated vasculitis. 
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1.5. Antineutrophil cytoplasmic autoantibodies (ANCA) 
1.5.1. ANCA as a pathogenic factor in vasculitis: clinical evidence 
Many studies have suggested that ANCA have an important role in the development of 
vasculitis and that they are not just a serologic marker of disease or an epiphenomenon. It 
has been suggested that ANCA are the primary pathogenic factor in the development of 
these diseases for several reasons (Jennette, Xiao et al. 2006). There is some clinical 
evidence to support the pathogenic role of ANCA in pauci-immune small-vessel vasculitis, 
including the presence of a high percentage of ANCA in these patients and a correlation 
between disease activity and ANCA titre. In addition, clinical remission is usually 
accompanied by a decrease in ANCA levels (Falk, Nachman et al. 2000; Savage 2001). 
Furthermore, Boomsma et al. showed that an increase in the ANCA titre in WG patients 
predicts relapse with 79% sensitivity and 68% specificity (Boomsma, Stegeman et al. 2000). 
On the other hand, this evidence does not prove that ANCA have a pathogenic role in the 
development of this disease. For example, Finkielman et al. could not confirm the 
association between disease activity and ANCA titre. They did not find an association 
between the rate of relapse and the increase in ANCA levels and the decrease in ANCA 
after treatment did not associate with a shorter time of remission (Finkielman, Merkel et al. 
2007). The case for the pathogenic potential of ANCA was strengthened when a newborn 
child developed glomerulonephritis and pulmonary haemorrhage after delivery following 
placental transfer of ANCA from the mother, who had microscopic polyangiitis (Bansal and 
Tobin 2004; Schlieben, Korbet et al. 2005). This is the only definite proof of the potential 
pathogenicity of anti-MPO antibodies (or a co-expressed antibody) in humans.  
1.5.2. In vitro evidence 
The pathogenicity of ANCA in vitro was based on the discovery by Falk et al. that showed 
the ability of ANCA to stimulate primed neutrophils to release reactive oxygen species and 
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other enzymes (Falk, Terrell et al. 1990). ANCA antigens are found in the cytoplasm of 
unstimulated neutrophils, although some antigens are found on the surface of neutrophils. 
The amount of the antigens that are expressed on the surface of neutrophils is determined 
by genetic factors and high expression is a risk factor for developing ANCA-associated 
vasculitis (Schreiber, Busjahn et al. 2003; Schreiber, Luft et al. 2004). In addition, the binding 
of ANCA to neutrophils could result in the activation of the complement system (figure 1.6). 
Schreiber et al. has shown that the supernatant from neutrophils that were activated by 
ANCA activated the alternative pathway of the complement immune system, resulting in the 
production of C5a. In addition, ANCA were able to induce neutrophil activation after priming 
with C5a and this process was abrogated when the C5a receptor on neutrophils was blocked 
(Schreiber, Xiao et al. 2009). Furthermore, it has been shown that ANCA can stimulate 
neutrophil-induced cytotoxicity toward endothelial cells (Ewert, Jennette et al. 1992). In 
addition, Radford et al. have shown that ANCA induce firm integrin-mediated adhesion of 
rolling neutrophils in a flow assay (Radford, Savage et al. 2000). This was confirmed by an in 
vivo experiment where it was shown that MPO-ANCAs reduced the rolling of leucocytes and 
induced adhesion and migration across the endothelium. This was inhibited by blocking Fcγ 
receptors and β2 integrins (Nolan, Kalia et al. 2008). Little et al. have shown ANCA-
enhanced leucocyte-vessel wall interactions in vivo (Little, Smyth et al. 2005). In addition, 
ANCA-activated neutrophils have been shown to induce the generation of neutrophil 
extracellular traps (NETs), which contain the autoantigens MPO and PR3. These NETs can 
cause damage to endothelial cells by adhering to them and can result in the activation of 
plasmacytoid dendritic cells and autoreactive B cells, thus contributing to the production of 
ANCA at the site of inflammation (Kessenbrock, Krumbholz et al. 2009). Furthermore, it has 
been suggested that MPO-ANCA have a pathogenic role, not only via the activation of 
neutrophils and monocytes, but also by activating MPO itself. The activation of MPO by 
ANCA in vitro results in the production of hypochlorous acid (HOCL); the by-products of this 
activation resulted in the lysis of endothelial cells (Guilpain, Servettaz et al. 2007). In 
conclusion, there are several lines of in vitro evidence to suggest that ANCA are pathogenic.      
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Figure 1.6: Proposed complement involvement in AAV pathogenesis. Activated neutrophils 
express ANCA antigens on their surfaces. This results in the binding of ANCA to neutrophils that 
adhere to the endothelium, causing neutrophils to release reactive oxygen species and resulting in 
damage to the endothelium. This could also result in the activation of the alternative complement 
pathway by factors released by neutrophils. (Chen and Kallenberg 2010) 
1.6. ANCA and neutrophils  
 
1.6.1. The role of neutrophils in ANCA-associated diseases 
Neutrophils play a major role in the pathogenesis of different ANCA-associated diseases 
such as necrotising and crescentic glomerulonephritis (NCGN) (Xiao, Heeringa et al. 2005). 
There is a correlation between the number of activated neutrophils and the severity of renal 
injury (Brouwer, Huitema et al. 1994). In addition, activated neutrophils have been found in 
affected glomeruli in NCGN patients (Brouwer, Huitema et al. 1994). These neutrophils may 
cause damage to endothelial cells and they could release inflammatory cytokines which 
would attract more effector cells (Rarok, Limburg et al. 2003). Mice can be protected from 
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MPO antibody-induced NCGN if neutrophils are depleted (Xiao, Heeringa et al. 2005). These 
results suggest that neutrophils are important in the development of MPO-induced NCGN 
and that neutrophils are key early effector cells. The activation of neutrophils by ANCA IgG 
has been reported in many in vitro studies. The Fc part of these autoantibodies bind to the 
surface of neutrophils, while they bind to antigens through the antigen-binding site (Kettritz, 
Jennette et al. 1997; Williams, Ben-Smith et al. 2003). ANCA have the ability to stimulate 
and induce neutrophils to travel through endothelial monolayers and induce them to injure 
these endothelial cells (Savage, Pottinger et al. 1992; Radford, Savage et al. 2000; Radford, 
Luu et al. 2001).  
1.6.2 Neutrophil priming and ANCA binding 
Studies have shown that ANCA are directed against two major antigens that are found in 
the granules of neutrophils and lysosomes of monocytes: MPO, which is an enzyme involved 
in the generation of reactive oxygen species, and PR3, which is a serine protease (Heeringa 
and Tervaert 2004). ANCA bind to MPO and PR3 on the surface of neutrophils (Mulder, 
Heeringa et al. 1994). However, these antigens are found inside the cells. Neutrophils have 
to be stimulated in order for them to express these antigens on the cell surface and it has 
been shown that treating these cells with tumour necrosis factor alpha (TNF-α) in vitro 
triggers these antigens to travel to the surface of the cell. Neutrophils are usually primed in 
vivo to prepare them for the appropriate response to different stimulus. In addition, this state 
of preactivation can be achieved or induced in response to different proinflammatory 
cytokines such as TNF-α (Csernok, Ernst et al. 1994; Reumaux, Vossebeld et al. 1995), 
transforming growth factor-β1 (Csernok, Szymkowiak et al. 1996), and granulocyte 
macrophage-colony stimulating factor (Hellmich, Csernok et al. 2000) that are released 
during inflammation or tissue damage. For example, the level of TNF-α in systemic vasculitis 
has been reported to be increased (Deguchi, Shibata et al. 1990; Noronha, Kruger et al. 
1993). Furthermore, neutrophil activation by TNF-α results in the degranulation of specific 
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granules and secretory vesicles (Luedke and Humes 1989) and the upregulation of cell-
surface expression of many molecules such as MPO and PR3.   
 The binding of ANCA to antigens on the cell surface results in the activation of these 
neutrophils (Figure 1.7). The activation of these cells causes an increase in adhesion and 
migration of these cells through endothelium. In addition, MPO and PR3 are released as a 
result of neutrophil activation and bind to the surrounding tissues, potentially causing more 
damage. Furthermore, neutrophils secrete pro-inflammatory cytokines which attract more 
effector cells and cause further damage to endothelial cells. ANCA bind to neutrophil Fcγ 
receptors via the Fc portion; these antibodies also use F(ab’)2 portions to bind to the antigen 
on the surface of these neutrophils (Day, Hewins et al. 2003). Furthermore, neutrophils 
predominantly express FcγRIIa (CD32) and FcγRIIIb (CD16) and these receptors differ in 
their ability to bind IgG and in their affinity to different subclasses of IgG (van de Winkel and 
Capel 1993; Dijstelbloem, van de Winkel et al. 2001). For example, FcγRIIa interacts with 
monomeric IgG2 and has high affinity to the IgG3 subclass (van de Winkel and Capel 1993), 
which is over-expressed in patients with ANCA-associated vasculitis during active disease 
(Jayne, Weetman et al. 1991). In addition, this receptor is also found to be involved in 
triggering the neutrophil oxidative burst. As a result, blocking FcγRIIa with monoclonal 
antibodies results in the abrogation of oxygen radical release in response to ANCA 
stimulation (Porges, Redecha et al. 1994; Reumaux, Vossebeld et al. 1995). However, 
blocking of FcγRIIa resulted only in partial blockade of the oxidative burst after stimulating 
neutrophils with ANCA in vitro, which suggests the involvement of other mechanisms as well 
(Mulder, Heeringa et al. 1994; Kettritz, Jennette et al. 1997). Another receptor expressed on 
neutrophils is FcγRIIIb, which has ten-fold higher density of expression than FcγRIIa (Hulett 
and Hogarth 1994). Its role in neutrophil activation is still not clear, but it is been suggested 
that it is involved in triggering the neutrophil response in the initial stage of activation 
(Kocher, Edberg et al. 1998). Furthermore, molecules other than FcγRs have been 
suggested to be involved in neutrophil activation by ANCA. For example, it has been shown 
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that F(ab’)2 fragments alone are capable of stimulating primed neutrophils to produce oxygen 
radicals (Kettritz, Jennette et al. 1997). However, signals from both Fab2 and FcγR could be 
required to produce full ANCA response. 
 
Figure 1.7: The pathogenesis of endothelial injury in ANCA-associated vasculitis. Adapted from: 
Mechanism of Disease: Pathogenesis and Treatment of ANCA-associated Vasculitides. Cees, G. M. 
Kalleenberg, P. Heeringa and C. A. Stegeman. Nature Clinical Practice Rheumatology (2006) 2, 661-
670. 
1.6.3. Signal transduction pathways involved in neutrophil activation by ANCA 
We know, from previous studies, that the binding of ANCA to antigens on the surface of 
neutrophils results in neutrophil degranulation. Although the pathways involved in this 
process have not been fully elucidated, there are different ways that ANCA could activate 
neutrophils. As mentioned earlier, the binding of both ANCA F(ab’)2 and Fc portions are 
required to induce effective neutrophil degranulation. It has been suggested that β2 integrin 
(CD11b/CD18) could help to propagate the signal by interacting with the Fcγ receptor. In 
addition, the signal transduction pathway initiated by F(ab’)2 binding to the antigens would 
be different from that initiated by the Fc portion binding to the Fc receptor (Williams, Kamesh 
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et al. 2005). For example, the F(ab’) portion of the antibody can activate G proteins and the 
RAS p21 protein activator. On the other hand, tyrosine kinases such as sarcoma virus 
kinases, Syk, phosphatidylinositol-3 kinase, protein kinase B, and protein kinase C are 
thought to be activated when the Fc portion of the antibody bind to its Fc receptor (Williams, 
Ben-Smith et al. 2003; Williams, Kamesh et al. 2005). The activation of tyrosine kinase 
pathways is thought to cause a respiratory burst via the activation of NADPH oxidase. Both 
of these pathways are thought to be important because G protein and tyrosine kinase 
pathways converge on the GTPase RAS p21 protein activator (Williams, Ben-Smith et al. 
2003). 
 
Figure 1.8: Proposed signalling pathways following neutrophil activation by ANCA F(ab)2 and 
whole IgG. The cross-linking of MPO or PR3 on the surface of neutrophils with Fc receptor results in 
intracellular signalling which causes a functional response. Morgan M. D. (2006)  
The p38 mitogen-activated protein kinase (p38 MAPK) pathway is an inflammatory 
pathway suggested to be involved in ANCA-mediated neutrophil activation (Kettritz, 
Schreiber et al. 2001). Kettriz et al. have shown a reduction in ANCA-mediated neutrophil 
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activation in vitro as a result of p38 MAPK activation inhibition. In addition, patients with 
ANCA-associated glomerulonephritis are found to have activated p38 MAPK in the 
glomerular lesions. On the other hand, p38 MAPK inhibition in vivo resulted in only a 
moderate reduction in crescentic glomeruli (van der Veen, Chen et al. 2011). This suggests 
the involvement of other pathways that contribute to disease activity.   
1.6.4. Neutrophil degranulation in response to ANCA IgG 
Part of my project was to study the variability in ANCA-induced neutrophil degranulation. 
For that reason, I think it is important for me to be knowledgeable on how ANCA induce 
neutrophil degranulation and the effect of this process on the induction of vasculitis. 
Neutrophils play an important role in host defence. Different types of granules are found 
inside neutrophils; they contain proteases, antimicrobial proteins, and components of the 
respiratory burst (Faurschou and Borregaard 2003). These granules also contain 
membrane-bound receptors for bacterial products and endothelial adhesion molecules. 
Neutrophil granules are classified as peroxidase-positive (azurophil) granules and 
peroxidase-negative granules that can be divided into specific (secondary) and gelatinase 
(tertiary) granules (Faurschou and Borregaard 2003). In addition, neutrophils contain 
secretory vesicles that contain membrane-associated receptors that are needed in the first 
stages of the neutrophil-mediated response; these vesicles have the highest ability for 
extracellular release. Mobilisation of granules and secretory vesicles can be achieved in vitro 
by increasing the level of calcium in the intracellular region (Sengelov, Kjeldsen et al. 1993). 
In addition, ligation of CD11b/CD18, L-selectin, and the fMLP receptor have been shown to 
increase cytosolic calcium concentration (Ng-Sikorski, Andersson et al. 1991; Sengelov, 
Kjeldsen et al. 1993; Laudanna, Constantin et al. 1994).   
Different studies have demonstrated the ability of ANCA to induce neutrophil 
degranulation in vitro (Falk, Terrell et al. 1990). In addition, it has been shown that ANCA 
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IgG induce neutrophil degranulation in a dose-dependent manner. Furthermore, neutrophil 
degranulation was enhanced when neutrophils were primed with TNF-α (Falk, Terrell et al. 
1990). The consequences of this activation by ANCA are that neutrophils degranulate and 
release PR3, MPO, and elastase which could result in the lysis of endothelial cells (Ewert, 
Jennette et al. 1992; Savage, Pottinger et al. 1992). It is believed that MPO, which is highly 
cationic, is released from neutrophils after stimulation by ANCA, binds to the endothelium via 
electrostatic interactions, creates a binding site for ANCA and results in cellular cytotoxicity 
(Savage, Gaskin et al. 1993). Furthermore, endothelial cell detachment and cytolysis is 
caused by PR3 and elastase release by ANCA-stimulated neutrophils (Savage, Gaskin et al. 
1993; Ballieux, Hiemstra et al. 1994). In addition, apoptosis of endothelial cells can also by 
induced by PR3 and elastase (Yang, Kettritz et al. 1996; Taekema-Roelvink, van Kooten et 
al. 1998). Also, the oxidative burst results in the release of H2O2 and halide ions that MPO 
reacts with to produce highly active reactive oxygen species (Johnson, Couser et al. 1987), 
which are involved in endothelial cell detachment. Furthermore, Eiserich et al. have 
demonstrated the involvement of MPO in the formation of nitric oxide-derived inflammatory 
oxidants (Eiserich, Hristova et al. 1998). These results show the injury that can be caused by 
the enzymes released by activated neutrophils. In addition, it has been shown that PR3-
ANCA from patients with WG can significantly inhibit the proteolytic activity of PR3 and 
interfere with its binding to α1-antitrypsin, which is a physiological PR3 inhibitor (van de Wiel, 
Dolman et al. 1992). This extensive activation of neutrophils will eventually lead to apoptosis 
and these cells should be cleared by macrophages. One of the important molecules involved 
in the recognition of apoptotic cells by macrophages is phosphatidylserine. It has been 
shown that activation of neutrophils by ANCA after priming with TNF-α accelerates apoptosis 
and results in delayed externalisation of phosphatidylserine (PS) (Harper, Ren et al. 2000). 
Externalisation of PS is considered to be an early feature of apoptosis in response to 
different stimuli. As a result, the delay in PS externalisation could result in a delay in clearing 
apoptotic cells because they are not recognised by macrophages.   
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1.7. Myeloperoxidase (MPO) 
Myeloperoxidase is considered to be one of the major antigens in ANCA-associated 
vasculitis. In addition, ANCA-associated vasculitis is induced in all animal models using anti-
MPO antibodies. Myeloperoxidase is a haemoprotein which is highly expressed in 
neutrophils, and accounts for up to 5% of the total cell protein content. It is thought to have a 
role in the host defence (Eiserich, Baldus et al. 2002). It has a molecular weight of about 144 
kDa and disulphide bridges between its two identical subunits (Furtmuller, Zederbauer et al. 
2006). Each one of these subunits is made up of a light and heavy polypeptide chain 
(Andrews, Parnes et al. 1984). Furthermore, it is believed that MPO is released into the 
extracellular space during neutrophil activation where it catalyses the formation of 
hypochlorous acid (HOCL), which is a microbicidal agent, and other oxidising species using 
hydrogen peroxide (H2O2) (Winterbourn, Vissers et al. 2000). Myeloperoxidase has been 
suggested to be involved in micro-organism killing because, in the presence of MPO 
inhibitors or neutrophils from individuals with an MPO-deficiency, a reduction in the killing 
rate was observed (Klebanoff 1970; Lehrer 1971; Koch 1974). Different studies have been 
performed to identify the target epitopes of ANCA on MPO. There is a strong homology 
between mouse and human MPO sequences, which is estimated to be around 90% 
(Erdbrugger, Hellmark et al. 2006). Despite this strong homology, most human ANCA 
against MPO do not bind to mouse MPO. This led Erdbrugger et al. to focus on the area of 
heterogeneity between mouse and human MPO and try to identify target epitopes for ANCA. 
They found that serum from patients with anti-MPO antibodies did not bind to the MPO light 
chain. In addition, serum from these patients bound to only one or two regions of MPO 
(Erdbrugger, Hellmark et al. 2006).      
These findings describe the importance of neutrophils in the pathogenesis of ANCA-
associated vasculitis. I wanted to investigate why some patients develop severe vasculitis 
while the disease in other individuals is moderate. People in our lab have previously shown 
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variability in ANCA-induced neutrophil degranulation from healthy donors. I decided to 
investigate this further by looking at neutrophil degranulation from several healthy donors to 
the same ANCA IgG.  
1.8. Cytokines and chemokines in ANCA-associated vasculitis 
 
Cytokines: 
We know that cytokines are secreted by different cells and that they play an important 
role in immunity; each of these cytokines produces a specific cellular response. Some 
cytokines play an important role in ANCA-associated diseases. For example, tumour 
necrosis factor (TNF-α) is required for priming neutrophils in vitro in order to stimulate them 
with ANCA (Falk, Terrell et al. 1990; Radford, Lord et al. 1999). Little et al. investigated the 
effect of blocking TNF-α, using an anti-rat TNF-α antibody, in an animal model of ANCA-
associated systemic vasculitis and showed that these antibodies reverse anti-MPO antibody-
associated glomerulonephritis in rats (Little, Bhangal et al. 2006). They also showed that 
treating rats that suffer from experimental autoimmune vasculitis (EAV) with anti-TNFα can 
inhibit the ANCA-induced exaggerated adhesion in response to CXCL1. This chemokine has 
been shown in previous studies by the same group to facilitate the adhesion and 
transmigration response in response to ANCA (Little, Smyth et al. 2005). Furthermore, 
blocking TNF-α in rats using a soluble TNF-α receptor has been shown to reduce crescent 
formation (Karkar, Smith et al. 2001). Therefore, TNF-α seems to be important and to play a 
role in the pathogenesis of vasculitis in this animal model. 
Another cytokine thought to play a role in the pathogenesis of ANCA is IL-18. It has been 
reported that IL-18 can prime neutrophils in vitro. IL-18 was found in patients with ANCA-
associated systemic vasculitis (ASV) and the expression of this cytokine was seen in the 
biopsies of these patients. In addition, IL-18 priming of ANCA-induced superoxide production 
was not inhibited by an anti-TNFα antibody which inhibited TNF-α priming of ANCA-induced 
22 
 
superoxide production. In the same study, it was demonstrated that interstitial macrophages 
contain IL-18 suggesting a possible role of these cells in AAV (Hewins, Morgan et al. 2006).  
In addition, Cook et al. have shown that IL-4 reduces proteinuria, fibrinoid necrosis, and 
macrophage infiltration among other effects in crescentic glomerulonephritis (nephrotoxic 
nephritis) model (Cook, Singh et al. 1999). Crescentic glomerulonephritis in these animals 
was induced using nephrotoxic serum. Furthermore, they showed that IL-4 treatment 
reduced glomerular ICAM-1 expression, which is known to be involved in macrophage 
infiltration. They suggested that the action of IL-4 protection is through reducing macrophage 
infiltration to the site of injury and preventing further damage. Having said that, they had also 
started IL-4 treatment after glomerular inflammation was established; no effect on 
macrophage infiltration was seen, but a reduction in injury was achieved. They suggest that 
IL-4 could affect macrophage-mediated injury because they have shown a reduction in cells 
expressing iNOS and sialoadhesin which are markers of macrophage activation. 
Chemokines: 
 The role of IL-8 has been also investigated in ANCA-associated vasculitis. IL-8 is a 
neutrophil chemoattractant chemokine (Yoshimura, Matsushima et al. 1987), and is believed 
to stimulate neutrophil degranulation and the production of reactive oxygen species (Peveri, 
Walz et al. 1988). Furthermore, Cockwell et al. have shown that ANCA can stimulate the 
production of IL-8 in vitro (Cockwell, Brooks et al. 1999). They demonstrated an effect of IL-8 
on neutrophil transmigration.  
Chemokines such as RANTES (Regulated on Activation Normal T cell Expressed and 
Secreted) and monocyte chemoattractant protein-1 (MCP-1) have been reported to be 
upregulated in a murine model of crescentic glomerulonephritis where the disease was 
induced using nephrotoxic serum. They have shown that blocking RANTES and MCP-1 
resulted in decreased accumulation of mononuclear phagocytes and T-lymphocytes. Also, 
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the blocking of these chemokines resulted in partial attenuation of proteinuria. In addition, 
MCP-1 blockade resulted in decreased formation of glomerular crescents and deposition of 
collagen I. However, macrophage infiltration was only inhibited by 50% as a result of MCP-1 
blockade (Lloyd, Minto et al. 1997). In addition, Ohlsson et al. have shown an increased 
level of urinary MCP-1 in patients with ASVV (Ohlsson, Bakoush et al. 2009). They were 
able to show a strong correlation between urinary-MCP-1 excretion and disease outcome.  
Van der Veen et al. have looked at chemokine expression in a mouse model of crescentic 
glomerulonephritis (ANCA-associated vasculitis model). They were able to produce a list of 
genes that were up regulated in renal disease using microarray techniques. They found that 
chemokines such as CXCL2 and the chemokine receptor CXCR2 were upregulated on day 1 
of the experiment. On the other hand, chemokines such as CCL2 and the chemokine 
receptor CCR2 were found to be upregulated when the mice were sacrificed at day 7 (van 
der Veen, Petersen et al. 2009). Blocking the action of CXCR2 did not affect the outcome of 
the disease and did not prevent neutrophil accumulation. CXCR2 is expressed on 
neutrophils which have an important role in ANCA-associated vasculitis. As a result, this 
study suggests that neutrophils are recruited to the glomeruli by a chemoattractant other 
than CXCR2 ligands (such as CXCL1, CXCL2, and CXCL5).    
I am interested in studying some of these chemokines and cytokines, especially those 
involved in macrophage infiltration to the glomeruli. It is important to identify these 
chemokines which could help in finding a way to block macrophage infiltration and studying 
the effect of this process on the disease development.  
1.9. In vivo models of ANCA-associated vasculitis 
Animal models have been useful tools in studying many human diseases. This is because 
mice can be used to induce diseases that resemble some human diseases. Studying these 
diseases in mice helps researchers observe the full immune response similar to how it 
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happens in humans. Until recently, animal models have not provided adequate evidence 
about the pathogenic role of ANCA in vasculitis (Heeringa, Brouwer et al. 1998). However, in 
groundbreaking experiments in 2002, Xiao et al. conducted a series of experiments to 
investigate the pathogenesis of ANCA in a murine model using MPO knockout (MPO-/-) 
C57BL/6J mice (Figure 1.9). These mice were immunised with MPO and developed anti-
MPO antibodies. These antibodies were then injected into wild type and immune-deficient 
mice. They found that these recipient mice developed pulmonary haemorrhagic capillaritis, 
crescentic and necrotising glomerulonephritis and systemic necrotising arteritis. The 
pathology in these mice was similar to human ANCA-associated vasculitis. Some of these 
mice received anti-MPO splenocytes while the others received anti-MPO antibodies. All mice 
developed glomerular crescents and necrosis. On the other hand, mice that received anti-
BSA antibodies did not develop glomerulonephritis (Xiao, Heeringa et al. 2002). This animal 
model, called murine experimental vasculitis, provided evidence that these anti-MPO 
antibodies are pathogenic because mice that received anti-MPO antibodies developed 
crescentic glomerulonephritis and small-vessel vasculitis.  
I used this model to help me understand the importance of macrophages in the 
development of ANCA-associated vasculitis. Tissues were also used to understand more 
about the disease and the role of the immune system.  
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Figure 1.9: The design of experiment that was used to induce vasculitis in mice. MPO-/- mice 
were used in this experiment to raise anti-MPO antibodies. These antibodies were then injected in 
wild type mice and they developed vasculitis. Adapted from Kidney International (2004) 65, 1564-
1567. 
In addition, Little et al. were able to induce vasculitis in WKY rats using human MPO 
(hMPO), termed experimental autoimmune vasculitis (figure 1.10). They showed that 
immunising these rats with hMPO resulted in the generation of anti-MPO antibodies that 
cross-reacted with rat MPO. Furthermore, they showed that the severity of the disease was 
hMPO antigen dose-dependent because all the immunised rats had crescentic nephritis and 
lung haemorrhages when the dose was increased to 1600 µg/kg. In addition, they showed 
that the addition of pertussis toxin and lipopolysaccharide resulted in establishing the 
disease in all animals using less hMPO for immunisation. On the other hand, non-WKY 
strains did not develop vasculitis despite the fact that those strains developed high titres of 
anti-hMPO antibodies. They were able to show in this model, using intravital microscopy, 
that the anti-MPO antibodies were able to convert rolling neutrophils into firmly adhered 
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neutrophils which resulted in necrotising vasculitis after these cells invaded into the vascular 
wall (Little, Smyth et al. 2005; Little, Smyth et al. 2009).  
 
Figure 1.10: Experimental autoimmune vasculitis model. Rats are immunised with human MPO 
and the immune system is boosted with addition of LPS and pertussis toxin. These rats develop lung 
haemorrhage and crescentic glomerulonephritis after 8 weeks.  
In contrast, finding an animal model of PR3 ANCA has proven to be more difficult. 
Different studies have been performed to try and establish an animal model of PR3-
mediated disease, including immunisation of PR3-deficient mice with recombinant murine 
PR3. These mice developed anti-PR3 antibodies, but they did not induce vasculitis following 
passive transfer of the antibodies into wild type mice (Pfister, Ollert et al. 2004). 
Furthermore, van der Geld et al. immunised rats with human-mouse chimeric PR3 and they 
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were able to induce antibodies to rat PR3, but again the rats did not develop vasculitis (van 
der Geld, Hellmark et al. 2007).    
The animal models that we have today depend on antibodies against MPO, which is 
thought to be, along with PR3, the main antigen in ANCA-associated vasculitis. Recently, 
Kain et al. were able to induce pauci-immune focal necrotising glomerulonephritis in rats by 
immunising them with rabbit IgG specific to lysosomal-associated membrane protein-2 
(LAMP-2) (Kain, Exner et al. 2008). This work indicates the presence of other potential 
antigens that are involved in the pathogenesis of vasculitis.  
In an effort to improve the mouse model of vasculitis, Xiao et al. have proposed, at a 
vasculitis and ANCA workshop (Lund, Sweden, 2009), a new mouse strain that is very 
susceptible to vasculitis (Xiao 2009). They used 129S6 mice that were shown to develop 
severe disease following injection with anti-MPO antibodies. It was not clear why this strain 
was more susceptible, but it could be due to genetic factors, as seen in the rat model where 
only the WKY strain develops the disease. Furthermore, they suggested that these mice 
develop 69% crescents compared to 8.56% crescents in C57BL/6J mice following injection 
with anti-MPO antibodies so we decided to use these mice in some of my work.     
1.10. Macrophages and monocytes 
Macrophages have long been suggested to play a role in the development of ANCA-
associated vasculitis. Part of my project was to look at the effect of depleting macrophages 
on the development of vasculitis in mice. Therefore, I will talk about the origin of these cells 
and their role in the immune system. In addition, I will mention some of the previous work 
targeting macrophages in other types of crescentic glomerulonephritis.  
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1.10.1. Macrophage origin and different types of monocytes 
The innate immune system is the first line of defence against infections; the cellular arm 
of this system includes specialised cells called phagocytes. These cells have many 
functions, including internalising and digesting bacteria and other cells, and also the 
secretion of inflammatory mediators that can kill bacteria and other infectious agents. 
Furthermore, these cells are able to scavenge toxic compounds and also stimulate cells from 
the adaptive immune system if needed. Monocytes represent about 10% of human 
leucocytes and 4% of mouse leucocytes (Auffray, Sieweke et al. 2009). One of the important 
functions of these monocytes is the renewal of some tissue macrophages and dendritic cells 
(DCs) (Geissmann, Jung et al. 2003; Auffray, Sieweke et al. 2009). These monocytes 
develop in the bone marrow from hematopoietic stem cells and they go through several 
progenitor stages, including the common myeloid progenitor (CMP), the 
granulocyte/macrophage progenitor (GMP), and the macrophage/DC progenitor (MDP) 
(Fogg, Sibon et al. 2006; Iwasaki and Akashi 2007). The growth factor CSF-1 is very 
important in the development of the blood monocytes and it is been shown that mice 
deficient in CSF-1R and CSF-1 demonstrate reduced numbers of blood monocytes 
(Cecchini, Dominguez et al. 1994; Dai, Ryan et al. 2002). One of the myeloid progenitors is 
MDP which is a cell in the bone marrow that expressed CSF-1R and also the chemokine 
receptor CX3CR1; this cell type gives rise to spleen conventional dendritic cells  (cDCs), 
monocytes, and several macrophage subsets (Fogg, Sibon et al. 2006; Varol, Landsman et 
al. 2007; Waskow, Liu et al. 2008).  
The migration of monocytes from the bone marrow to the blood is very important during 
inflammation. Recent studies have demonstrated the importance of CCR2 and its ligands 
CCL2 and CCL7 in the movement of inflammatory monocytes from the bone marrow to the 
blood (Serbina and Pamer 2006). In humans, these blood monocytes can be identified by 
specific markers such as the CSF-1 receptor and CX3CR1. Furthermore, these blood 
monocytes can be divided into three subsets defined by the expression of CD14 and CD16 
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(Auffray, Sieweke et al. 2009). Human CD14+CD16- monocytes express high levels of 
CCR2 and low levels of CX3CR1 and represent 80-90% of blood monocytes. In addition, 
these subsets are reported to produce IL-10 in response to LPS in vitro (Frankenberger, 
Sternsdorf et al. 1996; Geissmann, Jung et al. 2003). On the other hand, CD16+ monocytes 
express low levels of CCR2 and high levels of CX3CR1 and produce TNF-α in response to 
LPS in vitro (Belge, Dayyani et al. 2002; Geissmann, Jung et al. 2003).  
Mouse blood monocytes and human monocytes have some typical morphological 
features. Mouse monocytes are identified by the expression of CD115 and other markers 
such as CD11b, F4/80, and variable expression of Ly6c antigen. Furthermore, mouse 
monocytes can be divided into different subsets depending on the expression of Ly6C 
(GR1+) and other chemokine receptors. Similar to human CD14+ monocytes, 
CD115+Ly6C+ mouse monocytes express CCR2 and low levels of CX3CR1 chemokine 
receptors (Geissmann, Jung et al. 2003). Unlike human CD14 monocytes, mouse Ly6c 
monocytes have the ability to produce TNF-α and IL-1 during infection and are known as 
inflammatory monocytes (Geissmann, Jung et al. 2003; Serbina and Pamer 2006; 
Nahrendorf, Swirski et al. 2007) (figure 1.11). These cells are the source of inflammatory 
monocytes (Geissmann, Jung et al. 2003) and resident macrophages and DCs in the lung, 
skin, and digestive tract (Ginhoux, Tacke et al. 2006; Landsman and Jung 2007; Landsman, 
Varol et al. 2007; Jakubzick, Tacke et al. 2008). The second type of mouse blood monocyte 
are the CD115+ Ly6C- monocytes, which are known to express high levels of CX3CR1 and 
lack the expression of CCR2 (Geissmann, Jung et al. 2003; Sunderkotter, Nikolic et al. 
2004). These cells have a longer half-life and are found in inflamed and resting tissues after 
adaptive transfer (Geissmann, Jung et al. 2003).  
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Figure 1.11: Mouse blood monocytes. Mouse monocytes express CD115 and can be divided into 
two subsets. Some of these monocytes are Ly6C+ and express CCR2 and low levels of CX3CR1. 
The second subset is Ly6C- monocytes which lack CCR2 expression but express CX3CR1. 
CCR2 is the chemokine receptor for MCP-1 and has been mentioned previously to have 
a role in the development of crescentic glomerulonephritis. Blood monocytes that express 
CCR2 differentiate into inflammatory macrophages and dendritic cells. This receptor has an 
important role in macrophage recruitment to the site of injury. Furuichi et al. have shown 
protection from renal injury in an ischaemia reperfusion model in CCR2 deficient mice. In 
addition, they showed a reduction in the number of interstitial infiltrated macrophages 
(Furuichi, Wada et al. 2003). For these reasons, I decided to investigate the possibility of 
using anti-mouse CCR2 antibody to block or reduce macrophage infiltration into the 
glomerulus.  
1.10.2. Monocytes and macrophages as part of the innate immune system  
Monocytes are found in the bone marrow, blood, and spleen and they do not proliferate in 
a steady state (Auffray, Sieweke et al. 2009; Swirski, Nahrendorf et al. 2009). They express 
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different chemokine receptors that allow them to migrate to the tissue during infection, 
express pathogen recognition receptors, are involved in clearing cells and toxic molecules 
and also produce inflammatory cytokines. Furthermore, they differentiate to macrophages 
and inflammatory DCs during inflammation (Serbina, Jia et al. 2008) (figure 1.12). 
Macrophages are an important part of the immune system and are found in lymphoid and 
non-lymphoid tissues. In addition, they are known to be involved in tissue homeostasis by 
clearing apoptotic cells and also by producing growth factors. Furthermore, they express 
different ranges of pathogen recognition receptors and are able to produce inflammatory 
cytokines (Gordon 2002).  
 
Figure 1.12: The origin of tissue macrophages and DCs. As shown in the diagram, tissue 
macrophages arise from Ly6c+ (Gr1+) monocytes and from Ly6c- (Gr1-) monocytes during 
inflammation. Gr1+ monocytes are known as inflammatory monocytes and have been suggested to 
be the source of M1 macrophages and inflammatory DCs. On the other hand, Gr1- blood monocytes 
are thought to be the source of M2 tissue macrophages.  
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1.11. Macrophages and renal disease 
 
1.11.1. The role of macrophages in renal disease 
ANCA-associated vasculitis is characterised by glomerular crescent formation. The 
involvement of macrophages in this disease and in the progression of the disease has been 
identified by different groups. The involvement of macrophages was first reported in 1972 
when large numbers of macrophages were found infiltrating glomerular lesions (Atkins, 
Holdsworth et al. 1976). Researchers then suggested that macrophages must have a role in 
the progression of the disease and in crescent formation (Cattell 1994). The infiltration of 
macrophages to the site of injury is also a common feature in experimental models of 
glomerulonephritis (Figure 1.13) (Schreiner, Cotran et al. 1978; Bagchus 1990; Hara, 
Batsford et al. 1991). For example, the use of anti-rabbit macrophage serum in anti-
glomerular basement disease in rabbits helps to reduce the severity of the disease. In 
addition, it has been shown that protection from the disease can be achieved by inducing 
leucopoenia by nitrogen mustard, but injecting peritoneal macrophages can reconstitute the 
disease (Holdsworth, Neale et al. 1981; Holdsworth and Neale 1984). These results were 
confirmed by more recent work and it was demonstrated that the number of macrophages 
injected correlated with the severity of the disease (Ikezumi, Hurst et al. 2003). Furthermore, 
there are several examples of the involvement of macrophages in different types of renal 
diseases. For example, Diamond et al. have shown that a reduction in the number of 
glomerular and interstitial macrophages prevented progressive glomerular disease in a 
model of acute puromycin aminonucleoside nephrosis. The reduction in the number of 
macrophages was achieved by exposing the rats to a sublethal dose of X-irradiation 
(Diamond and Pesek-Diamond 1991). In addition, the involvement of macrophages has 
been investigated in a rabbit model of glomerulonephritis. The disease was induced using an 
anti-glomerular basement membrane (GBM) antibody and there was a reduction in 
histological lesions and proteinuria following treatment with sheep anti-rabbit macrophage 
serum. In addition, this treatment resulted in a reduction in the number of circulating 
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monocytes and also prevented macrophage accumulation in the glomeruli (Holdsworth, 
Neale et al. 1981). Furthermore, Tang et al. were able to reduce macrophage infiltration in 
glomeruli using anti MCP-1 antibodies in a rat model of glomerulonephritis. This reduction in 
macrophage infiltration resulted in a reduction in proteinuria (Tang, Qi et al. 1996). All of 
these findings suggest a role for macrophages in renal disease, but their involvement and 
their role in ANCA-associated vasculitis has not been fully investigated.      
 
Figure 1.13: Macrophage infiltration in murine experimental vasculitis. CD68 staining shows 
macrophage accumulation in the crescent region of the glomeruli.  
 
1.11.2. Potential mechanisms of glomerular injury by macrophages 
As mentioned earlier, macrophages are present in inflamed glomeruli in different renal 
diseases. These macrophages have different functions that make them capable of 
increasing the severity of the disease. For example, macrophages are able to produce 
reactive oxygen and nitrogen species and different cytotoxic products. In addition, 
macrophages can secrete different pro-inflammatory cytokines at the site of inflammation 
(Kluth, Erwig et al. 2004) (figure 1.14). The production of reactive oxygen species by 
macrophages from nephritic glomeruli was seen in rabbits and rats (Boyce, Tipping et al. 
1989; Cook, Smith et al. 1989). In addition, it has been shown that glomerular macrophages 
produce TNF-α in mice and rabbits with nephrotoxic nephritis (Boswell, Yui et al. 1988; 
Tipping, Leong et al. 1991). In addition, IL-1β has also shown to be produced by 
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macrophages and it was shown, in different disease models, that blocking this cytokine can 
lead to a reduction in glomerular inflammation (Kluth and Rees 1999).  
 
Figure 1.14: Potential role of macrophages in renal inflammation. Macrophages are capable of 
producing reactive oxygen and nitrogen species. Furthermore, macrophages can produce 
inflammatory cytokines such as TNF-α and IL-1β which can lead to inflammation and tissue injury.  
1.11.3. The activation of macrophages and susceptibility to glomerulonephritis 
Macrophages protect the body from microbial infection using different surface receptors. 
These receptors include Toll-like receptors (TLRs), scavenger receptors, and mannose 
receptors. These receptors are important for stopping microbial infection and recognise 
different microbial products. TLRs can recognise lipopolysaccharide (LPS) and also viral 
double-stranded RNA. Macrophages become classically activated when they receive two 
signals. The first signal is received when microbial products bind to the TLR and the second 
signal is received from T-helper cells or natural killer cells (Kluth, Erwig et al. 2004). These 
two signals lead to the classical activation of macrophages.  
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In addition, macrophages can be alternatively activated in the presence of IL-13 or IL-4 
(Stein, Keshav et al. 1992; Doyle, Herbein et al. 1994). The alternative activation of 
macrophages causes these cells to increase their expression of different receptors such as 
MHC class II receptors and mannose receptors. Furthermore, alternative activation results in 
a reduction in nitric oxide production (Fenton, Buras et al. 1992) and it has been suggested 
that these cells are involved more in tissue repair than in killing intracellular organisms 
(Jakubzick, Choi et al. 2003). 
Recently, different types of M2 macrophages have been identified such as type II 
activated macrophages with increased production of IL-10 and reduced production of IL-12 
(Anderson and Mosser 2002). Cells that follow the type II activation pathway have been 
reported to favour the shift of immune response toward Th2 (Anderson and Mosser 2002). 
It has been found that some rodent strains, such as WKY rats, are more susceptible to 
glomerulonephritis (Tam, Smith et al. 1999). On the other hand, Lewis rats have been found 
to be resistant to crescentic glomerulonephritis after injection with nephrotoxic serum. This 
susceptibility was found to be linked to two major quantitative trait loci, crescentic 
glomerulonephritis 1 and 2 (Crgn1 and Crgn2) (Aitman, Dong et al. 2006). It has been shown 
in a recent study that some transcripts located in the Crgn2 congenic interval are 
upregulated in the glomeruli of WKY rats and downregulated in the glomeruli of LEW rats. 
The activator protein-1 (AP-1) transcription factor gene (Jund) is one of these transcripts and 
has been found to be upregulated in the glomeruli of WKY rats compared to LEW rats. This 
gene has been found to have an important role in macrophage activation because 
knockdown of this gene resulted in a significant reduction in macrophage activation in WKY 
rats (Behmoaras, Bhangal et al. 2008). These findings support the fact that macrophages 
have an important role in the pathogenesis of glomerulonephritis.   
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1.12. Macrophages and their heterogeneity in renal injury and repair 
Macrophages are recruited to the site of inflammation in response to chemokines and 
they differentiate into two distinct subsets. In response to the disease state, macrophages 
can either be classically activated (M1) or alternatively activated (M2), depending on what 
they are exposed to (Martinez, Sica et al. 2008). For example, macrophages will differentiate 
toward M1 subtype when they are exposed to IFN-γ and LPS and these cells are known to 
produce IL-12 and IL-23. Interleukin-23  is reported to have a role in renal allografts and 
autoimmune diseases (Chen and Wood 2007). Traditionally, macrophages are thought to 
have a resolving role in renal disease by clearing apoptotic cells and promoting wound 
healing, but ongoing injury suggests a pathological role of macrophages in tissue destruction 
and irreversible fibrosis in the kidney (Figure 1.15). In addition, members of the TGF-β 
superfamily have been linked to renal fibrosis and it has been reported that macrophages, 
among other cell types, are capable of synthesising TGF-β when renal fibrosis lesions are 
developing (Border and Noble 1994; Eddy 2005). In addition, Isaka and colleagues have 
shown that overexpression of TGF-β can lead to the development of glomerulosclerosis 
(Border and Noble 1997). It has been shown that renal injury can be reduced by modulating 
the function and the phenotype of macrophages in models of renal diseases such as 
allograft injury (Yang, Reutzel-Selke et al. 2003), glomerulonephritis (Yokoo, Ohashi et al. 
1999; Anders, Frink et al. 2003), and interstitial fibrosis (Nishida, Okumura et al. 2005). It 
has been proposed that changing the activation state of macrophages from M1 to M2 can 
help in reducing renal injury in renal diseases. For example, Wang et al. showed in adaptive 
transfer studies that injecting M2-polarised macrophages into mice with chronic renal 
disease resulted in a reduction in renal injury. This was an ex vivo study where they 
stimulated macrophages isolated from the spleen with IL-4 and IL-13 to obtain M2 
macrophages (Wang, Wang et al. 2007).  
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Furthermore, the protective role of macrophages expressing hemeoxygenase-1 (HO-1) 
has been shown in different studies of autoimmunity and inflammatory activation (Roach, 
Moore et al. 2009; Tzima, Victoratos et al. 2009). In addition, expression of HO-1 in 
macrophages has been suggested to improve the outcome in hepatic and renal ischaemia-
reperfusion injury (IRI) (Gueler, Park et al. 2007; Devey, Ferenbach et al. 2009). Ferenbach 
et al. were able to upregulate HO-1 expression on mouse macrophages using haem arginate 
(HA). They were able to demonstrate an improvement in renal function in a mouse model of 
acute kidney injury after treatment with HA. This protection was absent in animals that were 
treated with HA but had their macrophages depleted (Ferenbach, Nkejabega et al. 2011). 
This result shows a diverse role of macrophages in renal diseases. Some studies have 
demonstrated a protective role of macrophages while others have shown an inflammatory 
role.   
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Figure 1.15: The consequences of macrophage infiltration in renal disease leading to renal 
damage. Macrophages infiltrate to the site of inflammation in response to glomerular and tubular 
injury. Macrophages that are recruited to sites of inflammation produce TGF-β and proinflammatory 
cytokines, causing more damage. Adapted from The Journal of Clinical Investigation (2008) 
118:3522-3530. 
1.13. Localisation and adhesion of macrophages in renal diseases 
 
1.13.1. The importance of adhesion molecules in macrophage localisation 
The involvement of macrophages in renal diseases requires the migration of these cells 
to the site of inflammation. This process involves lectin interaction, which results in the rolling 
of monocytes. This rolling allows the binding of VLA-4 to vascular cell adhesion molecule 
(VCAM) and LFA-1 to intracellular adhesion molecule (ICAM-1). The binding of these 
adhesion molecules is an important step in macrophage migration (Springer 1994). It has 
been found, in WKY rats with nephrotoxic nephritis, that macrophage infiltration can be 
reduced when the adhesion molecules ICAM-1 or LFA-1 are blocked (Nishikawa, Guo et al. 
1993). In addition to adhesion molecules, chemokines play an important role in directing 
macrophages to the site of inflammation. 
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1.13.2. Chemokines and macrophage localisation 
Macrophages follow a chemotactic gradient that leads them to the site of inflammation. 
Different chemokines play a key role in macrophage accumulation. These include MCP-1 
and its receptor CCR2 which are present in different diseases such as ANCA-associated 
vasculitis and other causes of crescentic glomerulonephritis (Rovin, Rumancik et al. 1994; 
Segerer, Cui et al. 2000). The level of this chemokine has been used in different studies to 
indicate the severity of the disease. For example, the level of urinary MCP-1 has been found 
to correlate with the severity of renal injury in some studies (Rovin, Doe et al. 1996; Saitoh, 
Sekizuka et al. 1998; Wada T, Furuichi K et al. 1999). In addition, additional chemokines 
such as MIP-1β, MIP-1α, and RANTES have been identified in different diseases such as 
crescentic glomerulonephritis and lupus nephritis (Cockwell, Howie et al. 1998; Wada T, 
Furuichi K et al. 1999). 
The role of chemokines in controlling the function of leucocytes is more complex since the 
functions of different chemokines overlap. This means that in the absence of one 
chemokine, another chemokine might have the ability to replace it. However, blocking the 
action of these chemokines using antibodies has proven to be a good approach to studying 
their effects. For example, blocking MCP-1 in mice with nephrotoxic nephritis results in a 
reduction in crescent formation, macrophage infiltration, and proteinuria (Tang, Qi et al. 
1996; Wada T, Yokoyama H et al. 1996; Lloyd, Dorf et al. 1997). In addition, it has been 
shown that vMIP-II, which is a chemokine analogue produced by herpes virus 8, is able to 
reduce proteinuria, crescent formation, and macrophage infiltration in mice with crescentic 
glomerulonephritis (Chen, Bacon et al. 1998). This is because vMIP-II can block MCP-1, 
MIP-1α, RANTES, and MIP-1β. The blockade of these chemokines seems to affect 
macrophage infiltration and might have an effect on the progression of different renal 
diseases. 
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1.14. Depletion of macrophages 
 
1.14.1. Liposomal clodronate 
Macrophage depletion is important in the study of the role of macrophages in different 
diseases because it allows us to see their role in disease development. One of these 
methods is clodronate administration, which is used to treat osteolytic bone diseases 
(Jordan, van Rooijen et al. 2003). It has been found that once clodronate is incorporated into 
liposomes then it can be used to deplete macrophages (van Rooijen and van Nieuwmegen 
1984; Claassen, Van Rooijen et al. 1990). Clodronate works by inducing apoptosis in 
macrophages after it has been taken up by these cells (Naito, Nagai et al. 1996; van 
Rooijen, Sanders et al. 1996) (figure 1.16). The type of injection has been found to affect the 
type of macrophages that are going to be depleted. For example, intravenous injection will 
result in depleting hepatic and splenic macrophages. On the other hand, injection into tissue 
will result in the depletion of macrophages in this tissue and the draining lymph nodes (van 
Rooijen, Kors et al. 1989). Van Rooijen at el. have shown that depleting macrophages using 
this method does not result in the secretion of pro-inflammatory cytokines by these cells 
when they undergo apoptosis (van Rooijen and Sanders 1997). In addition, liposomal 
clodronate has been found to affect macrophages and phagocytic dendritic cells, but not 
neutrophils or lymphocytes (van Rooijen, Kors et al. 1989; Van Rooijen and Sanders 1994; 
Alves-Rosa, Stanganelli et al. 2000).  
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Figure 1.16: Mechanism of macrophage depletion using liposomal clodronate. Liposomal 
clodronate is taken up by the macrophage through endocytosis. Then, the bilayers of the liposome are 
disrupted by phospholipases from lysosomes. This results in the release of clodronate, causing cell 
death.   
1.14.2. Diphtheria toxin in CD11b-DTR mice 
Another method of depleting macrophages involves using diphtheria toxin (DT) to deplete 
macrophages. Duffield et al. achieved this by generating transgenic mice that express the 
human diphtheria toxin receptor (DTR) under the control of the CD11b promoter, thereby 
leading to its expression on circulating monocytes. They used human DTR because mice 
respond poorly to DT. This allowed them to deplete macrophages by intravenous injection of 
minute quantities of DT (Duffield, Tipping et al. 2005). They used this method to test the 
effect of depleting macrophages on crescentic glomerulonephritis in mice. They found that 
following DT injection in mice, the percentage of resident macrophages in the kidney 
dropped by 98%. Depleting macrophages resulted in a reduction in the number of cellular 
glomerular crescents (Duffield, Tipping et al. 2005). In addition, renal function showed 
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improvement after depleting macrophages. Duffield et al. showed that renal injury and 
fibrotic scarring were reduced following macrophage depletion (Duffield, Tipping et al. 2005). 
1.14.3. The role of CCR2 in macrophage accumulation 
CCR2 is a chemokine receptor for MCP-1; it has been shown that MCP-1/CCR2 
signalling is involved in crescentic glomerulonephritis in humans (Segerer, Cui et al. 2000). 
The role of CCR2 in macrophage infiltration in kidney disease models has been investigated 
by different groups. For example, Furuichi et al. have shown a reduction in the number of 
macrophages infiltrating the kidney interstitium in CCR2 deficient mice after ischaemia-
reperfusion (Furuichi, Wada et al. 2003). Furthermore, they used a CCR2 antagonist and 
showed a reduction in the number of infiltrating cells and in tubular necrosis. In a different 
study, Kitagawa et al. showed a significant reduction in renal pathology after treatment with a 
CCR2 antagonist in the unilateral ureteral obstruction (UUO) model (Kitagawa, Wada et al. 
2004). In addition, the number of F4/80 positive cells was reduced after treatment with a 
CCR2 antagonist and most of these cells were positive for CCR2. These studies 
demonstrated the ability of anti-CCR2 antibodies to reduce macrophage infiltration which 
can be used in our model. 
1.15. The aim of the project 
 
The aim of my work was to study the innate immune system in ANCA-associated 
vasculitis. I also aimed to establish a mouse model of AAV in Birmingham and to work to 
improve this model. I focused on two cell types of the innate immune system: macrophages 
and neutrophils. I aimed to study the phenotype of macrophages in the injured kidney 
following treatment with anti-MPO antibodies. In addition, I studied the role of macrophages 
in AAV by blocking macrophage infiltration to the kidney following disease induction. My 
hypothesis was that macrophages are important in the development of the disease and 
blocking their recruitment should protect animals from developing severe disease. 
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Furthermore, I looked at gene expression in the kidney using mouse and rat models of AAV. 
The aim of this work is to help in the search for genes associated with macrophage 
activation (classical and alternative activation). It also provided a basis on which to study the 
pathways involved in disease induction such as complement pathways. In addition, was 
interesting to see if the mouse and rat models of AAV were similar and if the upregulated 
genes were similar. Finally, I performed some experiments to study the variability in ANCA-
induced neutrophil degranulation. Previous work in our lab has shown that there is variation 
in the ability of ANCA to induce neutrophil degranulation from healthy donors. I studied the 
metabolites present following neutrophil degranulation to identify why we see this variability.  
1.16. Experimental questions and hypothesis 
  
My hypotheses are: 
 Macrophages are involved in tissue injury in AAV and blocking their recruitment can 
improve disease outcome. 
 Macrophages that are recruited to the glomeruli are classically activated 
macrophages.  
 Variability in ANCA-induced neutrophil degranulation is due to variability in donors 
and the ANCA source. 
Questions to be answered: 
 Can we improve the mouse model of AAV by finding a reliable source of MPO for 
immunisation? 
 What are the phenotypes of macrophages in the glomeruli? 
 Does blocking macrophage recruitment prevent or reduce renal injury in AAV? 
 What genes are upregulated in the kidney of mice with MEV? 
 What are the sources of variation in ANCA-induced neutrophil degranulation? 
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Chapter 2 
 
2. General Materials and Methods 
 
This chapter describes the general methods used throughout my PhD. I have also 
included some of the techniques that I optimised during my work. I have included all specific 
methods in the relevant result chapters.  
Neutrophils that are used in my experiment were taken from healthy donors with their 
consent.  
2.1. Animals, reagents, and antibodies 
 
2.1.1. Animals 
 
Most mice had a C57BL/6 (B6) background and 129SvEv mice were used in one 
experiment. Myeloperoxidase heterozygous (MPO+/-) mice were kindly donated to us by Dr. 
Peter Heeringa (University Medical Centre, Groningen, the Netherlands). These mice were 
maintained by the Biomedical Services Unit (BMSU) at the University of Birmingham. The 
heterozygous mice were mated to establish an MPO-knockout (MPO-/-) colony. I immunised 
the MPO-/- mice with MPO when they were 10 weeks old. We also used 129S6/SvEv mice 
(Taconic, New York USA). All procedures were performed according to the Home Office 
Regulations for Animal Experimentation under the project licence of Dr. Mark Little.  
2.1.2. Reagents 
 
Company Reagents 
Sigma-Aldrich, Poole, Dorset, 
UK 
SIGMAFAST OPD tablets, methyl α-D-
mannopyranoside, hexadecyltrimethylammonium 
bromide (CTAB), rat serum, mouse serum, normal 
horse serum, SIGMAFAST 3,3’-diaminobenzine tablets 
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(DAB), penicillin-streptomycin, L-glutamine solution, 
rabbit serum, E-toxate kit, lipopolysaccharides from 
Escherichia coli 026:B6 (LPS), SIGMAFAST p-
nitrophenyl phosphate tablets (p-NPP), Freund’s 
incomplete adjuvant, goat serum, manganese (II) 
chloride tetrahydrate, McCoy’s 5A medium, ethidium 
bromide solution, phenylmethanesulphonyl fluoride, 
250 units ready Taq DNA polymerase. 
 
Qiagen, Crawley, West Sussex, 
UK 
DNeasy blood and tissue kit, RNeasy micro kit. 
Carl Zeiss Ltd., Welwyn Garden 
City, Hertfordshire, UK. 
MembraneSlide NF 1.0 PEN.  
 
Thermo Scientific, Epsom, 
Surrey, UK. 
Cap strip-strips of 8-120 strips of 8 ultra-clear, 1-Step 
PNPP, Slide-A-Lyzer dialysis cassettes, 20 K, 0.5-3 ml 
capacity. 
Applied Biosystems, 
Warrington, UK 
LCM staining kit. 
Lonza, Wokingham, Berkshire, 
UK 
PBS 10x w/o Ca, Mg, QCL-1000 CHROMOGENIC 
LAL 120 TESTS. 
Invitrogen, Paisley, UK SlowFade Antifade kit, Agarose 
GE Health Care, Little Chalfont, 
Buckinghamshire, UK 
Percoll, Amersham Hyperfilm ECL, HiTrap SP 
Sepharose HP 5 ml. 
 
Bunzl Healthcare, Coalville, 
Leics, UK 
BD Connecta™ Plus Stopcock, 10 cm. 
LGC Standards, Teddington, 
Middlesex, UK 
WEHI-3 
Surgipath Europe Limited, 
Bretton, Peterborough, UK 
Mayers haematoxylin. 
 
Gamidor Technical Services Ltd, 
Didcot, Oxfordshire, UK 
Diff-Quick. 
 
Bioline, London, UK dNTP Master mix. 
Promega, Southampton, UK Blue/orange loading dye, 100 bp DNA ladder, 
nuclease-free water. 
R&D Systems Europe, Recombinant mouse MPO. 
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Abingdon, UK  
Insight Biotechnology Limited, 
Middlesex, UK 
MPO heavy chain (L-20) blocking peptide. 
 
2.1.3. Antibodies 
 
I purchased and used the following antibodies in my experiments:  
Company Antibody 
ABD Serotec, Oxford, UK Rat anti-mouse CD68, rat anti-mouse 
CD206, 
rat anti-mouse CD206:FITC, rat IgG2a 
negative control:FITC, goat anti-rat IgG:HRP 
(mouse adsorbed), rat IgG2a negative 
control 
Invitrogen, Paisley, UK Alexa 488 goat anti-rabbit IgG, anti-
fluorescein/Oregon green goat IgG fraction, 
Alexa Fluor conjugate, Alexa 594 goat anti-
rat IgG, Alexa 488 goat anti-mouse IgG. 
Vector Labs, Peterborough, UK Biotinylated rabbit anti-rat IgG, Texas red 
streptavidin, rabbit unconjugated anti-rat IgG 
(H+L) mouse adsorbed, fluorescein rabbit 
anti-rat IgG, rabbit biotinylated anti-goat IgG 
(H+L) 
Abcam, Cambridge, UK MHC class II IA+IE antibody, rat IgG 
secondary antibody. 
 
2.2. In vitro methods 
 
2.2.1. Culturing WEHI cells as a source of murine MPO 
 
Murine WEHI-3 cells (a murine myeloid cell line, ATCC) were used as a source of murine 
MPO, which is not commercially available. These cells were frozen in liquid nitrogen in 1 ml 
of medium with DMSO. The cells were stored in a liquid nitrogen tank and directly 
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transferred to a water bath at 37°C prior to use. Then, McCOY5A medium with 10% FCS, 
5% penicillin/streptomycin, 5% HEPES, and 5% L-glutamine was used to culture these cells. 
The WEHI cells were added to a T75 flask drop by drop and then 15 ml of medium was 
added to the cells. The next day, the cells were transferred to a new flask and the following 
day they were split into two T75 flasks. The cells were incubated for two days and then spun 
down; the pellet was resuspended and 9 ml of medium was added to the cells. The cells 
were then transferred to a large flask containing 300 ml of medium. In early cultures, these 
large culture flasks were used to propagate the WEHI cells. I subsequently investigated the 
feasibility of using a rolling bioreactor instead of static flasks. With the assistance of Dr. 
Margaret Goodall, I started culturing these cells using bioreactors (Greiner Bio-One Ltd., 
UK). The bioreactors have two separate chambers or sections that are separated by a 
membrane that allows fluid exchange (figure 2.1). The cells were resuspended in 40 ml of 
medium with 10% FCS and 400 ml of medium without FCS was added to the top chamber. 
The medium in the top chamber was replaced twice a week and the cells were harvested 
from the bottom chamber once a week using a 50 ml Luer-Lock syringe (Medisave, Dorset, 
UK). I left about 5 ml of cells in the lower chamber and added 40 ml fresh medium with 10% 
FCS. The cells that were harvested were spun down and washed in PBS and then stored at 
-80ºC.    
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Figure 2.1: bioreactor or culturing WEHI cells. Cells are added to the bottom chamber with FCS 
and medium is added to upper chamber. 
The MPO content of the cells was periodically estimated using an MPO activity assay. 
Cells (at a concentration of 1 million cells per 50 µl) were spun down and 0.3% Triton was 
added to the pellet. The cells were incubated with Triton for 10 min at room temperature. 
Then, the cells were spun down and added to an ELISA plate and 100µl of o-
Phenylenediamine (OPD) substrate was added to each well. After this, I incubated the cells 
for 30 min and then the plate was read at 450 nm. This was done for both cell samples 
cultured under static and rolling conditions over a long period of time to ensure that MPO 
production did not decline over time.  
2.2.2. Neutrophil isolation for use in degranulation experiments 
 
I also investigated the variability in ANCA-induced neutrophil degranulation in healthy 
neutrophil donors using ANCA IgG. This followed on from a previous project that provided 
preliminary data to suggest that the neutrophil phenotype is more important than the source 
of IgG in determining neutrophil responses to ANCA. In order to optimise my technique, I 
started isolating neutrophils from human blood using a Percoll solution to prepare gradients 
for neutrophil separation. I first prepared a 100% solution (22.5 ml Percoll + 2.5 ml 1.5 M 
saline), from which I then prepared 81% (8.1 ml 100% solution + 1.9 ml PBS), 70% (7 ml 
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100% solution + 3 ml PBS), and 55% (5.5 ml 100% solution + 4.5 ml PBS) solutions. Then, 
blood was taken and slowly added to a 50 ml tube containing 5 ml of the anticoagulant ACD 
(4.2 g disodium hydrogen citrate, 5 g D-glucose, 200 ml pyrogen-free water). After this, I 
mixed blood with an equal volume of 2% Dextran (9 g NaCl, 20 g Dextran T500, and 1 L 
pyrogen-free water) and inverted the mixture several times. I spun down the mixture at 25 g 
for 10 min. While the blood was spinning, I prepared the gradient in a 15 ml white-top conical 
tube. First, I added 4.5 ml of the 81% solution to the bottom of the tube, being careful not to 
leave drops on the side of the tube. Then, I balanced a 21G needle on a 5 ml syringe near 
the top of the 81% solution and made sure that the opening of the needle was facing the wall 
of the tube so that the solution would not drip from the needle. Then, I added 3 ml of the 
70% solution to the syringe and left it to flow through and run down the side of the tube onto 
the top of the bottom layer. Then, the syringe was removed without moving the tube.  
After spinning the blood for 10 min, the supernatant was removed to new tubes, leaving 
behind all of the red blood cells, and spun at 150 g for 7 min. The pellet was resuspended 
and 3 ml of 55% Percoll solution was added to it. I balanced a 19G needle on a 5 ml syringe 
near the top layer of the gradient. A sample was then drawn into the syringe, left to flow as 
before, and spun down at 1500 g for 45 min. Two clear layers were separated by the 
gradient. I used a sterile transfer pipette to remove the top layer (monocytes). The bottom 
layer contained neutrophils, which were transferred to a fresh 15 ml tube, which was filled 
with PBS to dilute the Percoll solution. The tube was spun down at 400 g for 5 min; this was 
repeated twice. Then, the pellet was resuspended in HBH ready for use. I determined 
neutrophil viability and purity using trypan blue and Diff-quick staining on cytospins, 
respectively.  
2.2.3. Neutrophil degranulation assay 
 
I looked at the effect of different ANCA samples on the degranulation of neutrophils from 
different donors. The degranulation of MPO from neutrophils was measured by ELISA. 
Neutrophils were isolated using the Percoll gradient and the cells were resuspended at 2.5 × 
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106 cells/ml of HBH. In order to prime these neutrophils, the cells were incubated with 80 
U/ml of TNF-α (2 µl/ml of cells) in the presence of cytochalasin B (5 g/ml of cells) for 15 min 
at 37ºC. The ANCA IgG samples were spun down at 13,000 rpm (to remove any debris 
formed during storage) for 1 min and were then diluted to 1 mg/ml in HBH. N-formyl-
methionine-leucine-phenylalanine (fMLP) was used as a positive control and was diluted 
1:2,000 in HBH (final concentration 1 µM). Following this, 100 µl (2.5 × 105 cells) of 
stimulated neutrophils were added to each well of a round-bottomed 96-well plate. Then, I 
added 25 µl of either normal or ANCA IgG to the wells and 25 µl of the positive control was 
added to one well. The final concentration of IgG in each well was 200 µg/ml. The plates 
were incubated at 37ºC for 15 min. Next, the plates were spun down at 1500 rpm for 5 min 
and 75 µl of the supernatant was transferred to a flat-bottomed 96-well plate. Then, I added 
100µl of the OPD substrate to each well and the plates were incubated at room temperature 
for 30 min. Finally, I stopped the reaction by adding 100 µl of acetic acid and the plates were 
read at 450 nm.  
2.2.4. Superoxide release 
This assay was done by Dr. Julie Williams in parallel with my degranulation assay. 
The ability of ANCA IgG to stimulate superoxide production was measured by the 
superoxide dismutase-inhibitable reduction of ferricytochrome C as described elsewhere 
(Radford, Lord et al. 1999). Neutrophils were resuspended at 2 × 106/ml in HBH. Then, they 
were primed with 2 ng/ml TNF-α and 5 mg/ml cytochalasin B for 15 min at 37ºC. The cells 
were then stimulated with 1μM N-formyl-methionyl-leucyl-phenylalanine (fMLP), which was 
used as a positive control, or 200 μg/ml of IgG (MPO-ANCA, PR3-ANCA or normal IgG). The 
release of superoxide was then measured over 120 min.  
 
 
 
51 
 
2.2.5. Flow cytometry 
Confirming monocyte depletion in mice 
For this experiment, 50 μl of blood was taken from each mouse and placed into a tube 
with 5 μl of 50 mM EDTA. After this, antibodies were added to the bottom of 1 ml Eppendorf 
tubes in the dark. For double staining, two antibodies or their isotype control antibodies were 
added to the same Eppendorf tubes. Next, 20-30μl of blood was added to each tube 
containing the antibodies or isotypes. After vortexing, the tubes were incubated in the dark 
for 15-20 min. Then, I added 1 ml of 1× FACS lysis buffer (cat no. 349202, BD biosciences, 
UK) and incubated them in the dark for 15 min. The samples were then transferred to FACS 
tubes, 2 ml of cold PBS was added to each tube and the tubes were spun at 1,000 rpm for 5 
min. Finally, the supernatant was poured off and the pellet was resuspended in 500 μl PBS. 
The samples were then put on ice and analysed using a FACSCalibur flow cytometer (BD 
biosciences, Oxford, UK); the data were analysed using FlowJo. 
2.2.6. Immunohistochemistry and immunofluorescence staining 
Immunostaining of frozen sections 
Mouse kidneys were frozen in OCT compound after culling the animal and stored at -
80ºC until sectioning; 5 μm thick sections were prepared using a cryostat. The sections were 
collected on Superfrost plus glass adhesion microscope slides (Fisher Scientific, 
Leicestershire, UK). The sections were left to air dry for 2 h or overnight and stored at -80ºC 
until use. On the day of staining, the slides were taken out of the freezer and left to thaw at 
room temperature for 15 min. They were then fixed in ice-cold acetone for 15 min in the 
fridge before being taken out and left to dry; a circle was then drawn around each section 
using a wax pen (S2002, Dako, UK). The sections were rehydrated in PBS for 5 min and 
then blocked with 0.3% hydrogen peroxide in methanol for 30 min in a humidity chamber. 
Following this, the sections were washed three times in PBS for 5 min each. Then, I blocked 
non-specific binding with 10% horse serum (shown to be a good blocking agent during 
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optimisation) in PBS for 20 min. Next, I tapped off the serum and added a primary antibody 
to each section at a dilution of 1:100 in PBS/2% horse serum and incubated them for 2 h at 
room temperature or overnight in the cold room. Then, the sections were washed three times 
in PBS for 5 min each before a secondary antibody was added to each section at a 1:200 
dilution in PBS/2% horse serum and incubated for 45 min at room temperature in a humidity 
chamber. Then, the slides were washed as described above. Next, an ImmPRESS anti-
rabbit (peroxidase) kit (MP-7401-15, Vector Lab, UK) was added to each section (two drops 
on each section) and they were incubated for 30 min and then washed as described above. 
The staining was then visualised using DAB (Sigma, Dorset, UK) for 10 s and the reaction 
was stopped by immersing the slides in water. Then, the slides were washed under running 
water for 5 min. Counterstaining was then performed by immersing the slides in Mayer’s 
haematoxylin (01582E, Surgipath Europe Limited, UK) for 1 min and washed under running 
water for 5 min. After this, the slides were immersed in sodium bicarbonate for 1 min and 
were washed under running water for 10 min. Next, the sections were dehydrated in 75% 
and 100% ethanol for 20 s each and moved to xylene for 2 min. Finally, the slides were 
mounted using Immu-mount (Thermo Scientific, Surrey, UK) and left overnight to dry.  
Immunostaining of paraffin sections   
I started by removing the paraffin and rehydrating the sections by immersion in xylene 
and 100% ethanol for 5 min each. Next, peroxidase activity was blocked by 1% hydrogen 
peroxide in water for 15 min. After this, the antigens were retrieved by microwaving the 
sections for 20 min in 10 mM citrate buffer. The sections were washed with gentle agitation 
in TBS for 5 minutes (three times). The sections were then blocked with casein solution 
(Vector Labs, Peterborough, UK) that was kindly donated to me by Dr. Gary Reynolds 
(University of Birmingham, UK) for 10 min. Then, the sections were incubated with a primary 
antibody or negative control and placed in an incubation chamber for 1 h. After this, the 
sections were washed in TBS 0.025% Triton by gentle agitation twice for 5 min each. Rabbit 
anti-rat IgG (Vector Labs, Peterborough, UK), diluted at 1:200 in TBS, was added to the 
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sections. The sections were then placed in an incubation chamber for 15 min. After washing, 
I applied the ImmPRESS anti-rabbit Ig kit (Vector Labs, Peterborough, UK) for 30 min by 
adding 100 µl of the kit to each slide. After this, I washed the sections with TBS-Tween (six 
times) for 5 min each. The sections were visualised using ImmPACT DAB (Vector Labs, 
Peterborough, UK) for 5 min. The sections were counterstained in haematoxylin for 1 min 
and washed under warm running water for 10 min to allow the colour of the stain to develop. 
Then, the sections were rehydrated by immersing them in 100% ethanol and then xylene for 
5 min each. Finally, DPX mounting medium was used to mount the sections and they were 
left to dry before being examined. 
Quantitative assessment using Aequitas 1A 
I analysed the immunohistochemical staining using Aequitas 1A (DDL, Cambridge, UK). I 
started by taking five random images at 10× magnification from each kidney section. Images 
were taken from control and diseased animals. Then, I took one of the control images and 
used it to adjust the threshold. This threshold was used to analyse all of the images. The 
software gave a percentage of positive staining; this percentage was the percentage of 
positive staining in that area (the whole image). I analysed the percentage of positive 
staining in the glomeruli by selecting glomeruli only and then measuring the positive staining 
as a percentage of the area of glomeruli.  
2.2.7. Measuring the endotoxin level in LPS 
Lipopolysaccharide (LPS) (Sigma Aldrich, UK) was used to help induce vasculitis in mice. 
In order to give the same amount of active LPS to each mouse, I needed to measure the 
endotoxin level in the commercial LPS preparation. The E-Toxate kit (Sigma Aldrich) was 
used to calculate specific endotoxin activity. E-Toxate is prepared from a lysate of the 
circulating amoebocytes of the horseshoe crab. This lysate forms a gel when exposed to 
endotoxins such as LPS, depending on the concentration of the endotoxin. All tubes used in 
this experiment were autoclaved and then baked for 4 h at 200ºC. The E-Toxate multiple test 
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vials and endotoxin standard were re-constituted in the appropriate volume of endotoxin-free 
water (Sigma Aldrich, UK). The endotoxin standard was vigorously mixed for 2 min and then 
it was vortexed for 30 s at 10-min intervals over a 30 min period. After this, different dilutions 
of the endotoxin standard were prepared using endotoxin-free water (Table 2.1). In addition, 
serial dilutions of stock LPS were made in order for a negative result to be achieved (Table 
2.2). Then, the sample, water, and endotoxin standard dilution were added directly to the 
bottom of the tubes. Endotoxin-free water was used as a negative control. After this, the 
endotoxin detection solution was added to each tube by inserting a pipette just above the 
contents and allowing the solution to flow down the side of tube. Next, the contents of the 
tubes were gently mixed, the mouths of the tubes were covered using Parafilm, and the 
tubes were incubated at 37ºC for 1 h. Then, the tubes were slowly removed from the 
incubator and inverted by 180º to check for evidence of gel formation. The formation of a 
hard gel was considered a positive result. The endotoxin level of the LPS was calculated by 
multiplying the inverse of the greatest dilution of LPS found to be positive by the lowest 
concentration of the endotoxin standard found to be positive.  
Table 2.1: Different dilutions of endotoxin standard.  
Tube 
no. 
Endotoxin Endotoxin- 
free water 
(ml) 
Final conc. 
(EU/ml) 
1 0.2 ml endotoxin 
std. stock soln. 
1.8 400 
2 0.2 ml from tube 
no. 1 
1.8 40 
3 0.2 ml from tube 
no. 2 
1.8 4 
4 0.3 ml from tube 
no.3 
2.1 0.5 
5 1 ml from tube 
no. 4 
1 0.25 
6 1 ml from tube 
no.5 
1 0.125 
7 1 ml from tube 
no. 6 
1 0.06 
8 1 ml from tube 
no. 7 
1 0.03 
9 1 ml from tube 
no.8 
1 0.015 
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Table 2.2: Different dilutions of LPS. 
Tube  
No. 
LPS Endotoxin- 
free water 
Dilution 
factor 
Expected 
concentration 
(3,300,000 
EU/ml stock) 
A1 10µl LPS stock 990µl 1/100 33,000 EU/ml 
A2 10µl from tube 
no. A1 
990µl 1/10,000 330 EU/ml 
A3 100µl from 
tube no. A2 
900µl 1/100,000 33 EU/ml 
A4 100µl from 
tube no. A3 
900µl 1/1,000,000 3.3 EU/ml 
A5 100µl from 
tube no. A4 
900µl 1/10,000,000 0.33 EU/ml 
A6 100µl from 
tube no. A5 
900µl 1/100,000,000 0.033 EU/ml 
A7 100µl from 
tube no. A6 
900µl 1/1,000,000,000 0.0033 EU/ml 
 
2.3. Protein Methods  
 
2.3.1. MPO purification from WEHI-3 cells 
After 6 months of continuous culturing and harvesting of WEHI cells, I started isolating 
MPO from these cells. I estimated the number of cells to be 5 × 1010. There were 8.2 × 108 
cells in a 1 ml pellet (based on early counting estimates using a Coulter counter). I used a 
method similar to that of Xiao et al. (Xiao, Heeringa et al. 2002). The pellets were 
resuspended in buffer A (6.7 mM sodium phosphate, pH 6.0; 1 mM MgCl2; 3 mM NaCl; 0.5 
mM PMSF); 5 ml of buffer A was added to each 1 ml pellet. After this, the cells were lysed by 
Dounce homogenisation and then they were spun down in an ultracentrifuge at 25,000 rpm 
for 25 min. The supernatant, which had a green colour, was dialysed against buffer B (100 
mM sodium acetate, pH 6.3; and 100 mM NaCl) overnight; I called this SN1. Buffer A was 
added to the pellet (P1) and incubated overnight to obtain any residual MPO.  
The next day, concanavalin-A (Amersham Pharmacia Biotech, UK) was washed with 
buffer B con-A (100 mM sodium acetate, pH 6.3; 100 mM; 1 mM CaCl2; 1 mM MgCl2; and 1 
mM MnCl2). The material from the dialysis tubes was then added to the con-A pellet at a 
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ratio of 50 ml SN1 to 1.5 ml of con-A and incubated overnight end-over-end. After this, P1 
was spun down at 25,000 rpm for 20 min and dialysed against buffer B overnight.  
The next day, the mixture from SN1 and con-A was spun down and the supernatant 
(SN2) was re-incubated with con-A and incubated overnight. The MPO was eluted from the 
con-A using buffer B elution (100 mM sodium acetate, pH 6.3; 100 mM NaCl; 1 mM CaCl2; 1 
mM MgCl2; 1 mM MnCl2; and 750 mM methyl α-D-mannopyranoside), which was added to 
the pellet and incubated overnight end-over-end in a cold room.  
I used the same con-A extraction with the methyl α-D-mannopyranoside elution for the P1 
and SN2 samples and stored all samples at -80oC until I was ready to perform the final 
purification step using a Mono- cation exchange column (GE Healthcare, UK). When I was 
ready to run the samples through this column, the samples were dialysed against buffer D 
(50 mM sodium acetate, pH 8.5-9; and 100mM NaCl). Then, I washed the Mono-S column 
with buffer D and buffer E (50 mM sodium acetate, pH 8.5-9; and 1 M NaCl) and finally I 
equilibrated it with buffer D. Then, I loaded the sample into the column with buffer D and 
eluted with buffer E. I checked the absorbance of the purified fraction at A280 and A430. The 
concentration of MPO was calculated using the following formula: [MPO] = (A430/0.178) × 
0.144. Then, the MPO was dialysed with PBS overnight and then stored at -80ºC. 
MPO was also isolated from human blood using a similar protocol in order to optimise my 
technique before MPO was isolated from WEHI cells. 
2.3.2. Purification of IgG 
 
2.3.2.1. Affinity chromatography of mouse serum  
 
I purified IgG from mouse serum using protein G affinity chromatography. The column 
was packed using protein G matrix (Sigma, Dorset, UK) in a XK16 × 20 column (GE 
Healthcare, UK). The serum was first centrifuged at 10,000-15,000 rpm for 10 min to remove 
any debris that might have formed during storage. The column was first washed with a 
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loading buffer (20 mM sodium phosphate, pH 7.0). Then, the sample was loaded by injection 
using a syringe at a flow rate of 0.5 ml/min. The entire process was run using an AKTA 
Prime Plus chromatography system (GE Healthcare, UK) with a PC for visualisation of the 
results. When the entire sample was loaded, the machine was switched to the elution buffer 
(0.1 M glycine, pH 2.7). The pH of the sample was neutralised using a neutralisation buffer 
(Tris-HCl, pH 9.0), which was added to the collection tubes before I started eluting the IgG 
from the column. The size of the fractions was 1-2 ml. The IgG concentration was calculated 
using the formula: (C= A 280/1.35). Samples were injected into 20 K Slide-A-Lyzer dialysis 
cassettes using a needle and syringe and dialysed against PBS overnight. The purity of the 
anti-MPO antibody was checked using SDS-PAGE. 
2.3.2.2. Purification of human IgG from plasma exchange fluid 
Human IgG was purified from plasma exchange fluid (PEX) for use in the degranulation 
experiments. The purification process was similar to the one mentioned above with some 
modifications. Plasma exchange fluid that is normally discarded was obtained from patients 
with systemic vasculitis and stored at -20ºC. Serum was prepared by adding 1 ml of 1 M 
CaCl2 to 50 ml of PEX and left to clot overnight at 4ºC. The next day, the sample was spun 
down at 2,000 g for 15 min and the supernatant was collected and filtered through syringe 
filters. After this, the serum was diluted 1:1 with PBS before loading it into the column. I used 
a 5 ml HiTrap protein G HP column (GE Healthcare, UK) for this process. The column was 
washed with 4-5 column volumes of PBS by injecting PBS into the column using a 50 ml 
syringe; the flow-through was discarded. The serum was injected into the column (10 ml) 
and the column was then washed with PBS as previously described. After this, IgG was 
eluted from the column by injecting 20 ml of 0.1 M glycine pH 2.7 and the flow-through was 
collected and neutralised by adding 0.75-1 ml of 1 M Tris pH 9.0. Next, the samples were 
dialysed in sterile PBS by loading the samples into dialysis tubes (Medicell International, 
London, UK) and stirring them at 4ºC overnight. The next day, the samples were 
concentrated down using vivaspins (Appleton Woods, Birmingham, UK). These vivaspins 
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were first washed by adding 5 ml of PBS to the upper chamber and spinning them at 5,000 
rpm for 5 min at 4ºC. Then, the samples were loaded into the vivaspins and spun down until 
approximately 1 ml was left in the upper chamber. I removed the samples from the upper 
chamber using a syringe and needle and washed the membrane by trituration. Finally, the 
sample was filtered by passing it through a 0.2 μm syringe filter. The concentration of IgG 
was measured using a spectrophotometer. 
2.3.3. SDS-PAGE and Western blot 
 
 2.3.3.1. SDS-PAGE 
 
SDS-PAGE and Western blot were performed to confirm the presence and the purity of 
MPO (murine MPO and human MPO). The SDS-polyacrylamide gels were prepared by first 
pouring the 10% resolving gel between glass plates, leaving 2-3 cm at the top. Then, an 
upper layer of water was added to the top of the gel to prevent it from drying out. The gel 
was left to polymerise for 30 min. Then, I poured off the top layer of water and the remaining 
space was filled with the stacking gel. The comb was inserted and the gel was left to 
polymerise for 30 min. After this, the gels were placed onto a holder/electrode and 
transferred to a running tank, which was filled with 1× running buffer. Then, 1.6 µg or less of 
MPO was diluted 1:1 in loading buffer (without β-mercaptoethanol (β-ME)). For reducing 
conditions, the samples were diluted 1:1 in a loading buffer containing β-ME and boiled at 
95°C for 5 min. After this, the samples were loaded into the wells and a protein standard 
ladder was added to the first well. Two gels were made: one reduced and the other non-
reduced. Then, the gels were stained with Coomassie Blue overnight. The next day, the gels 
were destained and photographed. 
2.3.3.2. Western blot 
Proteins were transferred from the gel to nitrocellulose and blocked with a blocking buffer 
(10% non-fat dried milk in TBS-T) for 3 h. Then, the blot was covered with rabbit anti-human 
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MPO antibody diluted 1:100 in blocking buffer for human MPO and mouse anti-mouse MPO 
for mouse MPO and incubated overnight. Then, the blot was incubated with goat anti-rabbit 
Ig HRP secondary conjugate (Biosource, UK) diluted 1:1000 in blocking buffer for human 
MPO, and with goat anti-mouse immunoglobulin/HRP (DAKO, UK) for mouse MPO. I used 
the chemiluminescent method to detect MPO by incubating my Western blot with a substrate 
(Amersham, UK) and the light was detected by photographic film.  
2.3.4. ELISA techniques  
 
2.3.4.1. Anti-MPO ELISA    
  
The antibody level in the serum of MPO immunised MPO-/- mice was measured by an 
anti-MPO ELISA. The serum was obtained from the mice by leaving the blood to clot 
overnight at 4ºC and then spinning it down at 4,000 rpm for 10 min. The concentration of 
murine MPO was made up to 2 µg/ml using 0.015 M carbonate buffer (0.795 g Na2CO3, 
1.465 g NaHCO3, 500 ml water, pH 9.6). Then, 100 µl of the murine MPO was added to 
each well of 96-well ELISA plates and incubated overnight at 4ºC. The next day, serum 
samples from immunised mice were serially diluted in blocking buffer (PBS + 1% BSA + 0.1 
% Tween 20) in triplicates. The plates were washed three times using PBS-Tween. I then 
added 100 µl of a diluted sample, in triplicate, to each well and incubated it for 60 min at 
37ºC. The plate was washed three times in PBS-T and 100 µl of a secondary antibody (anti-
mouse IgG alkaline phosphatase developed in goat, Sigma Aldrich, UK) diluted 1:30,000 in 
blocking buffer was added to each well and incubated for 45 min at 37ºC. Then, the plate 
was washed three times and 100 µl of the substrate was added to each well (p-nitro-
phenylphospate tablets, Sigma Aldrich, UK) and incubated at room temperature for 30 min. 
The plate was read at 405 nm.  
A log dilution of 1:10,000 was performed in order to determine the anti-MPO antibody 
titre. The titre was estimated as the dilution that resulted in a 50% drop in the OD value 
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using non-linear fit with the following equation: Y=ODBottom + (ODTop-
ODBottom)/(1+10^((LogEC50-X))). A positive control was used for each ELISA experiment, 
consisting of serum from MPO-/- mice immunised with WEHI MPO. In addition, a negative 
control was also used, consisting of serum from MPO-/- mice immunised with BSA. 
2.4. Molecular techniques (genotyping, arrays) 
2.4.1. Mouse genotyping 
2.4.1.1. DNA isolation 
The DNA was extracted from murine tissue using a DNeasy Blood and Tissue kit 
(Qiagen, West Sussex, UK). I added 180 µl of ATL buffer to each tissue sample in 
Eppendorf tubes. This buffer is a lysis buffer which works by breaking open the membrane 
and of the cell and the nucleus. After this, 20 µl of proteinase K was added to each 
Eppendorf tube, which is important for denaturing hydrolytic enzymes and also for keeping 
the DNA intact. The samples were mixed by vortexing and then incubated at 56°C overnight 
using a heat block. The next day, the samples were mixed by vortexing and then 200 µl of 
AL buffer and 200 µl of ethanol were added to each sample and mixed by vortexing. Then, 
the samples were transferred to a DNeasy Mini spin column in a 2 ml collection tube and I 
centrifuged the sample at 8,000 rpm for 1 min. This allowed proteins and other cytoplasmic 
components to pass through and it also allowed the DNA to stick to the membrane in the 
column. The columns were then washed twice using AW1 and AW2 buffers. Finally, an 
elution buffer (AE) was used to collect the DNA from the membrane of the column. I added 
0.5 ml of the AE buffer to each column and incubated them at room temperature for 1 min. 
The samples were then centrifuged at 8,000 rpm for 1 min and the DNA was eluted and 
collected in Eppendorf tubes.  
2.4.1.2. PCR preparation 
Polymerase chain reaction (PCR) was used to amplify the DNA and MPO primers were 
used to ensure that only MPO was amplified. The PCR master mix was prepared; it 
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contained Ready TAQ polymerase (Sigma, IBR store, University of Birmingham, UK), buffer 
(Sigma, IBR store, University of Birmingham, UK), dNTP Master Mix (Bioline Products, IBR 
store, University of Birmingham, UK), MPO primers (Alta Bioscience, University of 
Birmingham, UK), and nuclease-free water (Promega Products, University of Birmingham, 
UK). 
The samples were then subjected to PCR using the specific settings shown in Chapter 3. 
Then, the samples were subjected to gel electrophoresis in order to identify MPO-/- mice. 
2.4.2. Affymetrix array 
2.4.2.1. Microdissection 
We wanted to study gene expression in glomeruli and tubules from mouse and rat models 
of ANCA-associated vasculitis. The laser microdissection technique was used to 
microdissect glomeruli from frozen kidney sections. I started by preparing sections from 
frozen kidneys. The kidneys were transferred from -80°C to a cryostat on dry ice, although 
they were not allowed to defrost. Then, I prepared 8 μm-thick sections from these tissues 
using the cryostat. I cleaned the blade and all the brushes using RNaseZap. The sections 
were then transferred to membrane slides (Zeiss, Germany). Each slide was then kept inside 
the cryostat for 2 min and a second tissue sample was added to the same slide. In order to 
do this, I put my finger behind the area where the new section would stick in order to defrost 
that area and allowed the tissue to stick without allowing the first section to defrost. Then, 
the sections were transferred to a storage box that contained silica gel (to remove any 
moisture) on dry ice. 
The sections were then stored at -80°C until I was ready for microdissection. On the day 
of microdissection, the sections were kept on dry ice and I stained one slide at a time. I used 
cresyl violet stain for visualisation. The sections were taken out of dry ice and quickly moved 
(without allowing them to defrost) to 95% ethanol for 30 s. Then, they were transferred to 
75% ethanol for 30 s and then 50% ethanol for 25 s. Next, I drained off any excess ethanol 
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and marked the edges of each slide with a barrier pen in order to keep the dye in place. 
Then, I added 300 μl of cresyl violet stain directly onto the tissue for 1 min. After this, I 
removed the excess dye and transferred the slide to 75% ethanol for a short period of time, 
then to 100 ethanol for 30 s. I then left the slides to dry at room temperature for 5 min. The 
sections were quickly transferred for laser microdissection. I started laser microdissection 
and the microdissected tissues were collected on collection caps containing 30 μl of lysis 
buffer (diluted with 1:100 β-ME). When the microdissection was finished, I removed the cap 
and added 10 μl of lysis buffer and mixed the contents. The cap was then replaced on the 
micro-tube and the tube was tapped to force the sample to the bottom of the tube. Then, the 
sample was centrifuged at 4,000 rpm for 15 s. The sections were used for microdissection 
for no longer than 45 min to prevent RNA degradation. Then, the tissues that were collected 
were stored in lysis buffer at -80°C until RNA extraction.  
2.4.2.2. RNA extraction from microdissected tissues  
I extracted total RNA from microdissected tissues stored in 30 μl of lysis buffer using an 
RNeasy micro kit (Qiagen, UK). Eight kidney sections from each animal were microdissected 
in order to obtain 400 glomeruli (50 glomeruli from each section). I pooled these samples 
together and I adjusted the sample volume to 350 μl with RLT buffer containing β-ME. After 
this, the sample was mixed by vortexing for 30 s. Next, I added 1 volume of 70% ethanol 
(350 μl) to the homogenised lysate and the sample was mixed well by pipetting (no 
centrifuging). Then, I transferred the sample, including any precipitate that may have formed 
to an RNeasy MinElute spin column placed in a 2 ml collection tube. I gently closed the lid 
and centrifuged the sample for 15 s at 10,000 rpm. The flow-through was then discarded 
from the lower chamber. Subsequently, I added 350 μl RW1 buffer (a wash buffer that 
contains ethanol) to the RNeasy MinElute spin column. The lid was gently closed and the 
sample was centrifuged for 15 s at 10,000 rpm in order to wash the spin column membrane 
(the flow-through was discarded). I added 10 l DNase I stock solution (to remove any DNA 
from the sample) to 70 μl RDD buffer and I mixed the mixture by gently inverting the tube. 
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Then I added the DNase I incubation mix (80 μl) directly to the RNeasy MinElute spin 
column membrane and placed the tube on the bench top for 15 min. Then I washed the 
column by adding 350 μl RW1 buffer to the RNeasy MinElute spin column and centrifuged 
the sample as described previously. The RNeasy MinElute spin column was placed in a new 
2 ml collection tube. Then, I added 500 μl Buffer RPE to the spin column and centrifuge as 
previously described. I washed the column again by adding 500 μl of 80% ethanol to the 
RNeasy MinElute spin column. Then, I centrifuged for 2 min at 10,000 rpm to wash the spin 
column membrane and I discarded the flow-through and collection tube. I placed the RNeasy 
MinElute spin column in a new 2 ml collection tube, opened the lid of the spin column and 
centrifuged at full speed for 5 min. This was done to make sure that the membrane was dry 
before eluting the RNA because ethanol can affect downstream applications. Finally, I 
placed the RNeasy MinElute spin column in a new 1.5 ml collection tube and added 14 μl 
RNeasy-free water directly to the centre of the spin column membrane before centrifuging 
for 1 min at full speed to elute the RNA. 
2.4.2.3. RNA amplification step 
The RNA samples were processed by the College of Medical and Dental Sciences 
Affymetrix Microarray Service (Dr. John Arrand). The RNA was amplified using an 
ExpressArt C&E Nano kit (AMSBIO, UK) in two amplification steps (figure 2.2). I will describe 
the protocol that was used to amplify the total RNA. 
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Figure 2.2: Affymetrix array procedure. RNA was amplified, followed by biotin labelling, 
fragmentation, and hybridisation to mouse or rat genome arrays. This was then followed by washing, 
staining and scanning according to standard Affymetrix protocols. Adapted from Staal et al. 
Leukaemia. 2003 Jul; 17(7):1324-32.  
2.4.2.4. First strand cDNA synthesis  
The procedure started by preparing the first strand cDNA synthesis Mix1. Then, 4 μl of 
Mix1 was added to 4 μl of each RNA sample. This was followed by 4 min incubation at 65ºC 
in a thermocycler with a heating lid. After this, the samples were cooled down to 37ºC. 
During that time, the first strand cDNA synthesis Mix2 was prepared at room temperature. 
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Then, 8 μl of Mix2 was added to each sample and mixed well. Next, the samples were run in 
a thermocycler using the following settings: 
37ºC/ for 45 min 
45ºC/ for 15 min 
50ºC/ for 5 min 
70ºC/ for 10 min 
4ºC/ Hold  
The samples were removed from the thermocycler and the tubes were centrifuged and kept 
on ice. 
First Strand cDNA Synthesis (Mix1) 
H2O 2.4 μl 
dNTP Mix 0.8 μl 
Primer A 0.8 μl 
 
First Strand cDNA Synthesis (Mix2) 
DEPC-H2O 3.2 μl 
5× RT Buffer 3.2 μl 
RNase Inhibitor 0.8 μl 
RT Enzyme 0.8 μl 
 
2.4.2.5. Template DNA synthesis 
The second strand DNA synthesis mix (Mix3) was prepared in the given order in a 1.5 ml 
reaction tube. Then, 104 μl of Mix3 was added to the first strand reaction on ice and the 
sample was gently mixed by pipetting. The samples were then incubated in a thermocycler 
at 16ºC for 2 h. After this, the samples were removed from the thermocycler and kept on ice. 
Finally, the samples were centrifuged to collect the liquid and then they were quickly moved 
to the purification step.   
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Second Strand DNA Synthesis (Mix3) 
H2O 73.0 μl 
Polymerase buffer 24.0 μl 
dNTP Mix 2.4 μl 
Polymerase A 3.2 μl 
Polymerase B 0.8 μl 
Polymerase C 0.8 μl 
 
2.4.2.6. Purification of template DNA with spin columns 
The purification step started by adding 246 μl of Mix4 to each template DNA reaction (120 
μl from the previous step). The samples were gently mixed by pipetting. Then, the column 
was prepared by inserting DNA purification spin columns into collection tubes. Samples were 
then transferred onto each column and centrifuged for 1 min at 10,000 rpm. The flow-
through was discarded and the column was re-inserted in the same collection tube. Then, 
the columns were washed with 200 μl washing buffer and centrifuged as previously 
described. The washing step was repeated again. After this, the flow-through was discarded 
and the column centrifuged again for 1 min at 10,000 rpm. Finally, the template DNA was 
eluted by inserting the columns in fresh 1.5 ml reaction tubes and then adding 10 μl of 
elution buffer to the columns. After this, the columns were incubated for 2 min and 
centrifuged for 1 min at 10,000 rpm. The purified template DNA was now ready for in vitro 
transcription.  
Purification (Mix4) 
Binding Buffer 244 μl 
Carrier DNA 2 μl 
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2.4.2.7. Amplification via in vitro transcription 
First of all, the samples for in vitro transcription (Mix5) were prepared at room 
temperature. Then, 10 μl of Mix5 was added to the template DNA obtained in the previous 
step. The transcription was then incubated overnight at 37ºC in a thermocycler with the 
heating lid adjusted to 45ºC. Next, 1 μl DNase was added to each reaction and thoroughly 
mixed. The mixture was then incubated at 37ºC for 15 min. 
In vitro Transcription (Mix5) 
NTP Mix 6.6 μl 
10× Buffer 1.7 μl 
RNA Polymerase 1.7 μl 
 
2.4.2.8. Amplified RNA purification using RNA spin columns 
The purification step was started by adding 987 μl of Mix6 to each in vitro transcription 
reaction and thoroughly mixing. Then, 700 μl of this mixture was transferred into a spin 
column and centrifuged for 30 s at 10,000 rpm and the flow-through was discarded. The 
remaining mixture was then transferred to the column and centrifuged as previously 
described. Next, the column was washed by adding 500 μl of wash buffer 1 and centrifuged 
as previously described. This was followed by a second washing step by adding 500 μl of 
wash buffer 2 and centrifuging as previously described. Then, 500 μl of 80% ethanol was 
added to the column and centrifuged. The flow-through was discarded and the column was 
centrifuged again for 1 min at maximum speed to remove residual salts from the spin column 
matrix. Finally, the column was inserted into a fresh 1.5 ml reaction tube and the RNA was 
eluted from the column by adding 30 μl of RNase-free water (pre-heated to 95ºC). The 
column was incubated for 2 min and then centrifuged for 1 min at maximum speed. The 
eluted sample was then reapplied to the column and treated as before. The RNA was now in 
a total volume of 30 μl and was used for the second amplification step.  
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aRNA Purification (Mix6) 
RNA LB Buffer 340 μl 
RNA DeS Buffer 87 μl 
100% Ethanol 560 μl 
 
2.4.2.9. Second amplification round 
Amplified RNA was again reverse transcribed into cDNA to produce high yields of aRNA 
via a second round of amplification because the starting quantity of RNA was low. 
First strand cDNA synthesis 
The amplified RNA was used for a second amplification step. First, 5 μl of Mix2-1 was 
added to 25 μl of each RNA (for smaller volumes, the final volume was adjusted to 30 μl with 
water). Then, the samples were incubated at 65ºC in a thermocycler for 4 min before being 
cooled to 37ºC. Then, 20 μl of Mix2-2 was added to each sample; this was mixed well by 
gently flicking the tube. Then, the samples were incubated in a thermocycler using the 
following settings: 
37ºC/ 45 min 
45ºC/ 15 min 
50ºC/ 5 min 
37ºC/ hold 
This was followed by adding 5 μl of Mix2-3 while the samples were in a thermocycler, and 
they were incubated using the following settings: 
37ºC/ 5 min 
80ºC/ 15 min 
37ºC/ hold 
Finally, 5 μl of RNase Mix2-4 was added to first strand cDNA reaction and the reaction was 
incubated at 37ºC for 20 min. 
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First Strand cDNA Synthesis (Mix2-1) 
dNTP Mix 2.5 μl 
Primer B 2.5 μl 
 
First Strand cDNA Synthesis (Mix2-2) 
DEPC-H2O 8.4 μl 
5 × RT Buffer 10.0 μl 
RNase Inhibitor 0.8 μl 
RT Enzyme 0.8 μl 
 
Primer Erase (Mix2-3) 
DEPC-H2O 3 μl 
5× Extender Buffer 1 μl 
Primer Erase 1 μl 
 
RNase (Mix2-4) 
DEPC-H2O 3 μl 
5× Extender Buffer 1 μl 
RNase 1 μl 
 
Template cDNA synthesis 
The procedure started by adding 35 μl of Mix2-5 to each first strand cDNA synthesis 
reaction; the samples were then incubated in a thermocycler using the following settings: 
96ºC/ 1 min 
37ºC/ 1 min 
Following this, 20 μl of Mix2-6 was added to each sample and this was mixed well by gently 
flicking the tube. Then, incubation was continued as follows: 
37ºC/ 30 min 
65ºC/ 15 min 
4ºC/ Hold 
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Second Strand cDNA Synthesis (Mix2-5) 
DEPC-H2O 10.0 μl 
5× Extender Buffer 10.0 μl 
Primer C 12.5 μl 
dNTP Mix  2.5 μl 
 
Extender Enzyme B (Mix2-6) 
DEPC-H2O 18 μl 
5× Extender Buffer  1 μl 
Extender Enzyme B  1 μl 
 
Purification of template DNA with spin columns 
First, 236 μl of Mix2-7 was added to each template DNA reaction and this was gently 
mixed. The sample with then transferred to the column and it was centrifuged for 1 min at 
10,000 rpm. The flow-through was discarded and the column was washed by adding 200 μl 
washing buffer to the column and then centrifuged as previously described. This washing 
step was repeated again. Then, the flow-through was discarded and the column was 
centrifuged as before. Next, the columns were inserted into fresh 1.5 ml reaction tubes and 
10 μl of an elution buffer was added to each column. The columns were incubated for 2 min 
and then they were centrifuged as previously described. 
Purification (Mix2-7) 
Binding Buffer 234 μl 
Carrier DNA  2 μl 
 
Amplification via in vitro transcription 
First, the in vitro transcription mix was prepared as shown in the table below. Then, 10 μl 
of transcription Mix5 was added to the template DNA. The samples were then incubated 
overnight at 37ºC in a thermocycler with the heating lid adjusted to 45ºC.  
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In vitro Transcription (Mix5) 
NTP Mix  6.6 μl 
10× Buffer  1.7 μl 
T7 RNA Polymerase  1.7 μl 
 
Synthesis of biotin-labelled cRNA 
The labelling process was started by transferring template cDNA to an RNase-free 
microfuge along with the other reaction components, as shown in the table below. These 
reagents were carefully mixed and the mixture was collected at the bottom of the tube by a 
brief 5 s of microcentrifugation. Following this, the samples were incubated at 37ºC for 16 h.  
Reagent Volume 
Template cDNA 12 μl 
RNase-Free Water 8 μl 
10× IVT Labelling Buffer 4 μl 
IVT Labelling NTP Mix 12 μl 
IVT Labelling Enzyme Mix 4 μl 
Total Volume 40 μl 
 
Cleanup of biotin-labelled cRNA 
It is essential to remove any unincorporated nucleotide triphosphate (NTPs) so that the 
concentration and the purity of the cRNA can be accurately measured. First, 60 μl of RNase-
free water was added to each sample and mixed by vortexing for 3 s. Then, 350 μl of IVT 
cRNA Binding Buffer was added to the sample and they were mixed by vortexing for 3 s. 
Next, 250 μl of 100% ethanol was added to the samples and mixed well by pipetting. 
Following this, the samples were transferred to the IVT cRNA clean-up spin columns and 
were centrifuged for 15 s at 10,000 rpm. The flow-through was discarded and the column 
was transferred to a new collection tube. The columns were then washed by adding 500 μl 
of IVT cRNA wash buffer to the spin columns. The columns were then centrifuged as 
previously described. Following this, 500 μl of 80% ethanol was added to the spin column 
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and centrifuged as previously described. The columns were then dried by centrifuging for 5 
min at maximum speed while leaving the cap open. Then, the columns were transferred to 
new 1.5 ml collection tubes and the cRNA was eluted by adding 11 μl of RNase-free water to 
the column and then centrifuging it for 1 min at maximum speed. This elution step was 
repeated again by adding 10 μl of RNase-free water. 
Fragmentation of cRNA for target preparation 
The fragmentation process of cRNA has been shown to be critical for obtaining optimal 
assay sensitivity. A fragmentation buffer is used for this process, which has been optimised 
to break down full-length cRNA to 35 to 200 base fragments. The following fragmentation 
reaction mixture was used: 
Component volume 
cRNA 20 μg (1 to 21μl) 
5× Fragmentation Buffer 8 μl 
RNase-Free Water To a final volume of 40 μl 
 
The reaction mix was incubated at 94ºC for 35 min; the samples were then kept on ice 
following incubation. The cRNA samples were then stored at -20°C until the time of 
hybridisation.  
Hybridisation 
The DNA microarray is a chip or solid surface that has microscopic DNA spots. Each 
DNA spot contains probes which are picomoles of specific DNA sequences. These are short 
sections of a gene that are used to hybridise a cDNA or cRNA sample. Hybridisation 
between two DNA strands is the core principle behind DNA microarray (figure 2.3). The 
hybridisation cocktail was prepared as shown below: 
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Component  Final Concentration 
Fragmented cRNA  15 μg 
Control Oligonucleotide B2 
(3 nM) 
 5 μl 
20x Eukaryotic 
Hybridisation Controls 
 15 μl 
Herring Sperm DNA (10 
mg/ml) 
 3 μl 
BSA (50 mg/ml)  3 μl 
2× Hybridisation Buffer  150 μl 
DMSO             30 μl 
H2O  To a final volume of 300 μl 
Final Volume  300 μl 
 
The hybridisation cocktail was then heated to 99ºC for 5 min in a heat block. The probe 
array was filled with 1× hybridisation buffer and incubated at 45ºC for 10 min with rotation. 
Following this, the hybridisation cocktail was transferred to a 45ºC heat block for 5 min. The 
hybridisation cocktail was centrifuged at maximum speed for 5 min to remove any insoluble 
material. After this, the buffer was removed from the probe array cartridge and replaced with 
200 μl of the hybridisation cocktail. Next, the probe was placed in the hybridisation oven at 
45ºC for 16 h. This was followed by washing, staining and scanning, according to the 
standard Affymetrix protocol.   
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Figure 2.3: Hybridisation process. The labelled complementary RNA samples were added to an 
Affymetrix chip that contained different probes. The sample was then bound to the complementary 
sequence on the chip. Fully complementary strands bind strongly whereas partially complementary 
strands bind weakly and are washed away in the washing step. 
www.thefullwiki.org/Gene_chip_technology  
2.5. In vivo experiments 
2.5.1. Generating anti-MPO antibodies 
MPO-/- mice were immunised with MPO or other antigens such as BSA, recombinant 
MPO, MPO peptides, and MPO heavy chain to raise specific antibodies. They were 
immunised when they were 8-10 weeks old. We started the immunisation process by 
injecting the mice with 10 μg of MPO in complete Freud’s adjuvant on day 10. They were 
boosted with 5 μg of MPO in incomplete Freud’s adjuvant on days 21 and 36. All of the 
injections were s.c. injections. The tails of the mice were bled after the first boost to check for 
anti-MPO antibodies. The mice were sacrificed on day 42 and blood was collected via 
cardiac puncture. The blood was stored at 4ºC overnight. Then, the blood was centrifuged at 
2,000 rpm for 5 min and the serum was removed and stored at -80°C.  
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2.5.2. Murine Experimental Vasculitis  
The mice were injected with anti-MPO antibodies to induce crescentic glomerulonephritis. 
The specific treatment protocols are described in the relevant chapters. The mice were then 
injected with 1,500 EU/g of LPS 1 h after the first injection of anti-MPO antibodies via i.p. 
injections. The urine was collected on days 1 and 6 and the mice were sacrificed on day 6. 
Blood was collected via cardiac puncture. In addition, kidney, lung, liver and spleen tissues 
were also collected. They were snap frozen by embedding the tissue in OCT and then 
immersing it in iso-pentane in liquid nitrogen. Some of the tissues were also stored in 10% 
formalin saline for histological processing and analysis.  
2.5.3. Tissue collection and histological analysis  
The disease in these experiments was assessed by histological analysis and also by 
immunohistochemical staining. After culling the animals, I collected the kidney, liver, spleen 
and lung tissues and immediately fixed them in formalin for histological evaluation. In 
addition, the tissues were also snap frozen. Formalin-fixed tissues were sent to the histology 
department where they were sectioned. Periodic acid Schiff-stained and H&E sections were 
prepared and used to quantify crescentic glomerulonephritis. The histological scoring in 
these experiments was performed without any knowledge of the experimental conditions, 
and the sections were assessed by myself and Prof. Mark Little. Glomeruli were scored 
blindly as normal, mild (evidence of cell infiltration and ubnormal glomeruli), and severe ( 
evidence of necrosis, tuft disruption, and cresent formation). 
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Chapter 3 
Murine experimental vasculitis: establishing and improving the 
model 
 
3.1. Introduction 
Since the discovery of ANCA in 1982 (Davies, Moran et al. 1982), a lot of work has gone 
into trying to understand the pathogenesis behind ANCA-associated vasculitis and if ANCA 
are really pathogenic. In vitro evidence has shown the ability of ANCA to stimulate 
neutrophils to degranulate and release reactive oxygen species (Falk, Terrell et al. 1990). 
The binding of ANCA to the antigens on the surface of neutrophils results in the adhesion 
and migration of leucocytes across the endothelium, which results in injury to endothelial 
cells and underlying tissues. These in vitro findings are very important to help understand 
the pathogenesis behind ANCA-associated vasculitis, but these findings need to be 
confirmed in vivo using animal models. 
Animal models are considered to be a great tool in science and help in understanding the 
biology of different human diseases. Until recently, there was no animal model of vasculitis 
to help study the effect of ANCA on neutrophils and monocytes. We needed an animal 
model that resembles the human disease with circulating ANCA and crescentic 
glomerulonephritis, with no or little immune complex deposition. There were many attempts 
to produce an animal model of vasculitis, including the attempt by Brouwer et al. (Brouwer, 
Huitema et al. 1993) to induce crescentic glomerulonephritis in rats. Initially, they were not 
able to induce necrotising crescentic glomerulonephritis after immunising the rats with 
human MPO, even though these rats produced anti-MPO antibodies. However, subsequent 
administration of a neutrophil extract including MPO in combination with hydrogen peroxide 
(H2O2) resulted in severe crescentic glomerulonephritis. In this model, immune complexes 
were reported to be present shortly after kidney perfusion, but they seemed to disappear 
when kidney injury was at its peak. In a different study, Yang et al. found an association 
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between the degree of kidney injury in this model and the amount of IgG immune complex 
deposits, which suggests the involvement of immune complex deposition in the injury and 
not anti-MPO antibodies. This finding argues against this being a good model of AAV 
because immune deposition is absent in this disease, as shown by different investigators.  
The possibility of ANCA having a potentially pathogenic effect in ANCA-associated 
vasculitis was addressed by a model developed in 2002. Xiao et al. were able to produce a 
reliable model of ANCA-associated vasculitis with no immune deposition by immunising 
MPO knockout mice with murine MPO, purified from WEHI cells, and then injecting mouse 
splenocytes or IgG from these immunised mice into Rag2-/- mice or wild type mice (Xiao, 
Heeringa et al. 2002). Rag2-deficient mice developed severe renal lesions following injection 
of splenocytes from mice immunised with murine MPO and they also developed circulating 
anti-MPO antibodies. In addition, intravenous injection of anti-MPO antibodies into wild type 
or Rag2-/- mice resulted in the development of renal injury similar to that seen in humans, 
albeit much milder. 
Like all other animal models, this model needed to be modified to resemble the human 
disease because the disease in this model is moderate compared to human disease. One of 
the approaches to try and aggravate the disease was by using bacterial lipopolysaccharide 
(LPS). The idea came following experimental evidence indicating an association between 
infection and ANCA in vasculitis. Huugen et al. tested this hypothesis and they were able to 
increase renal injury in mice following anti-MPO IgG administration (Huugen, Xiao et al. 
2005). The severity of injury was LPS dose-dependant and they found that the minimum 
dose of LPS needed to induce significant increase in renal injury was 0.5 μg/g (1,500 EU/g). 
 In addition, Little et al. produced a rat model of vasculitis by immunising rats with human 
MPO (Experimental Autoimmune Vasculitis); these rats produced antibodies in response to 
the immunisation that cross-reacted with rat MPO (Little, Smyth et al. 2009). In an effort to 
improve their model, they increased the dose of MPO and they were also able to induce 
78 
 
disease in all the animals when they added pertussis toxin and killed Mycobacterium 
tuberculosis. It has been shown in these two models that another proinflammatory signal, 
beside ANCA, is necessary to induce full-blown disease. For example, the importance of 
LPS could be due to the increased level of TNF-α as shown in other murine models 
(Huugen, Xiao et al. 2005). TNF-α is a cytokine involved in systemic inflammation and it has 
been shown that priming human neutrophils with TNF-α is necessary to induce the 
respiratory burst in response to ANCA IgG. Indeed, blocking TNF-α in mouse model of 
vasculitis attenuated crescent formation (Huugen, Xiao et al. 2005). Little et al. have also 
shown a protective role of anti-TNF-α in a rat model where there was a reduction in 
albuminuria, crescent formation and lung haemorrhage (Little, Bhangal et al. 2006). The 
effect of TNF-α seen here could be through the involvement in leucocyte adhesion and 
transmigration because Little et al. have shown a reduction in leucocyte adhesion and 
transmigration following TNF-α treatment in vivo.    
One of the difficulties of the mouse model of ANCA-associated vasculitis is finding a 
reliable source of murine MPO. Unlike the rat model of vasculitis where the disease is 
induced by immunising the rats with human MPO, which is available commercially, the 
mouse model requires immunisation of MPO-/- mice with murine MPO to generate anti-MPO 
antibodies. The current source of murine MPO is WEHI-3 cells which are myelomonocytic 
leukaemia, macrophage-like, Balb/C mouse cells. These cells are used by different groups 
as a source of murine MPO which can be used to raise anti-MPO antibodies in MPO-/- mice 
and then induce disease in WT mice (Xiao, Heeringa et al. 2002; Huugen, Xiao et al. 2005; 
Xiao, Heeringa et al. 2005). Culturing these cells is extremely time-consuming and a large 
quantity of cells is required to produce a sufficient yield of murine MPO to immunise MPO-/- 
mice and raise anti-MPO antibodies. Another cell line that is being investigated now as a 
source of MPO is an IL-3 dependent cell line, 32Dc13. These cells have been found to 
express similar amounts of mouse MPO as mouse neutrophils following stimulation with 
mouse granulocyte colony stimulating factor (G-CSF) (Guchhait, Tosi et al. 2003). In 
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addition, the possibility of using recombinant mouse MPO was investigated by 
Apostolopoulos et al. (Apostolopoulos, Ooi et al. 2006). When the MPO-/- mice were 
immunised with the recombinant MPO, they produced anti-MPO antibodies that were found 
to react with native mouse MPO isolated from 32Dc13 cells.  
The aim of this work was to establish a mouse model of ANCA-associated vasculitis in 
our institute and find new ways to improve it. I looked at different ways to improve this model 
and, especially when it comes to finding a good source of MPO antigen to generate anti-
MPO antibodies. As it stands, the model is not used by many researchers because of its 
high costs and because the disease is moderate. As a result, I spent a lot of time trying to 
find a reliable source of MPO because the current approach required culturing and 
harvesting a large quantity of WEHI cells. This method of generating MPO is costly and time-
consuming. Therefore, I investigated the possibility of using recombinant mouse MPO or 
MPO multi-antigenic peptides to raise anti-MPO antibodies that react with native mouse 
MPO and induce disease in mice. In addition, the current approach of generating anti-MPO 
antibodies requires using a large number of MPO-/- mice for immunisation. I decided to do 
an experiment that could potentially lead to using fewer mice. I performed a maternal 
transfer experiment where a mother mouse immunised with MPO was mated with a WT 
male to produce heterozygous offspring that could potentially develop vasculitis. If the 
offspring developed vasculitis, fewer mice would be required for the experiment because 
there would be no need to immunise large numbers of MPO-/- mice with MPO to raise anti-
MPO antibodies. In the end, the disease in this model was moderate and I decided to use 
LPS to aggravate the disease.  
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3.2. Methods 
 
3.2.1. Mice Genotyping 
When I first started my PhD, I had to establish an MPO-/- colony to raise anti-MPO 
antibodies. We started the colony by mating MPO+/- mice; 25% of the litters were expected 
to be MPO-/-. To identify the MPO-/- mice, I had to genotype all the litters by extracting DNA 
from tissues that were obtained from these mice and then running the samples on PCR with 
MPO primers.  
DNA isolation 
DNA was isolated from animal tissues as previously described in Chapter 2. We mated 
MPO heterozygous mice to produce MPO knockout mice. In order to identify MPO knockout 
mice, I extracted DNA from all the animals. DNA was extracted from ear clippings that were 
obtained from all newborn mice and the DNA samples were then used for genotyping as 
described below. 
PCR preparation 
PCR was used to amplify the DNA, and MPO primers were used to ensure that only MPO 
was amplified. PCR mix was prepared containing Ready TAQ polymerase, buffer, dNTP 
Master Mix, MPO1 (5’ TGA-CAC-CTG-CTC-AGC-TGA-AT 3’), MPO2 (5’ TGC-AGG-CAG-
CTG-GTC-TCG-CA- 3’), MPO3 (5’ CTA-CCG-GTG-GAT-GTG-GAA-TGT- 3’), and nuclease-
free water. The concentrations of these reagents are shown in Table 3.1.  
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Table 3.1: Preparing PCR mix. 
Reagent Volume Stock concentration Final concentration 
10* Buffer 5 µl - 1× 
dNTP 5 µl 10 mM 1 mM 
MPO1 2.5 µl 10 µM 0.5 µM 
MPO2 2.5 µl 10 µM 0.5 µM 
MPO2 2.5 µl 10 µM 0.5 µM 
TAQ 2.5 µl - 0.05 unit/µl 
Water 30 µl - - 
 
After that, samples were run on PCR using the settings shown in Table 3.2. The primers 
anneal to the target DNA and amplify it; these products can be seen as bands when run on 
2% gel electrophoresis. When the MPO-/- mice were identified, they were mated to establish 
the MPO-/- colony. 
Table 3.2: PCR setting for mice genotyping. 
Temperature (°C) Time Number of cycles 
95 5 min 1 
94 1 min 35 
60 1 min 35 
72 1 min 35 
72 5 min 1 
10 Hold - 
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Confirming MPO-/- mice by indirect immunofluorescence 
In order to be completely sure that I had correctly identified the MPO-/- mice, I used 
indirect immunofluorescence to confirm MPO-/- mice. I sacrificed two wild type, four 
heterozygous, and one MPO-/- mice. Blood was collected from these mice by cardiac 
puncture, from which I created mixed leucocyte cytospins. Each slide had two spots; one 
spot was coated with 20 µl (100 µg/ml) of murine anti-BSA (a kind gift from Sarah Nolan) 
and the second spot was incubated with 20 µl (100 µg/ml) murine anti-MPO antibody (kindly 
provided by Dr. Peter Heeringa). The slides were incubated for 30 min in a moist chamber. 
Then, the slides were washed three times in PBS. Next, 20 µl of anti-mouse IgG FITC (1:20, 
Dako, UK) was added to each spot and incubated for 30 min. Slides were then washed and 
images were acquired with a fluorescent microscope.  
3.2.2. Pilot experiment to evaluate the possibility of inducing AAV in mice (MEV1) 
I decided to perform a pilot experiment to test the feasibility of inducing vasculitis in mice 
and also to test the efficacy of liposomal clodronate in depleting macrophages. The aim of 
this experiment was to make sure that we had a good animal model on our hands to use in 
future experiments. Six wild type mice on a C57BL/6J background were used in this 
experiment and divided into two groups (Table 3.3). All animals were treated with the 
intravenous anti-MPO antibodies, purified as described in the methods section, in an effort to 
induce systemic vasculitis.  
We started by injecting these mice intravenously (IV) with either 100 µl clodronate or 100 
µl saline 48 hours prior to the first anti-MPO antibody injection (day -2). In addition, these 
mice were injected with either clodronate or saline on days 0, 2, 4, and 7 (Figure 3.1). All the 
mice received 50 µg/g anti-MPO antibodies intravenously on days 0 and 3 (Figure 3.1). 
These mice were put in metabolic cages to collect urine on day 8 and sacrificed on day 9. 
Blood was obtained by cardiac puncture. Kidney, liver, spleen, and lung were stored in 
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formalin for later sectioning and staining, and the same tissues were snap-frozen in liquid 
nitrogen and stored at -80°C.  
Table 3.3: Mice that were used in the MEV1 experiment. Mice treated with clodronate (red) or 
saline (black). 
 
 
Figure 3.1: The design of the pilot MEV experiment. Mice were injected with 50 µg/g of i.v. anti-
MPO antibody on days 0 and 3. Some of the mice received 100 µl of liposomal clodronate (LC) on 
days -2, 0, 2, 4, and 7. 
 
3.2.3. Using anti-MPO antibodies and LPS to induce vasculitis in mice (MEV2)  
As MEV1 was characterised by relatively mild vasculitis, I embarked on a second 
experiment using an adjusted protocol that made use of an additional LPS step. We decided 
Mouse Age (weeks) Sex Weight Group 
1 16 M 30.2g 1 
2 16 M 33.3g 2 
3 16 F 22.7g 1 
4 16 F 22.5g 2 
5 12 M 25.0g 1 
6 10 M 24.7g 2 
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to use LPS to stimulate the immune system in mice and produce more severe disease. LPS 
was measured as previously described and stored at -80°C. On the day of the experiment, 
LPS was taken and diluted to 1,500 EU/g in water for injection. I used 10 mice in this 
experiment (figure 3.2): five were injected with 75 μg/g anti-MPO antibodies and five with 75 
μg/g anti-BSA antibodies. I was not able to give 75 µg/g in one day because of limitations of 
the project licence. As a result, the mice received an i.v. injection of 50 µg/g on day 0 and 25 
µg/g on day 3 of either anti-BSA or anti-MPO antibody. In addition, mice received LPS 
(1,500 EU/g IP) 1 hour after the first antibody injection on day 0. Mice were put in metabolic 
cages on day 5 for urine collection and they were culled on day 6. The urine was tested for 
haematuria on days 1 and 6 using multistix for urinalysis. Kidney, lung, liver, and spleen 
sections were obtained from all of these mice at day 6 and they were either fixed in formalin 
or snap frozen in liquid nitrogen for use in the histological analysis. 
 
 
Figure 3.2: Experimental design of MEV2. Mice received 75 μg/g of either anti-MPO (n=5) or anti-
BSA (n=5) antibodies on day 0 and 3 through i.v. injection. All the mice received 1,500 EU/g of LPS 
through i.p. injection on day 3. Urine was collected on day 1 and 6 and mice were culled on day 6.  
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3.2.4. Alternative approaches to raising anti-MPO antibodies  
I investigated the possibility of finding another source of MPO to generate anti-MPO 
antibodies. I used three approaches to raise anti-MPO antibodies: multi-antigenic MPO 
peptides, recombinant mouse MPO, and MPO heavy chain. All of these are commercially 
available and could make the model more accessible if they work.   
3.2.4.1. Induction of MEV using antibodies raised against MPO multi-antigenic 
peptides 
In an effort to use an alternative to the laborious and expensive approach of purifying 
native MPO from cells, I tried to use MPO peptides to raise anti-MPO antibodies. Three 
MPO peptides were recommended by the Binding Site (Dr. Phil Stubbs) and produced by 
Alta Bioscience at the University of Birmingham. The sequences of the three peptides used 
here are as follows: 
Peptide Sequence 
1 VTCPPNDKYRTITGHCNNRR-(MAPs) 
2 PAEYEDGVSMPFGWTPGVNRNG-(MAPs) 
3 LNCETSCLQQPPCFPLKIPPND- (MAPs) 
 
We selected these peptides for the following reasons: VTCPPNDKYRTITGHCNNRR-
(MAPs) was selected as it is at the N-terminus of the MPO light chain. 
LNCETSCLQQPPCFPLKIPPND-(MAPs) was selected as it is at the N-terminus of the MPO 
heavy chain. These were selected by the Binding Site because from previous use of peptide 
MAPs, it was found that N-terminal sequences often give a good antibody response, with 
antibodies recognising the target protein. PAEYEDGVSMPFGWTPGVNRNG-(MAPs) was 
selected as it covers a “loop” region in the X-ray structure of the protein. As there is no 
published X-ray structure of mouse MPO, human MPO was used and sequence alignment 
was performed using the GCC package. This sequence was extended beyond this loop with 
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the aid of hydrophilicity, surface probability and flexibility predictions (using the 
“peptidestructure” programme, part of the GCC Wisconsin package). Exposed loops are a 
good target for antibodies on the surface of a protein. All the peptides were synthesised as 
8-branch multi-antigenic peptides (MAPs). Eight copies of the sequence were synthesised 
directly onto a poly-lysine core. This increases the molecular size of the peptide, overcoming 
the need for a carrier protein, and avoiding the generation of non-specific anti-carrier protein 
antibodies. Peptides were dissolved in 0.1 M acetic acid to a final concentration of 4 mg/ml. 
The three peptides were mixed before immunisation and the mice were divided into three 
groups (Figure 3.3). Each group received different concentrations of the MPO peptides to 
test the ability of these peptides to raise anti-MPO antibodies against native mouse MPO. 
Mice were immunised as described in the general methods section.  
These doses of MPO peptides (40, 200, and 400 μg) were selected to induce a high level 
of anti-MPO antibodies. Brouwer et al. have demonstrated that immunising WKY rats with 10 
μg of hMPO induced anti-MPO antibodies, but not vasculitis (Brouwer, Weening et al. 1993). 
However, Little et al. have shown that a greater dose of human MPO was required to induce 
vasculitis in rats and that a dose of 1,600 μg/kg reliably induced vasculitis. As a result, I 
decided to start with this dose to immunise MPO-/- mice with MPO peptides, which was 
around 40 μg for a mouse. In addition, I decided to use greater doses because this was the 
first time these peptides were used for immunisation and we did not know what to expect.  
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Figure 3.3: Immunising MPO-/- mice with multi-antigenic peptides. Mice were immunised with 
different doses of multi-antigenic peptides: 400 μg (n=8), 200 g (n=6), 40 μg (n=7). These were the 
first doses on day 0 in complete Freund’s adjuvant (S/C). They were boosted on days 21 and 36 in 
incomplete Freund’s adjuvant.   
In this experiment, I tried to test the ability of anti-MPO antibodies derived from MPO-/- 
mice that were immunised with multi-antigenic murine MPO peptides. I wanted also to 
compare them to anti-MPO antibodies from mice immunised with murine MPO. I used these 
antibodies to induce vasculitis in C57BL/6J mice using a comparable protocol to that used in 
MEV2. I used four mice in this experiment: two mice were injected with 75 μg/g of anti-MPO 
peptides and two mice were injected with 75 μg/g of anti-murine MPO antibodies. The mice 
also received 1,500 EU/g of LPS.  
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 Group 1 Group 2 
No. of Mice two mice two mice 
Treatment 
 
 
 
 75 µg/g anti-
mMPO 
antibody on 
day 0 
 1,500 EU/g of 
LPS after 1 
hour 
 
 
 75 µg/g anti-
pMPO 
antibody on 
day 0 
 1,500 EU/g of 
LPS after 1 
hour 
 
 
3.2.4.2. Immunising with recombinant mouse MPO 
I also tried using recombinant mouse MPO (R&D systems, Abingdon, UK). We decided to 
try this approach following a study by an Australian group where they immunised MPO-/- 
mice with recombinant mouse MPO; these mice mounted a significant antibody response to 
native mouse MPO (Apostolopoulos, Ooi et al. 2006), but this protocol was not used to 
induce disease in mice because they were only interested in producing the recombinant 
MPO. Mice were immunised with recombinant mouse MPO as previously described; 19 mice 
were used in this experiment. Mice were injected with 10 μg of recombinant MPO on day 0 in 
complete Freund’s adjuvant and boosted on days 21 and 36 (Figure 3.4). 
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Figure 3.4: Immunising MPO-/- mice with recombinant MPO. MPO-/- mice (n=19) were immunised 
with recombinant mouse MPO. They received 10 μg (same dose used by Apostolopoulos et al.) in 
complete Freund’s adjuvant on day 0 and were boosted (with half the dose) on days 21 and 36 in 
incomplete Freund’s adjuvant.  
3.2.4.3. Immunising with MPO heavy chain 
I also tried immunising the mice with MPO heavy chain (Insight Biotechnology Limited, 
Middlesex, UK). This antibody was used previously by Kuligowski et al. (Kuligowski, Kwan et 
al. 2009) to raise anti-MPO antibodies in MPO-/- mice which were used to study neutrophil 
adhesion in vivo. Mice were divided into two groups. Mice in group 1 received 5 μg (the 
same dose used by Kuligowski et al.) of MPO on day 0 in complete Freund’s adjuvant and 
were boosted on day 7 with 5 μg of MPO in incomplete Freund’s adjuvant; they were culled 
on day 14 (this is the same immunisation protocol used by Kuligowski et al.). The mice in 
group 2 were immunised with 20 μg on day 0 in complete Freund’s adjuvant and boosted 
with 5 μg on day 21 in incomplete Freund’s adjuvant, and then were sacrificed on day 42 
(Figure 3.5). Blood was collected from these mice by cardiac puncture.  
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Figure 3.5: Immunisation with MPO heavy chain (L-20). Mice were divided into two groups. A: 
mice were immunised with 5 μg of L-20 at day 0 in complete Freund’s adjuvant, boosted at day 7 and 
sacrificed at day 14. B: mice in group 2 were immunised with 20 μg at day 0, boosted on day 21 and 
sacrificed at day 42.   
3.2.5. Induction of MEV by maternal trans-placental transfer of anti-MPO antibodies 
In an effort to reduce the number of mice required and to remove the IgG purification 
step, we investigated the possibility of inducing vasculitis in newborn litters. In order to do 
that, we immunised MPO-/- females with MPO peptides and monitored the level of anti-MPO 
antibodies. We selected two females with the highest titre of anti-MPO antibodies as 
measured by ELISA. These females were mated with wild type males, which meant that all 
of the offspring should be heterozygous for MPO and express normal amounts of MPO. The 
offspring were sacrificed on day 21 to examine them for evidence of vasculitis. In addition, 
selected animals were sacrificed at earlier time points (day 2) to ascertain the kinetics of the 
passively transferred anti-MPO antibody (Figure 3.6).  
91 
 
 
Figure 3.6: Induction of MEV by maternal trans-placental transfer of anti-MPO antibodies. MPO-
/- females (n=2) that were immunised with 400 μg of multi-antigenic peptides were mated with WT 
males. The offspring were sacrificed either at day 2 or day 21; they received 1,500 EU/g of LPS once 
a week if they were sacrificed at day 21. 
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3.3. Results 
 
3.3.1. Mice Genotyping 
All the litters from mated MPO+/- pairs were genotyped using PCR. I used three MPO 
primers. If the size of the band was 400 kb, then the mouse was MPO-/- (Figure 3.7, B). On 
the other hand, MPO+/+ mice were identified by a band at 600 kb (Figure 3.7, C). MPO+/- 
mice had two bands at 600 and 400 (Figure 3.7, A). At the beginning, I did not get any 
results from genotyping the first batch, but after optimising my technique and using fresh 
samples, I was able to genotype all the mice. I started by trying to increase the amount of 
DNA in each well, but that did not work. Then I started changing the concentration of 
reagents such as dNTP, Taq polymerase, and MPO primers. There were still no clear bands, 
so I decided to extract DNA from fresh samples. I got strong bands when I used fresh 
samples; this meant that the DNA must have degraded in the old samples.  
 
Figure 3.7: Mouse genotyping using PCR. PCR was effective in identifying the genotype of the 
mice. Two bands were produced from MPO+/- mice (A) and the sizes of these bands were 600 KD 
and 400 KD. MPO-/- mice were identified by one band with size of 400 KD (B). On the other hand, a 
600KD band was produced from MPO+/+ mice (C). 
500 
C B A 
500 KD 
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3.3.2. Confirming MPO-/- mice 
Indirect immunofluorescence on peripheral leucocyte cytospins was done to confirm the 
absence of MPO in MPO-/- mice. Anti-BSA antibody was used as the control. If MPO was 
present in neutrophils, then anti-MPO antibodies will bind to it and will give a bright green 
colour when stained with anti-mouse IgG-FITC. This was seen when leucocytes from 
MPO+/+ and MPO+/- mice were incubated with 100 µg/ml anti-MPO antibody and then 
stained with FITC (Figure 3.8, B and D). On the other hand, neutrophils from MPO-/- mice 
should not have any MPO and therefore no bright green fluorescence (Figure 3.8, F). MPO-
/- mice were confirmed by both PCR and indirect immunofluorescence and these mice were 
used to establish an MPO knockout colony which was of sufficient size to begin the 
generation of anti-MPO antibodies.  
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Figure 3.8: Indirect immunofluorescence to identify MPO-/- mice. A and B: mixed leucocytes from 
an MPO+/- mouse were incubated with (A) anti-BSA antibodies and (B) with anti-MPO antibodies. C 
and D: mixed leucocytes from an MPO+/+ mouse were incubated with anti-BSA antibodies (C) and 
with anti-MPO antibodies (D). E and F: mixed leucocytes from an MPO-/- mouse were incubated with 
anti-BSA antibodies (E) and with anti-MPO antibodies (F). Anti-mouse IgG-FITC was used for 
staining. 
3.3.3. MPO activity assay and culturing WEHI Cells 
An MPO activity assay was used to determine the presence and the concentration of 
MPO in WEHI cells because I needed to confirm the presence of MPO in these cells before 
we started isolating MPO from them. This was also done to make sure that the concentration 
of MPO did not drop over time. The assay was also used to compare the MPO concentration 
in WEHI cells that were cultured under two different conditions (static and rolling conditions). 
MPO from human leucocytes (Calbiochem, UK) was used to create a standard curve, which 
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was used to estimate the concentration of MPO from WEHI cells. The MPO 
concentration/million cells was measured once a week from WEHI cells that were cultured 
under either static or rolling conditions. The MPO concentration was relatively higher when 
WEHI cells were cultured under rolling conditions compared to the MPO concentration from 
WEHI cells that were cultured under static conditions (Figure 3.9, A). We also found that it 
was markedly less expensive to culture these cells using bioreactors because less medium 
and FCS was required (results not shown). In addition, the cell yield was higher when cells 
were cultured under rolling conditions. 
 
Figure 3.9: WEHI cells under static and rolling conditions. The MPO concentration in WEHI cells 
that were cultured under static and rolling conditions was monitored during cell culture using an MPO 
activity assay. A: MPO concentration (ng/million cells) over time from WEHI cells under static and 
rolling conditions. B: comparing the MPO concentration in ng/million cells from WEHI cells that were 
cultured under static and rolling conditions; these tests were done on different days. A t-test was used 
to determine statistical significance. 
3.3.4. Optimisation of MPO isolation from WEHI cells 
Following con-A extraction as described in the general methods section, I loaded my 
samples onto the Mono-S column. I first loaded all eluate 1 from all samples (SN1, SN2, P1, 
and P2) and I pooled eluates 2 and 3 together from all samples and loaded them in the 
second run. Most of the MPO was in the first run, and it was identified by the high green 
peak (Figure 3.10, A) which represents the absorbance at A430. On the other hand, samples 
in the second run had only tiny amounts of MPO, as shown by the small peak (Figure 3.10, 
B). Most of the MPO was collected in eluate which had the highest A430 value. 
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Figure 3.10: MPO isolation from WEHI cells using the Mono-S column. The green peak in the 
graph shows the dissociation of MPO from the column and it also shows the absorbance at A430. 
Most of the MPO was collected in eluate 1 (E1), as shown by the green peak. The blue peak 
represents the total protein absorbance at A280. 
SDS-PAGE and Western blot were performed to assess the purity of the MPO (Figure 
3.11). The first run contained all E1 samples. The second run contained E2 and 3 from all 
samples. Most of the MPO was in the first run, as shown by the strong band of E1, which 
was supported by the green colour and the absorbance at A430 and A280. Other elution 
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fractions had some MPO in addition to many contaminants. The band in E1 had a similar 
size to the control commercial human MPO.  
 
 
Figure 3.11: SDS-PAGE for murine MPO. This figure shows the SDS-PAGE that was done for 
different elution fractions from two separate runs in the Mono-S column. E1-E5 in the first run are 
different elution fractions that were collected after eluting the MPO from the column after loading the 
first batch. E2-E7 in the second run are different elution fractions that were collected after eluting the 
MPO from the Mono-S column after loading the second batch. E1 in the first run had most of the 
MPO, as shown by the strong band at 50 kD, which had similar size to hMPO. WEHI lysate is the 
supernatant from WEHI cells that were lysed with 0.3% triton. The unbound sample is the run-through 
that was collected from the column and did not bind to the column.  
3.3.5. Immunising MPO-/- mice with murine MPO 
 
MPO knockout mice were immunised with murine MPO isolated from WEHI cells to raise 
anti-MPO antibodies. Day 42 serum was pooled together from all MPO-immunised mice and 
then I used anti-MPO ELISA to measure the level (Figure 3.12, A) and titre (Figure 3.12, B) 
of anti-MPO antibodies. The titre of anti-MPO antibodies (EC50) was 679.4.  
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Figure 3.12: The level of anti-MPO antibodies in MPO-/- mice. Mice were immunised with MPO or 
BSA and the production of anti-MPO antibodies was detected in the serum using an anti-MPO ELISA. 
A high level of anti-MPO antibodies was detected in the pooled serum from MPO-immunised mice 
compared to BSA-immunised mice at 1:100 dilution (A). The titre of anti-MPO antibodies was 
calculated using non-linear regression analysis (B). The anti-MPO titre was 679.  
3.3.6. Anti-MPO antibody (IgG) isolation from mouse serum 
We used murine MPO to immunise MPO-/- mice and to generate anti-MPO antibodies. 
Blood was obtained from the immunised mice on day 42 and then serum was collected after 
leaving the blood to clot. Serum was then run on a protein G column. A sample 
chromatogram from protein G affinity chromatography is depicted in Figure 3.13.  
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Figure 3.13: IgG isolation from murine serum using protein-G column. The red line represents 
the pH. When the elution buffer was added to the column, the pH dropped and IgG started to 
dissociate from the column. The small blue peak (arrow) represents the dissociation of the IgG from 
the column after adding the elution buffer, and eluates were collected at this point. This graph 
represents two runs and the two small peaks represent the dissociation of IgG from the column from 
the two runs. 
SDS-PAGE was done to confirm the presence of IgG. One band at 160 kD appeared on a 
non-reduced gel (Figure 3.14, A) and the heavy chain and light chain were seen on the 
reduced gel (Figure 3.14, B), thereby confirming the presence of acceptably pure IgG, which 
means that there was no contamination of other proteins. 
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Figure 3.14: SDS-PAGE for anti-MPO antibody. A: non-reduced SDS-PAGE and B: reduced SDS-
PAGE. In the reduced one, there is one band at about 160 kD. On the other hand, there are two 
bands on the reduced one and these bands are about 50 kD (heavy chain) and 20 kD (light chain). 
The results from this confirm the presence and the purity of IgG.  
3.3.7. Pilot experiment to evaluate the possibility of inducing AAV in mice (MEV1) 
 After confirming that I had generated high titres of anti-MPO antibodies, I passively 
transferred these into wild type recipients. Urine was collected from all of the mice in the 
MEV1 experiment on day 8 and was tested for haematuria using a dipstick. One mouse from 
the saline group had blood present in the urine and the other mice from the control group 
showed traces of blood. On the other hand, mice from the clodronate-treated group showed 
negative results when tested for blood in the urine (Table 3.4).  
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Table 3.4: Testing for blood in urine using dipstick. Mice in clodronate treated group showed 
negative results. 
 
Mouse Treatment Haematuria 
17 Liposomal clodronate No urine 
23 Saline +2 
24 Liposomal clodronate Negative 
27 Saline Trace 
39 Liposomal clodronate Negative 
59 Saline Trace 
 
3.3.7.1. Monitoring anti-MPO antibodies level in MEV1 
The level of passively transferred anti-MPO antibodies in the mice that were used in the 
MEV1 experiment was also measured using anti-MPO ELISA. I included serum from WKY 
rats immunised with human MPO to the plate coated with murine MPO. These rats develop 
glomerulonephritis when they are immunised with hMPO and produce anti-MPO antibodies. I 
found that these antibodies cross-reacted with murine MPO. On the other hand, human 
MPO-ANCA did not react with murine MPO. I was able to detect anti-MPO antibodies in the 
mice that were injected with anti-MPO antibodies (Figure 3.15, A). A dilution curve was also 
constructed to calculate the antibodies titre, which was (71-92) (Figure 3.15, B). This 
represents the point where the dilution resulted in 50% drop of OD value compared to the 
highest OD. 
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Figure 3.15: Measuring anti-MPO antibodies in MEV1 mice. All the mice received the same 
concentration of anti-MPO antibodies and then either received clodronate or saline. A: Anti-MPO 
antibodies level in MEV1 mice and in MPO-/- mice immunised with MPO, MPO-/- mice immunised 
with BSA, human ANCA, and serum from a rat immunised with hMPO. B: Dilution curve to calculate 
antibody titres using non-linear regression analysis.  
3.3.7.2. Histology analysis from pilot experiment 
We expected that crescents would appear in 5% of the glomeruli in the kidneys from the 
mice not receiving clodronate. However, most of these mice were healthy and showed only 
mild glomerulonephritis (Figure 3.16, D). Only one mouse (from the saline-treated group) 
had evidence of crescents. None of the clodronate-treated mice displayed 
glomerulonephritis. (Figure 3.16, A). I also saw abnormal glomeruli in both groups, but this 
was relatively more frequent in the control group (Figure 3.16, C).  
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Figure 3.16: Histological appearance of glomeruli in the MEV1 experiment. All the mice in this 
experiment received two doses of anti-MPO antibody. Some of these mice received liposomal 
clodronate to deplete macrophages (n=3), while the others received saline and were used as the 
control (n=3). A: Crescent formation in glomeruli was seen in one of the mice that received saline. B: 
Normal glomerulus from a mouse that received clodronate. C: Abnormal glomeruli were seen in the 
kidney of a mouse that received saline. D: This graph represents the histological appearance of the 
kidneys in all six mice that were used in this experiment. The p value represent the difference in 
cresent formation between the two groups (Mann-Whitney test) 
3.3.8. Induction of AAV using anti-MPO antibodies and LPS (MEV2) 
Mice in the MEV2 experiment received 75 µg/g of either anti-MPO or anti-BSA antibody 
and all received 1,500 EU/g of LPS. I collected urine from all the mice in MEV2 on days 1 
and 6 to assess kidney function. All the mice that received anti-MPO antibodies had 
haematuria on days 1 and 6; the score was between +3 to +4 on day 1 and between 0 to +4 
on day 6. On the other hand, all the mice that received anti-BSA antibodies had negative 
haematuria on days 1 and 6, except for one mouse (Figure 3.17, A). There was a significant 
difference in the albumin:creatinine ratio between anti-MPO- and anti-BSA-treated mice 
(Figure 3.17, B). All the mice that received anti-MPO antibodies developed crescentic 
glomerulonephritis (Figure 3.18, A). On the other hand, none of the mice that received anti-
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BSA antibody developed crescentic glomerulonephritis. The percentage of crescents in the 
mice that were injected with anti-MPO antibody was variable with a mean percentage of 
crescentic glomeruli of 13.4% (4%-30%). In addition, glomerular necrosis was seen in some 
of the mice that received anti-MPO antibody (Figure 3.18, B). On the other hand, most of the 
glomeruli from the mice that received anti-BSA antibody were normal (Figure 3.18, C).  
 
Figure 3.17: Urine analysis in MEV2. All the mice that received anti-MPO antibodies (n=5) (75 μg/g) 
had haematuria on days 1 and 6 compared to only one mouse that had haematuria from the anti-
BSA-treated mice (n=5) (A). In addition, there was a significant difference (p<0.05) between anti-
MPO- and anti-BSA-treated mice in the albumin:creatinine ratio (B). One tailed t-test (Mann-Whitney 
test).   
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Figure 3.18: Histological analysis of kidney sections from MEV2 (H&E stain). Mice received 75 
µg/g of either α-MPO or α-BSA antibody i.v. A: Crescentic glomerulonephritis (arrowhead) in a mouse 
injected with 75 µg/g of α-MPO antibody (n=5). B: Glomerular necrosis (arrowhead) in a mouse 
injected with 75 µg/g of α-MPO antibody. C: Normal appearing glomerulus in a mouse injected with 75 
µg/g of α-BSA antibody (n=5). D: Statically significant differences between groups in the percentage 
of crescents were assessed by a t-test (Mann-Whitney test). 
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Figure 3.19: Further histological sections from anti-MPO- and LPS-treated mice. Histological 
sections from mice that were injected with 75 μg/g of anti-MPO antibodies and 1,500 EU/g of LPS. 
These mice developed severe crescentic glomerulonephritis and necrosis. PAS staining (A, B, E, and 
F), and H&E staining (C and D).  
Immunohistochemical staining 
Macrophage infiltration in the kidney was identified by CD68 immunohistochemistry 
staining. All mice that received anti-MPO antibodies had positive staining for CD68 (Figure 
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3.20, A and C) and none of the mice that received anti-BSA antibodies (Figure 3.20, D) had 
CD68 positive staining. CD68 positive cells in the kidney were found mainly in the crescent 
area in the glomeruli (Figure 3.20, A and C).   
 
Figure 3.20: CD68 staining on MEV2 frozen kidney sections. Anti-MPO treated mice had positive 
staining for CD68 (A) and (C). CD68 positive cells were mainly found in the crescent area in the 
glomeruli (arrows). B: IgG2b negative control on kidney section from an anti-MPO treated mouse. D: 
anti-BSA treated mouse showing negative staining for CD68.  
I counted the total number of CD68 positive cells in the kidney sections (in both in the  
glomeruli and tubulo-interstitium); there was a significant difference between the anti-MPO- 
and anti-BSA-treated mice (Figure 3.21, A). In addition, I found a positive correlation 
between the number of CD68 positive cells and percentage of crescents in the anti-MPO-
treated mice (Figure 3.21, B).   
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Figure 3.21: CD68 count in MEV2. The number of CD68 positive cells was counted using Aequitas 
1A software. There was a significant difference between anti-MPO- (n=5) and anti-BSA-treated (n=5) 
mice in the number of CD68 positive cells (A) (two-tailed t-test (Mann-Whitney test)). Also, there was 
a positive correlation between the number of CD68 positive cells and the percentage of crescents in 
anti-MPO treated mice (B).   
3.3.9. MEV6 and immunising mice with MPO peptides and recombinant MPO 
Immunising MPO-/- mice with MPO peptides 
Mice were immunised with MPO peptides to try and raise anti-MPO antibodies that cross-
react with murine MPO. Three MPO peptides were used in this experiment and they were 
given at different doses. I performed an anti-MPO ELISA to check for anti-MPO antibodies in 
the serum of these mice. The plate was coated with murine MPO purified from WEHI cells. 
The titre of anti-MPO antibodies was EC50= 40.64 at the (40+20 mg) dose, EC50= 84.28 at 
the (200+100 mg) dose, and EC50= 66.05 at the (400+200 mg) dose. The titre was low when 
the plate was coated with murine MPO as shown in Figure 3.22. I isolated IgG from these 
immunised mice and injected 75μg/g of antibody plus 15000EU/g of LPS into WT mice but 
they did not develop any disease on day 6.  
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Figure 3.22: Anti-MPO ELISA on serum from MPO peptide-immunised mice. Mice were divided into 
three groups. Each group received a different concentration of MPO peptides on day 0 and were then 
boosted with half the dose on day 21. The level of anti-murine MPO antibodies generated by these 
mice was much less than that generated from a mouse immunised with murine MPO. A: The titre was 
calculated from the dilution curve using non-linear regression analysis. B: Pooled serum from the mice 
in the three groups and their OD value. C: Individual mice that were immunised with 400+200 μg of 
MPO peptides. Plate was coated with murine MPO.  
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Immunising MPO-/- mice with recombinant mouse MPO 
Mice were immunised with recombinant mouse MPO to raise anti-murine MPO 
antibodies. In order to detect the anti-MPO antibodies generated by these mice, I coated two 
plates with either recombinant MPO or murine MPO. I used serum from MPO-/- mice that 
were immunised with murine MPO as a positive control and also used serum from mice that 
were injected with 75 μg/g of anti-MPO antibodies to induce vasculitis. There was a high titre 
of anti-recombinant MPO (plate coated with recombinant MPO) in the MEV6 mice serum 
(immunised with recombinant MPO) (Figure 3.23, A). On the other hand, the titre of anti-
murine MPO in the serum from MEV6 was low and significantly less than that from anti-MPO 
antibodies injected mice (Figure 3.23, B).  
 
Figure 3.23: Titre of anti-recombinant and anti-murine MPO in MEV6. Plates were coated with 
either recombinant MPO (A) or murine MPO (B). A serial dilution was done to calculate the titre of 
anti-MPO antibodies. The titre was calculated from the log dilution by indicating the point where the 
OD value drops below 50% using non-linear regression analysis. There was no significant difference 
in the titre of anti-rMPO between rMPO immunised (MEV6) and anti-MPO treated mice (MEV2 and 
MEV8). However, there was a significant difference in the titre of anti-murine MPO between MEV6 
and MEV2 or MEV8. Non-linear fit was used to calculate the titre. An unpaired t-test was used to 
analyse the differences between the groups.  
 
 
111 
 
Injecting WT mice with anti-rMPO antibodies 
I used the anti-recombinant MPO generated by immunising MPO-/- mice with 
recombinant MPO to induce vasculitis in WT mice. Mice were injected with 50 μg/g of either 
anti-recombinant MPO or anti-BSA antibodies; they also received 1,500 EU/g of LPS. Mice 
were sacrificed on day 6 and blood was collected for anti-MPO ELISA. These mice had a 
detectable level of anti-rMPO antibodies with an antibody titre between 87-166 for all the 
animals that were treated with anti-rMPO antibodies (Figure 3.24). The histological sections 
from these mice looked normal and there were no crescents (Figure 3.25).  
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Figure 3.24: The level of anti-MPO antibodies in mice treated with anti-rMPO. A: Dilution curve to 
measure the titre of anti-rMPO antibodies at day 6 post antibody injection. The EC50 was between 87 
and 166 in mice injected with anti-rMPO antibodies using non-linear regression analysis. B: The anti-
MPO titre in mice injected with r-MPO compared to murine MPO-immunised mice and r-MPO-
immunised mice that were used as the positive control. The plate was coated with rMPO.   
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Figure 3.25: Histological sections from mice treated with anti-rMPO. Mice were treated with 50 
μg/g of anti-rMPO; none developed crescents. A and B showing normal glomeruli from anti-rMPO 
treated mice at 20x and 60x. 
Maternal transfer experiment (MEV4): 
Two female MPO-/- mice that were immunised with MPO peptides (400+200mg) were 
mated with WT males. The newborn mice were either sacrificed on day 2 or day 21. The 
mice that were sacrificed at day 21 were injected with 1,500 EU/g of LPS once a week. I 
measured the level of anti-MPO peptides in these mice using an anti-MPO ELISA coated 
with MPO peptides. These newborn mice had a detectable level of anti-MPO peptides in the 
serum on day 2 and day 21. The titre of anti-MPO peptides was 1960 on day 2 and 2251 on 
day 21 (Figure 3.26). The histological sections from these newborn mice were normal and 
no crescents were seen (Figure 3.27).  
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Figure 3.26: The level of anti-MPO peptides in maternal transfer experiment. A dilution curve was 
used to measure the titre of anti-MPO peptides in 2-day-old and 21-day-old mice from a mother 
immunised with MPO peptide (A). Pooled serum from MPO peptide-immunised mice, rMPO-
immunised mice, and mMPO-immunised mice used as the positive control. Newborn mice had anti-
MPO titre of 1960 on day 2 and 2251 on day 21 (B). Non-linear regression analysis. Plate was coated 
with MPO peptides.  
 
Figure 3.27: MEV4 histology results. Kidneys were fixed in formalin and sections were prepared 
and stained with H&E. The kidney sections from these mice were normal.  
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3.4. Discussion 
The aim of this work was to induce AAV in mice using anti-MPO antibodies raised in 
MPO-/- mice and also to test different methods for generating anti-MPO antibodies. First, I 
injected six mice with 100 μg/g of anti-MPO antibodies; they also received either clodronate 
or saline. The disease was very mild and only one mouse had crescents, at a rate of 1.4%. I 
moved on to do another experiment using anti-MPO antibodies and LPS. I injected five mice 
with anti-MPO antibodies and five mice with anti-BSA antibodies; I also injected all the mice 
with 1,500 EU/g of LPS. Mice that received anti-MPO antibodies developed crescentic 
glomerulonephritis at a percentage of around 13%. Macrophages were present in the kidney 
and they were found mainly in the crescent region of the glomeruli, as shown by CD68 
staining. We also looked at different approaches to generate anti-MPO antibodies. I 
immunised MPO-/- mice with MPO peptides, MPO heavy chain, or recombinant mouse 
MPO. Although I was able to detect anti-MPO antibodies after immunising the mice with 
these antigens, I was not able to induce disease in WT mice. 
WEHI cells were previously used by Xiao et al. (Xiao, Schreiber et al. 2007) as a source 
of MPO which we need for immunising MPO-/- mice to produce anti-MPO antibodies. I 
started culturing these cells in large 1 litre flasks that required large volumes of medium and 
FCS. The yield was higher when cells were cultured using a bioreactor and less FCS was 
required compared to the other technique. Less FCS was required because a bioreactor has 
a membrane that separates the cells that were re-suspended in medium with FCS from the 
feeding medium (no FCS); this membrane allows fluid to pass through. On the other hand, I 
had to use medium with FCS when using flasks for cell culturing and that is why I required a 
large volume of FCS. My results showed that more MPO was present in the cells that were 
cultured in the bioreactor than in the static flasks. This could be because the cells change 
their phenotype when they stick to the bottom of the flask, possibly differentiating towards a 
macrophage phenotype. Therefore, for the remainder of the experiments, I used a rolling 
bioreactor to generate WEHI cells. 
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I decided to do a preliminary experiment to ensure the reproducibility of the model. In this 
case, I was only able to induce very mild glomerulonephritis and only one crescent was seen 
in one of the mice. This is clearly not sufficiently severe to allow us to address questions of 
pathogenesis. In contrast to my results, Xiao and colleagues were able to induce 
glomerulonephritis in all anti-MPO antibody treated mice (Xiao, Heeringa et al. 2002). One 
reason for this difference between my results and their results is that the titre of anti-MPO 
antibodies in my experiment was relatively low. Another explanation is that another stimulus 
was required for inducing severe glomerulonephritis and anti-MPO antibody alone was not 
sufficient in this experiment to induce severe glomerulonephritis. Although Xiao et al. did not 
use LPS in their experiment, we found it to be required in ours. These differences could be 
due to the animal house where the animals are kept. The animal house at the University of 
Birmingham is known to be very clean and many people here have struggled with their 
animal models. In a different study, it has been shown that systemic administration of 
bacterial lipopolysaccharide (LPS) increased disease severity compared to using anti-MPO 
antibody alone (Huugen, Xiao et al. 2005). These authors suggested that proinflammatory 
stimuli may be required along with ANCA to induce full disease in humans.  
I started looking for explanations as to why I was not able to induce severe vasculitis in 
the pilot experiment. One explanation was that the mice did not receive the full dose or 
volume of anti-MPO antibodies and that could be due to a loss of antibodies during i.v. 
injection. Another explanation was that the antibodies were trapped in the spleen when they 
were injected intravenously. In order to find a good explanation, I decided to measure the 
level of anti-MPO antibodies in the serum of the mice that were used in the MEV1 
experiment using ELISA to check for any differences in the level of anti-MPO antibodies. I 
was able to detect a sufficient amount of anti-MPO antibodies in the saline-treated mice. We 
concluded that we have to stimulate the immune system of these mice with LPS to augment 
the immune response. 
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In order to induce severe vasculitis, I used LPS, which was used by another group to 
aggravate anti-MPO antibody-induced glomerulonephritis (Huugen, Xiao et al. 2005). All the 
mice received LPS and they either received anti-MPO or anti-BSA antibody. All of the mice 
that received anti-MPO antibody developed crescentic glomerulonephritis. The mean 
percentage of crescentic glomeruli in these mice was 13.4%, in which some mice developed 
a high percentage of crescents while some mice developed fewer crescents. On the other 
hand, none of the mice that received anti-BSA antibody developed crescents or glomerular 
necrosis and most of the glomeruli were normal. A logical explanation for the effect of LPS 
on the immune system is that it results in an increase in the serum TNF-α level. Priming 
human polymorphonuclear leucocytes with TNF-α has been found to be required in vitro to 
induce the respiratory burst by ANCA. In addition, priming neutrophils with TNF-α in vitro 
results in the translocation of ANCA antigens to their surface. Blocking TNF-α in both rat and 
mouse models of ANCA-associated vasculitis resulted in a reduction crescent formation 
(Huugen, Xiao et al. 2005; Little, Bhangal et al. 2006). In addition, LPS could induce 
leucocyte and macrophage recruitment to the tissue, resulting in more severe disease.   
I also investigated macrophage infiltration using CD68 staining. Positive staining was 
seen in all the mouse kidneys that were injected with anti-MPO antibodies. CD68 positive 
staining was found mainly in the crescent region of the glomeruli, and there was a positive 
association between the crescent percentages and the number of CD68 positive cells. In 
humans, CD68 positive macrophages are the dominant cell type infiltrating glomeruli 
(Weidner, Carl et al. 2004). Macrophage infiltration has been reported in previous studies of 
vasculitis. Huugen et al. have shown influx of CD45+ leucocytes and most of these were 
FA11+ macrophages. They also noticed an increase in the number of macrophages 
following administration of LPS. We have shown the ability to induce vasculitis in mice using 
anti-MPO antibodies and LPS and also shown the presence of macrophages in the site of 
injury.     
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In addition, I investigated the possibility of raising anti-MPO antibodies in MPO-/- mice 
using MPO peptides and recombinant MPO. I investigated giving different concentrations of 
MPO peptides: 40, 200, 400 g. We found an increase in the level of anti-murine MPO in 
correlation with increasing the dose of MPO peptides as measured by anti-MPO ELISA. 
Although there was a detectable amount of anti-MPO antibodies generated by MPO-/- mice 
in response to MPO peptide immunisation, this was much less than that detected from mice 
immunised with murine MPO and I described the reason behind this in chapter 6.  
I used two females from the group that were immunised with MPO peptides for the 
maternal transfer experiment. The aim of this experiment was to investigate the possibility of 
inducing vasculitis in newborn mice from MPO-/- mothers that were immunised with MPO 
peptides and were mated with WT males. The idea came after a study was published 
describing a newborn child from a mother with microscopic polyangiitis who developed 
glomerulonephritis and pulmonary haemorrhage (Bansal and Tobin 2004; Schlieben, Korbet 
et al. 2005). We sacrificed the newborn mice at different time points (day 2 and day 21) and 
some of these mice received LPS to stimulate the immune system. We were not able to see 
any evidence of vasculitis on the histological sections; however I was able to detect clear 
evidence of efficient antibody transfer. This does not mean that it is not possible to induce 
vasculitis in newborn mice from mothers immunised with MPO, but antibodies produces in 
this mice were specific to the MPO peptides and did not react with murine MPO. With further 
optimisation, I believe this approach holds promise for a reduction in the requirement for 
animals both in this model and in other models of autoantibody-driven disease; moreover, it 
removes the requirement for potentially wasteful IgG purification from serum. 
In addition, we tried using recombinant mouse MPO to raise anti-MPO antibodies. A high 
titre of anti-recombinant MPO was achieved as shown by ELISA when the plate was coated 
with recombinant MPO. On the other hand, the level of anti-MPO antibodies was significantly 
less than that seen in mice injected with anti-murine MPO when the plate was coated with 
murine MPO. Antibodies purified from these mice were injected into WT mice, but they did 
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not develop the disease. This could be because anti-recombinant mouse MPO antibodies 
did not cross-react with murine MPO due to differences in the structure between native and 
recombinant MPO as described in chapter 6. This was seen when an ELISA plate was 
coated with murine MPO and there was a significant difference in the MPO titre when serum 
from anti-murine MPO-treated mice was compared to mice immunised with recombinant 
MPO.  
In conclusion, optimising the animal model was one of my priorities before starting any 
further investigations. I tried different approaches to try and find a source of MPO that would 
make the model easier to work with. I was able to induce severe vasculitis in mice using anti-
MPO antibodies and LPS, which was found to be required to induce severe disease.  
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Chapter 4 
Macrophage Phenotyping and monocyte depletion in murine 
experimental vasculitis 
 
4.1. Introduction 
This chapter covers the work I did in trying to understand the role of macrophages in 
ANCA-associated vasculitis. This involved identifying macrophage phenotypes in the kidney 
by immunohistochemical staining following disease induction. In addition, I used a 
microarray approach to study upregulated genes in the kidney, especially those genes that 
are associated with macrophage activation. Finally, I investigated the effect of preventing 
macrophage infiltration in the kidney on disease development.   
Macrophage infiltration to the site of injury is a common feature of ANCA-associated 
vasculitis. Atkins et al. reported the accumulation of large numbers of macrophages in 
necrotising/crescentic lesions (Atkins, Holdsworth et al. 1976). However, the phenotype of 
these macrophages has not been investigated in the mouse model of ANCA-associated 
vasculitis (MEV). Nevertheless, the role and type of macrophages has been investigated in 
other kidney diseases, such as ischaemic injury. For example, Lee et al. reported a switch in 
the macrophage phenotype during ischaemic kidney injury from the M1 phenotype to M2 
(Lee, Huen et al. 2011). In addition, they showed an accumulation of M1 macrophages 
during the first 48 hours following injury, but M2 macrophages were dominant in later stages 
of the disease. These results suggest the involvement of both M1 and M2 macrophages in 
kidney injury and repair in ischaemic injury of the kidney. In addition, Ferenbach et al. 
showed a protective role of HO-1-positive macrophages in ischaemic-reperfusion injury (IRI) 
(Ferenbach, Nkejabega et al. 2011). These results show the variability of macrophage 
phenotypes in kidney injury. I believe that identifying macrophage phenotypes in AAV in 
mice is important, as it should help to identify whether they were inflammatory or anti-
inflammatory and whether the depletion was beneficial or not.  
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I discussed the different macrophage subsets in Chapter 1, including M1 and M2 
macrophages. If macrophages are involved in the pathogenesis of crescentic 
glomerulonephritis, then these would be expected to be M1 macrophages. On the other 
hand, M2 macrophages are mostly involved in repair and can be identified by the expression 
of specific M2 markers such as the mannose receptor (CD206) and CD163. I investigated 
the phenotype of macrophages in kidney sections from animals treated with anti-MPO 
antibodies.  
The understanding of macrophages in AAV can be strengthened by studying gene 
expression and upregulation in the glomerulus using microarray analysis. The Affymetrix 
array works by loading labelled cDNA onto a microarray chip that contains thousands of 
genes, allowing complementary sequences to form strong bonds that can then be detected 
by laser scanning. The development of new scientific techniques and molecular biological 
tools has provided new directions for evaluating the pathophysiology of different diseases. 
Gene expression analysis has made it possible to study the expression of thousands of 
genes in a relatively short period of time using small amounts of starting materials. In 
mammalian tissues, some genes are upregulated or downregulated depending on a given 
disease process. Comprehensive gene expression analysis is possible and has been 
performed on different animal models of renal injury. For example, Yoshida et al. used 
microarray analysis to study gene expression in ischaemia-induced renal failure (Yoshida, 
Tang et al. 2002). They were able to identify upregulated and downregulated genes on both 
days 1 and 4. Using microarray analysis, they were able to identify several novel genes, 
such as serine protease inhibitors, that might be involved in kidney repair. I used this 
approach to identify upregulated genes in crescentic glomerulonephritis induced by anti-
MPO antibodies in mice and rats.  
I used this approach to look for genes that are upregulated in the glomeruli and tubules in 
the kidney in mouse and rat models of vasculitis. These two animal models develop the 
same disease, but it is induced by different methods. In mice, this disease is induced by the 
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passive transfer of anti-MPO antibodies into wild-type mice. On the other hand, rats are 
actively immunised with human MPO with an adjuvant and they produce anti-MPO 
antibodies that cross-react with rat MPO and cause vasculitis. The purpose of using the rat 
model here is to use mouse, rat and human microarray data for a web-based analysis that 
may facilitate the integration of data across species. Human data were obtained from our 
collaborators at the European Renal Cell Bank (ERCB) in Zurich (Dr. Clemens Cohen). Their 
data were obtained from microdissected glomeruli of vasculitis patients using Affymetrix 
array analyses. I used a similar approach to collect data from mouse and rat models of 
vasculitis. The aim of this study was to use the network analysis tool to generate a network 
of human, mouse and rat data sets and to then generate an overlay of the mouse and the rat 
model with the human data set. This analysis will be undertaken by our collaborators at the 
University of Michigan (Matthias Kretzler). This will then act as the starting point for 
biological analyses investigating which pathways and networks are model specific and which 
ones are common between species. This could lead to finding common transcriptional 
factors that are conserved between species.  
Meanwhile, the data from the gene expression and upregulation analyses were used to 
study genes associated with macrophage activation, which could identify pathways 
associated with macrophage activation that result in kidney injury. Also, upregulated genes 
could be used to identify the type of macrophages that accumulate in the kidney and help 
strengthen the results on macrophage phenotyping.  
As a result, the main question that I hoped to answer from the Affymetrix array study was: 
could these results be used to study the type of macrophages that accumulate in the kidney 
in order to help understand the effect of macrophage infiltration on the development of 
vasculitis? The second goal was to find common transcriptional factors or pathways in mice, 
rats and humans.  
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Macrophage depletion has been used as a technique for studying the role of 
macrophages in kidney injury (Duffield, Tipping et al. 2005). There are different methods for 
depleting macrophages, including the diphtheria toxin approach, liposomal clodronate and 
CCR2 blockade. Clodronate is used to treat osteolytic bone diseases (Jordan, van Rooijen 
et al. 2003). It has been found that once clodronate is incorporated into liposomes it can be 
used to deplete macrophages (van Rooijen and van Nieuwmegen 1984; Claassen, Van 
Rooijen et al. 1990). Clodronate works by causing macrophage apoptosis after it has been 
taken up by these cells (Naito, Nagai et al. 1996; van Rooijen, Sanders et al. 1996). The 
type of injection used has been found to affect the type of macrophages that will be 
depleted. For example, an intravenous injection will result in hepatic and splenic 
macrophages being depleted. On the other hand, tissue injection will result in the depletion 
of macrophages from this tissue and the draining lymph nodes (van Rooijen, Kors et al. 
1989). Van Rooijen et al. showed that using this method to deplete macrophages does not 
result in the secretion of pro-inflammatory cytokines by these cells when they undergo 
apoptosis (van Rooijen and Sanders 1997). In addition, liposomal clodronate was found to 
affect macrophages and phagocytic dendritic cells, but not neutrophils or lymphocytes (van 
Rooijen, Kors et al. 1989; Van Rooijen and Sanders 1994; Alves-Rosa, Stanganelli et al. 
2000).  
The anti-mouse CCR2 antibody MC-21 has also been used to block CCR2 in mice (Mack, 
Cihak et al. 2001). Mack et al. showed that MC-21 blocked the binding of monocyte 
chemotactic protein (MCP)-1 to CCR2. In addition, MC-21 prevented monocyte infiltration in 
the model of thioglycollate-induced peritonitis. Furthermore, Bruhl et al. demonstrated the 
ability of MC-21 to deplete GR1+ cells from peripheral blood (Bruhl, Cihak et al. 2007). 
These cells differentiate into inflammatory macrophages, as I will explain below. MC-21 
could be used to deplete GR1+ monocytes and to study its effect on the development of 
vasculitis. The purpose of this experiment was to determine whether the blockage of CCR2 
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prevents macrophage infiltration, as reported previously, as part of a study on the effects of 
macrophage depletion on disease development.  
Mouse and human blood monocytes have typical morphological features and originate 
from the bone marrow. These monocytes can differentiate into macrophages and 
inflammatory DCs during inflammation (Serbina, Jia et al. 2008), and they are also involved 
in renewing tissue DCs and macrophages (Geissmann, Jung et al. 2003; Auffray, Sieweke et 
al. 2009). Mouse monocytes are divided into different subsets depending on their expression 
of receptors such as Ly6C (GR1). The GR1+ monocytes differentiate into inflammatory DCs 
and M1-type macrophages, whereas GR1- monocytes differentiate into M2-type 
macrophages (Auffray, Sieweke et al. 2009). The GR1+ monocytes express CCR2 and a 
low level of CX3CR1. On the other hand, GR1- monocytes lack the expression of CCR2. 
This chemokine receptor has been shown to be involved in monocyte migration from the 
bone marrow to the bloodstream (Serbina and Pamer 2006). This is a chemokine receptor 
for monocyte chemoattractant protein-1 (MCP-1), which has been shown to be involved in 
macrophage recruitment in several inflammatory models (Flory, Jones et al. 1993; Huffnagle, 
Strieter et al. 1995). This suggests the possibility of the involvement of CCR2 in monocyte 
trafficking during inflammation. Kurihara et al. showed that macrophage recruitment following 
inflammation is significantly lower in CCR2-deficient mice compared to wild-type mice 
(Kurihara, Warr et al. 1997). In addition, they found that the absence of CCR2 in these mice 
did not affect the recruitment of other cell types such as neutrophils and eosinophils, and 
that the defect was specific for macrophage recruitment. These results suggest an important 
role of CCR2 and its ligands in macrophage recruitment following inflammation. Furuichi et 
al. a reagent (RS-504393) that is a specific antagonist of CCR2. They found that the number 
of interstitial infiltrated cells and tubular necrosis was reduced in ischaemia-reperfusion injury 
following treatment with RS-504393 (Furuichi, Wada et al. 2003). This study and other 
studies showed the importance of CCR2 in macrophage recruitment. As a result, we decided 
to use antibodies to block the function of this receptor in order to eliminate macrophage 
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recruitment in the mouse model of vasculitis. This should allow for the effect of macrophage 
depletion on AAV in mice to be studied.  
Disease severity in the mouse model of vasculitis is relatively mild compared to human 
vasculitis. We wanted to improve this model and induce a more severe disease, similar to 
the type seen in humans. Previously, we used C57Bl/6J mice in our model. However, Xiao et 
al. recently reported that they were able to increase the severity of the disease by using a 
different strain of mice (129S6) (Xiao 2009). They were able to increase crescent formation 
to 69%. For this reason, we decided to use this mouse strain in our experiment.   
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4.2. Methods  
4.2.1. The macrophage phenotype in AAV in mice  
I used kidney sections from mice that were treated with anti-MPO or anti-BSA antibodies 
to study macrophage phenotypes in crescentic glomerulonephritis. These mice only received 
anti-MPO or anti-BSA antibodies and LPS, and they were also used to study gene 
expression.  
Different markers were used to stain for macrophages and also to identify their 
phenotype: CD68 was used to stain for macrophages and CD206 (mannose receptor) was 
used as an M2 marker (Chavele, Martinez-Pomares et al. 2010). I started by optimising the 
antibodies and performing serial dilutions to find the right concentration. Wild-type spleen 
sections were used to optimise staining. I also tried double staining (CD68+CD206), but this 
proved to be difficult because all of my primary antibodies were made in the same species 
(rat anti-mouse). I will describe some of the methods that I used. 
First, frozen sections were fixed in acetone and re-hydrated in PBS as described in 
Chapter 2. Sections were blocked with 5% normal goat serum to block non-specific binding. 
Then, I added the first primary antibody (rat anti-mouse CD68) that was diluted by 1:100 in 
2% horse serum in PBS (optimised to this dilution) and incubated for 1 hour. After this, 
sections were washed three times in PBS and incubated with a secondary antibody (Alexa 
Fluor 594 goat anti-rat IgG) for 45 minutes in the dark. Next, the sections were washed and 
blocked with 5% normal mouse serum for 30 minutes, washed again, and the second 
primary antibody (rat anti-mouse CD206) was added and diluted by 1:100. The sections 
were then incubated in the dark for 2 h. After this, the sections were washed in PBS and 
incubated with a secondary antibody (FITC rabbit anti-rat IgG) for 45 minutes. Finally, the 
sections were washed three times in PBS and mounted.  
I could not get the double staining to work, so I used serial sections instead. The serial 
sections were prepared from frozen kidneys and three serial sections were placed onto one 
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slide. I selected three important markers to identify the type of macrophages in the kidney: 
CD68, CD206 (mannose receptor) and MHC class II. The CD68 marker is a general 
macrophage marker, whereas expression of the mannose receptor increases in alternatively 
activated macrophages. On the other hand, MHCII expression is increased in classically 
activated macrophages (Gordon and Taylor 2005). Staining for CD68, CD206, and MHCII 
was performed as previously described. Serial images of the same area were taken to 
analyse the staining. 
Staining for T cells, neutrophils, and macrophages: 
Frozen serial kidney sections were used to stain for different cell type in the kidney to 
compare macrophages to other cells in the kidney as shown below. The staining was done 
by MRC, UK. The procedure started by fixing the sections in 2% paraformaldehyde for 10 
minutes on ice. The sections were then washed 3 times in PBS/0.1%Tween. The sections 
were incubated with quench for 15 minutes at 37ºC in oven and then washed in PBS. Then, 
sections were blocked with 5% normal goat serum for 30 minutes and then washed in PBS. 
This was followed by avidin blocking for 15 minutes and then washing the sections in PBS. 
After that, sections were incubated with biotin blocking for 15 minutes and then they were 
washed in PBS. Next, primary antibody was added using the dilution shown below and 
incubated for 1 hour at room temperature and then washed in PBS. Then secondary biotin 
goat anti-rat IgG (Jackson labs, UK) diluted 1:500 was added to each section and incubated 
at room temperature for 30 minutes and then wash in PBS. After that, sections were 
incubated with ABC kit for 30 minutes and then washed. Then procedure continued as 
previously described.  
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Antibody Supplier Dilution 
F4/80 (macrophage marker) ABD Serotec, UK 1:100 
CD4 (T Cells) // 1:100 
CD8 (Cytotoxic T cells) // 1:100 
CD3 (mature T cells) // 1:100 
GR-1 (neutrophil marker) // 1:200 
Dectin-1 // 1:20 
 
4.2.2. Affymetrix array and tissue preparation for laser microdissection 
Tissues and animals 
Tissues for the laser microdissection experiment were obtained from mouse and rat 
models of vasculitis. Mice tissues were obtained from mice treated with 75 µg/g of anti-MPO 
(n=5) or anti-BSA (n=5) and 1,500 EU/g of LPS and sacrificed on day 6. Rats were 
immunised with either human MPO (n=5) or human serum albumin (n=5) (this experiment 
was performed by Dr. Bahjat Al-Ani). The rats received 1 µg of pertussis toxin through an i.p. 
injection on day -5. Then, they received 3.2 mg/kg of MPO or HSA in complete Freund’s 
adjuvant on day 0 by i.m. and s.c. injections. In addition, they received 1,500 EU/g of LPS on 
days 7, 28, 35 by i.p. injections. The rats were boosted with 100 μg/kg of MPO or HSA in 
weeks 3 and 5 and they were sacrificed in week 8. They also received pertussis toxin and 
LPS. These rats were then sacrificed after 8 weeks. The kidneys were collected from these 
animals for laser microdissection; they were kept in cryo tubes, snap frozen in liquid nitrogen 
and stored at -80°C.  
This study was performed following work undertaken on human kidneys from ANCA-
associated vasculitis patients to study gene expression and upregulation in glomeruli which 
was performed by our collaborators in Zurich (Dr. Clemens Cohen). For this reason, we tried 
to replicate their work as close as possible to allow us to compare the results. For human 
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crescentic glomerulonephritis, they used an HG-U 133 Plus 2.0 Affymetrix array; therefore, I 
used Affymetrix arrays that were similar to the one they used: these were Affymetrix rat 
genome 230 2.0 and mouse genome 430 2.0 arrays (Affymetrix UK Ltd., UK).  
Optimising the microdissection technique 
I optimised my technique before starting the actual work on laser microdissection. The 
aim of this work was to compare the results that we obtained from the animal models (rat 
and mouse) with the results that were obtained from human patients with AAV. We wanted 
to compare the results that we obtained from the animal models with the human results, 
which meant following the same protocol that was used for the human kidneys in order to 
minimise variations in the data. They started with 20 ng of total RNA; therefore, I decided to 
start with the same quantity. I microdissected glomeruli from wild-type mouse kidneys and 
tried to measure the RNA using the Nano-drop UV instrument, but the reading was not 
accurate and I also lost RNA during the process because I needed 2 μl of RNA to get a 
reading. I therefore decided to use a bioanalyser to measure the RNA concentration, which 
also measures the integrity of the RNA. I microdissected 250 glomeruli and extracted the 
RNA from these and also from a whole kidney section to use as a positive control. I obtained 
13 ng of total RNA from 250 glomeruli, so we decided to microdissect 400 glomeruli, which 
gave a sufficient amount of starting RNA material for the experiment.  
I also investigated the maximum time that I could store microdissected tissue before 
starting RNA extraction. We decided to microdissect glomeruli and tubules from four animals 
each week by doing one animal each day, which meant storing microdissected tissues in 
lysis buffer for a maximum of 4 days. I found that the quality of the RNA was not affected 
after 4 days, as measured by the bioanalyser and compared to tissues that were only stored 
for 1 day.   
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Preparing sections 
Kidney tissues frozen in cryo vials were transferred to dry ice in the cryostat. The tissues 
were placed inside the cryostat and left for 10 minutes to equilibrate. All brushes were 
treated with RNase Zap to eliminate contamination. Then, I cut 8 μm-thick tissues and 
transferred them to a membrane slide (Carl Zeiss, UK). These are special glass slides 
covered with a thin membrane that can be easily cut together with the tissue, without 
affecting the morphological integrity. The slide was kept inside the cryostat for 2 minutes and 
the second section was transferred to the slide by keeping my finger on the slide where the 
section would be located. This was done to make the section stick to the cold slide. The 
slides were then transferred to a storage box on dry ice that contained silica gel to control 
the moisture level and stored at -80°C until they were ready for microdissection.  
Staining with cresyl violet  
I prepared 12 slides from each tissue; each slide had two sections. I used 10 mouse 
kidneys and 10 rat kidneys for this experiment. We had disease and control groups from 
each species. Five animals were from the disease group and these were either injected with 
anti-MPO antibodies and LPS (mouse) or immunised with human MPO with pertussis toxin 
and LPS (rat). The control groups contained five animals and these were either injected with 
anti-BSA and LPS (mouse) or immunised with human serum albumin with pertussis toxin 
and LPS (rat). This resulted in a total number of 20 animals. Kidney sections from these 
animals were used to microdissect 400 glomeruli and the interstitial tubules. These were 
divided into five groups as shown below. Each group contained four animals (two rats and 
two mice): mouse control, mouse disease, rat control, and rat disease. 
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Table 4.1: Mouse and Rat tissues that were used for microdissection. Kidney sections were 
prepared from control and disease groups.  
Mouse tissues  
(anti-MPO treated) 
Mouse tissues (anti-
BSA treated) 
Rat tissues (MPO 
immunised 
Rat tissues (HSA 
immunised) 
75 µg/g anti-MPO + 
1,500 EU/g  
75 µg/g anti-BSA + 
1,500 EU/g 
3.4 mg/kg 
MPO+LPS+pertussis  
3.4 mg/kg 
HSA+LPS+pertussis  
// // // // 
// // // // 
// // // // 
// // // // 
 
Table 4.2: Describing the type of tissues used each week for microdissection. Each week, two 
mouse (control and disease) and two rat (control and disease) tissue were used for microdissection.  
Week 1 Week 2 Week 3 Week 4 Week 5 
Anti-MPO-treated 
mouse 
Anti-BSA treated 
mouse  
MPO-immunised 
rat 
HSA-immunised 
rat  
MPO-
immunised 
rat 
MPO-immunised 
rat 
HSA-immunised 
rat  
Anti-MPO-treated 
mouse 
Anti-BSA-treated 
mouse  
Anti-MPO-
treated 
mouse 
Anti-BSA-treated 
mouse 
Anti-MPO-treated 
mouse 
HSA-immunised 
rat  
MPO-immunised 
rat 
HSA-
immunised 
rat  
HSA-immunised 
rat 
MPO-immunised 
rat 
Anti-BSA-treated 
mouse  
Anti-MPO-treated 
mouse 
Anti-BSA-
treated 
mouse  
 
It took one day for 400 glomeruli and interstitial tubules from one animal to be 
microdissected (12 hours). On the day of microdissection, I took the slides from one animal, 
which were stored in a small box, and transferred them onto dry ice. I stained one slide at a 
time and performed the microdissection and then did the next one using cresyl violet stain 
(figure 4.1), as previously described in Chapter 2.   
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Figure 4.1: Cresyl violet staining. Sections were stained for visualisation before laser 
microdissection was started. The slides were fixed and hydrated in 95% (30 seconds), 75% (30 
seconds), and 50% (25 seconds) ethanol. The sections were then stained for 1 minute with cresyl 
violet and then quickly washed in 75% ethanol and rehydrated for 30 seconds in 100% ethanol. 
Laser microdissection and RNA extraction 
The tissues were microdissected as previously described in Chapter 2. For each animal, I 
used eight slides to microdissect 400 glomeruli and four slides for the interstitium. Four 
tissues were microdissected each week (two mice and two rats), which resulted in the 
production of eight samples (glomeruli and tubules from each animal). The microdissected 
tissues were stored at -80°C until ready for RNA extraction (no more than 4 days stored at -
80°C). The RNA was extracted as previously described in Chapter 2.    
The RNA samples were processed by the College of Medical and Dental Sciences 
Affymetrix Microarray Service under the guidance of Dr. John Arrand. The quality of the RNA 
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was measured by a bioanalyser, which is an instrument used to measure the quality and 
quantity of total RNA. When eukaryotic RNA is broken down, it produces two distinct bands 
representing 18S and 28S. The quality of RNA is measured by the RNA integrity number 
(RIN), which is calculated using an Agilent software algorithm. This gives a number between 
1 and 10, where 1 is considered degraded RNA and 10 indicates intact RNA. An RIN of 7 is 
considered good for working with microarray 
http://biomedicalgenomics.org/The_RNA_Integrity_Number.html. The RNA was amplified 
using an ExpressArt C&E Nano kit according to the manufacturer’s instructions, followed by 
biotin labelling, fragmentation, hybridisation to the Affymetrix Rat Genome 230 2.0 or Mouse 
Genome 430 2.0 arrays, washing, staining, and scanning, all according to standard 
Affymetrix protocols. The protocol is described in Chapter 2.  
The samples were analysed using Linear Model for Microarray Analysis (LIMMA) 
software (http://www.statsci.org/smyth/pubs/limma-biocbook-reprint.pdf) to find upregulated 
genes. The LIMMA software uses linear models to analyse data from microarray 
experiments. For upregulated genes in mouse and rat glomeruli, the P value was set to 0.05 
and a two-fold change compared to the control group was required. In addition, PANTHER 
(Protein Analysis Through Evolutionary Relationships) software was used to separate these 
upregulated genes in different groups. I uploaded the symbols of upregulated genes to the 
PANTHER website at the following link 
http://www.pantherdb.org/tools/compareToRefListForm.jsp. Each list was compared to the 
reference list using the binomial test (Cho and Campbell 2000) for each molecular function, 
biological process, or pathway term in PANTHER. 
4.2.3. Macrophage depletion using clodronate 
I decided to investigate the possibility of using liposomal clodronate to deplete 
macrophages in a pilot experiment. Mice were treated with 100 μl clodronate on days -2, 0, 
2, 4, and 7 relative to the first anti-MPO injection, as shown in Figure 4.2. Huang et al. 
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showed >95% elimination of macrophages 48 hours after clodronate administration, which is 
why I chose to administer clodronate every two days, in order to achieve macrophage 
depletion at all disease stages (Huang, Tipping et al. 1997). Clodronate was given through 
i.v. injections, except on day 0 where it was given through an i.p. injection for technical 
reasons. Macrophage depletion was assessed by CD68 immunohistochemical staining on 
paraffin sections from the kidney and spleen, as previously described. I also measured the 
anti-MPO antibody titre in the serum of these mice following clodronate treatment using an 
anti-MPO ELISA, as described in Chapter 2.  
 
Figure 4.2: Macrophage depletion using clodronate. The mice were injected with liposomal 
clodronate on days -2, 0, 2, 4, and 7. The mice were sacrificed on day 9 and their blood was 
collected. 
4.2.4. Depletion of CCR2+ monocytes to investigate role of monocyte recruitment in 
MEV 
Clodronate affected the level of transferred antibodies, so we decided to use another 
method for depleting macrophages. We used anti-mouse CCR2 (MC-21; kindly donated by 
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Dr. Matthias Mack, Germany) to deplete Gr1+ monocytes. This antibody was produced 
when Chinese hamster ovary cells were transfected with murine CCR2 and then Wister rats 
were immunised with these cells (Mack, Cihak et al. 2001). The anti-mouse CCR2 antibody 
was shown to increase the level of interlukin-6 (IL-6) when introduced at a high dose (e.g. 
50-100 µg), but it did not do so when given at a low dose (e.g. 10 µg). Therefore, I decided 
to use this antibody at 20 µg because this dose showed good depletion during the 
optimisation stage. I used a different strain of mice in this experiment than was previously 
used: 129 SvEv (Taconic, USA). The reason for using this strain was that it was reported to 
develop severe crescentic glomerulonephritis following the passive transfer of anti-MPO 
antibodies. Eight mice were used in this experiment and rat anti-mouse CCR2 antibody was 
used to deplete the blood monocytes (figure 4.3). The mice were divided into two groups and 
received 20 µg of either anti-mouse CCR2 antibody (MC-21, n=4) or rat IgG2b (isotype 
control, n=4) via i.p. injections from day -1 to day 5. All mice received 75 µg/g of anti-MPO 
antibody via an i.v. injection on day 0. Monocyte depletion was monitored using flow 
cytometry. Urine was collected on days 1 and 6 to check for haematuria. No haematuria 
detected on day 1, so we elected to give LPS to boost the immune response. The mice were 
culled on day 6 and tissues were collected and either snap frozen or fixed in a 10% 
formalin/saline solution.  
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Figure 4.3: Experimental design for the monocyte depletion experiment. Monocytes were 
depleted in order to study their role in the induction of vasculitis. Mice were injected with 75 µg/g anti-
MPO antibodies (n=8) and received 20 µg of either anti-mouse CCR2 (MC-21) or rat IgG2b from day -
1 to day 5.  
4.2.5. Monitoring monocyte depletion using flow cytometry 
Blood was obtained from the mice treated with MC-21 to check for monocyte depletion, 
where 50µl of blood was taken on a daily basis by tail bleeding from all MC-21-treated mice 
(n=4), one mouse from the IgG2b-treated group and one untreated mouse. I stained for Ly-
6G (GR1) and CD11b, which are expressed by monocytes that also express CCR2. The 
staining was performed as previously described in Chapter 2. The following antibodies were 
used: Alexa Fluor 647 anti-mouse Ly-6G (Gr1) (0.125μg), Alexa Fluor 488 anti-mouse 
CD11b (0.5μg), Alexa Fluor 647 rat IgG2b isotype control, and Alexa Fluor 488 rat IgG2b 
isotype control (eBioscience, UK). 
Staining analysis 
Immunohistochemical staining was analysed and quantified using Aequitas 1A software 
as described previously in Chapter 2. Briefly, the threshold of the grey scale was kept 
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constant and positive staining was expressed as a percentage of the image area (Balding, 
Howie et al. 2001).  
. 
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4.3. Results 
4.3.1. Macrophage phenotyping in AAV induced in mice 
Macrophage infiltration into the injured kidney was investigated by IHC staining. 
Macrophages are identified by the CD68 marker and can be divided into classically activated 
(M1) or alternatively activated (M2) macrophages. M2 macrophages are identified by 
upregulation of the mannose receptor (CD206). I used serial sections to identify macrophage 
types as double staining was not possible. Positive CD68 staining was observed in the 
injured kidneys, with strong positive staining in the crescent region of the glomeruli (Figure 
4.4, A, D, and J). The macrophages in the crescent region were most likely M1 
macrophages as they did not express CD206, which is an M2 marker, as shown by the serial 
section staining (Figure 4.4). There was little or no staining of CD206+ cells in the glomeruli, 
but there was strong positive staining of CD206 on mesangial cells. On the other hand, MHC 
class II was found to be heavily expressed in the injured kidney and we also know that 
MHCII is upregulated in M1 macrophages but downregulated in M2 macrophages (Gordon 
and Taylor 2005). The MHCII marker was also expressed by other antigen presenting cells, 
which suggests the presence of other cells, such as dendritic cells (DCs), in the injured 
kidney. Positive staining of CD206 and MHCII was found in the control (anti-BSA treated) 
kidney sections (Figure 4.4, N and O).     
 
 
 
 
 
 
139 
 
 
Figure 4.4: Immunohistochemical staining to identify the macrophage phenotype. Frozen 
kidney sections from mice treated with anti-MPO or anti-BSA antibodies and LPS. Each row 
represents serial sections of the same kidney and the same area stained for CD68, CD206, and 
MHCII. Arrows show the same area in each image in order to compare the staining. Sections M, N, 
and O are serial sections from mice injected with anti-BSA antibodies and stained with CD68, CD206, 
and MHCII, respectively.   
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Analysis of CD68, CD206, and MHCII staining 
I analysed CD68 and CD206 staining in the kidney sections from anti-MPO and anti-BSA-
treated mice. CD68-positive cells were found in the injured glomeruli and also in the 
interstitial region of the anti-MPO-treated mice. We found a significant difference between 
anti-MPO and anti-BSA-treated mice in the number of CD68-positive cells in both glomeruli 
and the interstitial compartment (figure 4.5 A and B). On the other hand, there was no 
significant difference between anti-MPO and anti-BSA in CD206 staining in the glomeruli, but 
there was a significant difference between them in the interstitial compartment (figure 4.5 C 
and D). This could be because mesangial cells in glomeruli have been reported to express 
CD206, and I found strong, positive staining of CD206 in mesangial cells. There was a 
strong positive staining of MHCII in anti-MPO treated mice (figure 4.6). 
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Figure 4.5: Staining analysis of CD68 and CD206. A significant difference was found between anti-
MPO (n=4) and anti-BSA-treated (n=5) mice in the number of CD68-positive cells in both the 
glomeruli and interstitial compartments (A and B). Significant staining of CD206 only occurred in the 
interstitial compartment (D); t-test (Mann-Whitney test).  
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Figure 4.6: MHCII staining analysis. Kidney sections from α-MPO (A) and α-BSA (B)-treated mice 
with 1,500 EU/g of LPS. There was positive correlation between the percentage of MHCII staining and 
the crescent percentage (C) with r2=0.85 and P<0.001, as measured by linear regression. A 
significant difference was found in MHCII staining between α-MPO and α-BSA-treated mice by 
measuring positive staining and taking the percentage of this staining to the whole area in the image. 
The t-test (Mann-Whitney test) was used for analysis (D).  
4.3.2. Comparing the presence of other cell types to macrophages: 
I investigated the presence of T cells and neutrophils using different markers and 
compared that to the presence of macrophages.  There were very view CD4+ (T helper 
cells) and CD8+ (cytotoxic T cells and NK cells) cells (figure 4.7 D and C). In addition, there 
were almost no GR1+ cells (neutrophil) (figure 4.7 B) or CD3+ cell (mature T cells) (figure 
4.7 E). Dectin-1 staining was also very low. However, there were a large number of 
macrophages in the kidney as shown by F4/80 staining (figure 4.7 A).  
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Figure 4.7: Immunohistochemistry results of different cell types in anti-MPO treated mice. 
These are serial section from mouse treated with anti-MPO antibodies. There were large number of 
F4/80+ macrophages in both glomeruli and tubules (A). There were very view CD8+ and CD4+ T cell 
(C and D). There were almost no CD3+ T cells or Gr1+ neutrophils (E and B).    
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Figure 4.8: Staining analysis of different cells in the glomeruli. Manual count of positive staining 
in the glomeruli from anti-MPO treated mice. The dominating cells in both glomeruli and tubules were 
found to be F4/80+ macrophages. There were very few other cells. The p value represent the 
variation between groups (one way ANOVA). 
4.3.3. Gene modulation in AAV in mice 
One of the approaches that we used in an attempt to understand vasculitis was studying 
gene expression in kidney sections from anti-MPO-treated mice and comparing it to that in 
the tissues of anti-BSA-treated mice. A total of 400 glomeruli from anti-MPO and anti-BSA-
treated mice and MPO and HSA-immunised rats was microdissected. This is a very difficult 
technique and required a lot of time and effort to microdissect the areas of interest without 
compromising RNA integrity.  
RNA quality and quantity   
Total RNA was extracted from laser microdissected tissues (Figure 4.9). I measured the 
quality and quantity of RNA using an Agilent bioanalyser (figure 4.10). All of the RNA 
samples used in this experiment had an RIN of 7 or above, which is considered good for 
microarray usage (table 4.3). The concentration of the RNA from microdissected glomeruli 
(from rats and mice) is shown in table 4.4.  
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Figure 4.9: Laser microdissection. Glomeruli from rats (A) and mice (C) were microdissected. 
Kidney sections were prepared and stained with the cresyl violet stain for visualisation. (A) Rat section 
before cutting and (B) after cutting. (C) Mouse section before cutting and (D) after cutting.   
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Figure 4.10: RNA quality and quantity. The RNA extracted from the microdissected glomeruli. A: 
The RNA from mouse glomeruli had clear bands at 28S and 18S with an RIN value of 8. B: The RNA 
from rat glomeruli had an RIN value of 8. The RNA fragments were separated by size, where the 
smaller fragments travelled faster. The software automatically compares unknown samples to ladder 
fragments in order to determine the concentration of unknown samples and to identify ribosomal RNA 
peaks. Two peaks and two bands are shown in each figure and they represent RNA fragments at 18S 
and 28S.  
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Table 4.3: RNA integrity number (RIN) for microdissected tissues from mouse and rat as 
measured by bioanalyser.  
Mouse (α-MPO) 
RIN 
Mouse (α-BSA) 
RIN 
RAT (MPO-
immunised) RIN 
Rat (HSA-immunised) 
RIN 
Glom 
 
Glom 
 
Glom Glom 
7.7  
 
7.8 
 
8.1 8.2 
7.9 
 
8.0 
 
7.9 8.1 
8.3 
 
7.7 
 
8.5 8.4 
9.0 
 
8.7 
 
8.3 8.7 
8.0 
 
8.1 
 
8.0 8.6 
 
Table 4.4: RNA concentration of microdissected glomeruli. 
Mouse (α-MPO) 
ng 
Mouse (α-BSA) 
ng 
RAT (MPO-
immunised) 
ng 
Rat (HSA-immunised) 
ng 
Glom 
 
Glom 
 
Glom 
 
Glom 
16.02 
 
32.60 
 
46.48 
 
27.19 
42.93 
 
14.31 
 
89.18 
 
51.48 
20.67 
 
20.65 
 
45.85 
 
21.54 
6.74 
 
8.05 
 
52.84 
 
40.81 
18.99 
 
17.96 
 
46.91 31.23 
 
Confirming the quality of the microdissections  
The quality of the microdissections was investigated by looking at genes that are only 
expressed in the glomeruli or tubules. This was done to make sure that the microdissected 
glomeruli did not contain any tubules and vice versa. Nephrosis 1 (Nphs1) is one of the 
genes used to identify the quality and purity of microdissected glomeruli. The Nphs1 gene is 
solely expressed in glomeruli and encodes a member of the immunoglobulin family of cell 
adhesion molecules that functions in the glomerular filtration barrier in the kidney. I found 
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that Nphs1 was expressed in microdissected glomeruli but not in microdissected tubules in 
both the mouse (Figure 4.11, A) and rat (Figure 4.11, C), which confirms the purity of the 
microdissected glomeruli. On the other hand, the Lrp2 gene encodes low-density lipoprotein-
related protein 2 (LRP2) or megalin. This protein is solely found in tubules. I found that this 
gene was mainly expressed in microdissected tubules and less so microdissected glomeruli 
in both the mouse (Figure 4.11, B) and rat (Figure 4.11, D). However, there was some 
expression of Lrp2 on the microdissected glomeruli because I microdissected a small area 
outside the glomeruli to avoid losing glomeruli, which resulted in contamination with of some 
tubules.  
 
Figure 4.11: Confirming the quality and purity of the microdissections. Glomeruli and tubules 
were microdissected from rats and mice (control and diseased). The Nphs1 gene was used to identify 
the purity of the microdissected glomeruli. It was found to be expressed in microdissected glomeruli 
from the rat and mouse but not in microdissected tubules (A and C). The Lrp2 gene was used to 
identify the purity of microdissected tubules and was mainly found in the tubules of both the rat and 
mouse (B and D). 
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Analysis of microarray results 
The microarray results were analysed using LIMMA software with the assistance of Dr. 
Wenbin Wei at the University of Birmingham. In order to eliminate any false results, we set 
the P value to 0.05, with at least two-fold changes between anti-MPO and anti-BSA groups. 
We identified 146 genes that were upregulated in mouse glomeruli and 139 genes that were 
upregulated in rat glomeruli (figure 4.12). I found 42 common genes that were upregulated in 
both the mouse and rat (Table 4.5). Some genes known to be biomarkers of kidney injury 
were upregulated. For example, lipocalin, which is also known as neutrophil gelatinase-
associated lipocalin (NGAL), was found to be highly upregulated in mouse glomeruli with an 
8.7-fold increase compared to and 3.7 in the rat model. In addition, Havcr1, which is also 
known as kidney injury molecule 1 (Kim 1), was highly upregulated in the mouse model with 
a 7.3-fold increase compared to 2.9 in the rat model. The Fibronectin 1 (Fn1) gene, which is 
associated with inflammation, was upregulated in both the rat and mouse with a 3.8-fold 
increase in the mouse and a 3.48-fold increase in the rat.   
 
Figure 4.12: Common upregulated genes in both rat and mouse glomeruli. There were 139 
genes upregulated in rat glomeruli and 146 genes upregulated in mouse glomeruli. There were 42 
upregulated genes common to both the rat and mouse.  
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Table 4.5: Common upregulated genes in diseased mouse and rat glomeruli compared to the 
control groups of each species.  
Mouse Rat 
Gene  Fold change Gene  Fold change 
lipocalin 2, NGAL 
(LCN2) 
8.7 lipocalin 2 (NGAL) 3.7 
collagen, type III, 
alpha 1 (Col3a1) 
4.9 collagen, type III, alpha 
1 (Col3a1) 
6.3 
fibronectin 1 3.8 fibronectin 1 3.5 
CD44 antigen 3.3 CD44 molecule 2.0 
complement 
component 1, q 
subcomponent, alpha 
polypeptide (C1qa) 
3.3 complement component 
1, q subcomponent, A 
chain (C1qa) 
2.9 
complement 
component 1, q 
subcomponent, C 
chain (C1qc) 
3.0 complement component 
1, q subcomponent, C 
chain (C1qc) 
2.2 
early growth response 
2 (Egr2) 
2.9 early growth response 2 
(Egr2) 
2.5 
C-type lectin domain 
family 7, member a 
(Clec7a) 
2.8 C-type lectin domain 
family 7, member a 
(Clec7a) 
3.4 
Interleukin-33 (IL-33) 2.8 Interleukin-33 (IL-33) 2.3 
B-cell 
leukaemia/lymphoma 
2-related protein A1a 
(Bcl2a1a /// Bcl2a1b /// 
Bcl2a1d) 
2.7 B-cell 
leukaemia/lymphoma 2-
related protein A1d 
(Bcl2a1d) 
2.0 
collagen, type I, alpha 
1 (Col1a1) 
2.7 collagen, type I, alpha 1 
(Col1a1) 
2.5 
histocompatibility 2, 
class II antigen A, 
alpha (H2-Aa) 
2.6 RT1 class II, locus Ba 
(RT1-Ba) 
2.6 
membrane-spanning 
4-domains, subfamily 
A, member 6D 
(Ms4a6d) 
2.6 membrane-spanning 4-
domains, subfamily A, 
member 11 (Ms4a11) 
3.6 
histocompatibility 2, 
class II antigen A, beta 
1 (H2-Ab1) 
2.6 RT1 class II, locus Bb 
(RT1-Bb) 
2.6 
Lysosomal-associated 
protein 
transmembrane 5 
(Laptm5) 
2.6 lysosomal-associated 
protein transmembrane 
5 (Laptm5) 
2.3 
membrane-spanning 
4-domains, subfamily 
A, member 6B 
(Ms4a6b) 
2.5 membrane-spanning 4-
domains, subfamily A, 
member 6B (Ms4a6b) 
2.2 
histocompatibility 2, 
class II antigen E beta 
(H2-Eb1) 
2.4 RT1 class II, locus Db1 
(RT1-Db1) 
 
2.6 
lectin, galactose 
binding, soluble 3 
(Lgals3) 
2.4 lectin, galactoside-
binding, soluble, 3 
(Lgals3) 
3.6 
serine (or cysteine) 
peptidase inhibitor, 
2.3 serine (or cysteine) 
peptidase inhibitor, 
3.9 
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clade E, member 1 
(Serpine1) 
clade E, member 1 
(Serpine1) 
CD74 antigen 
(invariant polypeptide 
of major 
histocompatibility 
complex, class II 
antigen-associated) 
(CD74) 
2.3 Cd74 molecule, major 
histocompatibility 
complex, class II 
invariant chain (CD74) 
2.7 
lysozyme 2 (Lyz2) 2.3 lysozyme 2 (Lyz2) 2.4 
CD68 antigen (CD68) 2.2 CD68 molecule (CD68) 2.0 
cathepsin S (Ctss) 2.2 cathepsin S (Ctss) 2.1 
allograft inflammatory 
factor 1 (Aif1) 
2.1 allograft inflammatory 
factor 1 (Aif1) 
3.0 
secreted 
phosphoprotein 1 
(Spp1) 
2.1 secreted 
phosphoprotein 1 
(Spp1) 
5.8 
hepatitis A virus 
cellular receptor 1 
(Havcr1) 
2.0 hepatitis A virus cellular 
receptor 1 (Havcr1) 
2.9 
collagen, type VI, 
alpha 1 (Col6a1) 
2.0 collagen, type VI, alpha 
1 (Col6a1) 
2.5 
EGF-like module 
containing, mucin-
like, hormone 
receptor-like 
sequence 1 (Emr1) 
2.0 EGF-like module 
containing, mucin-like, 
hormone receptor-like 1 
(Emr1) 
2.3 
coronin, actin binding 
protein 1A (Coro1a) 
2.0 coronin, actin binding 
protein 1A (Coro1a) 
2.1 
ecotropic viral 
integration site 2a 
(Evi2a) 
2.0  ecotropic viral 
integration site 2A 
(Evi2a) 
2.1 
 
Organising the genes according to their biological processes 
I also studied the upregulated genes in tubules of the diseased mouse and rat compared 
to the control groups. I organised upregulated genes in mouse glomeruli according to their 
biological processes. I also included the upregulated genes in the glomeruli that were 
common to both the mouse and rat and also the upregulated genes in mouse tubules 
compared to the control. Some of the genes that were upregulated in mouse glomeruli are 
involved in macrophage activation, such as Aif1, Col3a1, Col1a2, and Cd209a. For example, 
Aif1 is related to the inflammatory status of macrophages and it is also involved in the 
migration, survival, and pro-inflammatory properties of macrophages (Yang, Ho et al. 2005). 
Other genes were found to be involved in complement activation, as shown in Table 4.6. In 
addition, some of the genes identified are involved in antigen processing and presentation, 
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such as the MHCII gene. Furthermore, some of the genes found are related to cell adhesion, 
such as CD44, Fn1, Havcr1, CD48, and CD209a. We also identified genes that are involved 
in cell surface receptor-linked signal transduction, such as CX3CR1, CCR2, CCL9, and Fn1.  
Table 4.6. Grouping of the upregulated genes according to their biological processes. The 
genes that were upregulated in mouse glomeruli and mouse tubules, and also the upregulated genes 
common to both mouse and rat glomeruli, were divided into different groups according to their 
biological processes.  
Biological 
process 
Diseased mouse vs. control 
(glomeruli) 
Common to both mouse and rat 
G (glomeruli) 
Macrophage 
activation 
Collagen alpha-1(III) chain (Col3a1), 
Collagen alpha-1(I) chain (Col1a1),  
C-type lectin domain family 6 member 
A (Clec6a),  
Cxcl5,  
Allograft inflammatory factor 1 (Aif1),  
Cxcl2 M1,  
Collagen alpha-1(VI) chain (Col6a1), 
CD209 antigen-like protein A 
(Cd209a),  
Arachidonate 5-lipoxygenase-
activating protein (Alox5ap),  
EGF-like module-containing mucin-like 
hormone receptor-like 1 (Emr1) 
F4/80M1/M2,  
Collagen alpha-2(I) chain (Col1a2), 
CXCl9, Protein S100-A9 (S100a9) M1 
Protein S100-A8 (S100a8) M1 
Collagen alpha-1(III) chain (Col3a1), 
Collagen alpha-1(I) chain (Col1a1), 
Allograft inflammatory factor 1 (Aif1),  
Collagen alpha-1(VI) chain (Col6a1), 
EGF-like module-containing mucin-
like hormone receptor-like 1 (Emr1), 
Complement 
activation 
Complement C1q subcomponent 
subunit C (C1qc),  
Collagen alpha-1(III) chain (Col3a1), 
Complement C1q subcomponent 
subunit A (C1qa),  
Collagen alpha-1(I) chain (Col1a1), 
Collagen alpha-1(VI) chain (Col6a1), 
Collagen alpha-2(I) chain (Col1a2), 
Haptoglobin beta chain (HP), 
Complement factor I light chain (Cfi), 
Complement C1q subcomponent 
subunit B (C1qb), 
Complement C1q subcomponent 
subunit C (C1qc), Collagen alpha-
1(III) chain (Col3a1), Complement 
C1q subcomponent subunit A (C1qa), 
Collagen alpha-1(I) chain (Col1a1), 
Collagen alpha-1(VI) chain (Col6a1), 
Cell Adhesion Collagen alpha-1(III) chain (Col3a1), 
Complement C1q subcomponent 
subunit C (C1qc),  
C-type lectin domain family 7 member 
A (Clec7a),  
CD44 antigen (CD44),  
Hepatitis A virus cellular receptor 1 
homolog (Havcr1),  
Complement C1q subcomponent 
subunit A (C1qa),  
Dipeptidyl-peptidase 1 light chain 
(Ctsc),  
Cadherin-11 (Cdh11),  
Collagen alpha-1(I) chain (Col1a1),  
C-type lectin domain family 6 member 
Collagen alpha-1(III) chain (Col3a1), 
CD44 antigen (CD44), Complement 
C1q subcomponent subunit C (C1qc), 
C-type lectin domain family 7 member 
A (Clec7a), Complement C1q 
subcomponent subunit A (C1qa), 
Hepatitis A virus cellular receptor 1 
homolog (Havcr1), Collagen alpha-
1(I) chain (Col1a1), Fibronectin (Fn1), 
Collagen alpha-1(VI) chain (Col6a1), 
Cathepsin S (Ctss), EGF-like module-
containing mucin-like hormone 
receptor-like 1 (Emr1), Sphingosine-
1-phosphate phosphatase 1 (Spp1), 
Galectin-3 (Lgals3), Leucocyte 
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A (Clec4n),  
Collagen alpha-1(VI) chain (Col6a1), 
Fibronectin (Fn1),  
CD209 antigen-like protein A 
(CD209a),  
Cathepsin S (Ctss),  
CD48 antigen (CD48),  
EGF-like module-containing mucin-like 
hormone receptor-like 1 (Emr1), 
Collagen alpha-2(I) chain (Col1a2), 
Sphingosine-1-phosphate 
phosphatase 1 (Spp1),  
Galectin-3 (Lgals3),  
Leucocyte common antigen (Ptprc), 
Osteopontin (Spp1),  
Fibrinogen gamma chain (Fgg), 
Leucine-rich repeat LGI family member 
2 (Lgi2),  
Complement C1q subcomponent 
subunit B (C1qb), 
common antigen (Ptprc),  
Antigen 
processing and 
presentation 
H-2 class II histocompatibility antigen, 
E-B beta chain (H2-Eb1), 
H-2 class II histocompatibility antigen 
gamma chain (CD74), 
Allograft inflammatory factor 1 (Aif1), 
Cathepsin S (Ctss), 
H-2 class II histocompatibility antigen, 
A-B alpha chain (H2-Aa), 
H-2 class II histocompatibility antigen, 
A beta chain (H2-Ab1), 
H-2 class II histocompatibility antigen, 
E-B beta chain (H2-Eb1), H-2 class II 
histocompatibility antigen gamma 
chain (CD74), Allograft inflammatory 
factor 1 (Aif1), Cathepsin S (Ctss), H-
2 class II histocompatibility antigen, 
A-B alpha chain (H2-Aa), H-2 class II 
histocompatibility antigen, A beta 
chain (H2-Ab1), 
Cell surface 
receptor signal 
transduction 
Membrane-spanning 4-domains 
subfamily A member 6D (Ms4a6d), 
Mast cell surface glycoprotein Gp49A 
(Gp49a), 
CX3C chemokine receptor 1 (Cx3cr1), 
Hepatitis A virus cellular receptor 1 
homologue (Havcr1), 
CCL9 (31-101) (CCL9), 
Ras-related protein Rab-32 (Rab32), 
Cadherin-11 (Cdh11), 
C-type lectin domain family 6 member 
A (Clec4n), 
GCP-2(9-78) (CxCl5), 
C-X-C chemokine receptor type 4 
(Cxcr4), 
Allograft inflammatory factor 1 (Aif1), 
C-X-C motif chemokine 2 (Cxcl2), 
Fibronectin (Fn1), 
CD209 antigen-like protein A 
(CD209a), 
CD48 antigen (CD48), 
C3a anaphylatoxin chemotactic 
receptor (C3ar1), 
EGF-like module-containing mucin-like 
hormone receptor-like 1 (Emr1), 
Forkhead box protein I1 (Foxi1), 
Leucocyte common antigen (Ptprc), 
C-C chemokine receptor type 2 (Ccr2), 
Leucine-rich repeat LGI family member 
2 (Lgi2), 
Membrane-spanning 4-domains 
subfamily A member 6D (Ms4a6d), 
Hepatitis A virus cellular receptor 1 
homologue (Havcr1), Allograft 
inflammatory factor 1 (Aif1), 
Fibronectin (Fn1), EGF-like module-
containing mucin-like hormone 
receptor-like 1 (Emr1), Leucocyte 
common antigen (Ptprc), Membrane-
spanning 4-domains subfamily A 
member 6B (Ms4a6b), Regulator of 
G-protein signalling 10 (Rgs10),  
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C-X-C motif chemokine 9 (Cxcl9), 
Olfactomedin-4 (Olfm4), 
Membrane-spanning 4-domains 
subfamily A member 6B (Ms4a6b), 
Regulator of G-protein signalling 10 
(Rgs10), 
Suppressor of cytokine signalling 2 
(Socs2) 
 
Gene organisation in the different pathways 
These upregulated genes are involved in different pathways, as shown in Figure 4.13. 
Five genes were found to be related to T-cell activation: CD74, H2-Aa, H2-DMa, H2-DMb1, 
and Vav1. Furthermore, genes such as Eif2s1, Aif1, and Bcl2a1a are involved in the 
apoptosis signalling pathway. In addition, genes that are involved in inflammation mediated 
by the chemokine and cytokine signalling pathways include Cxcr1, Ilf1f6, C3ar1, CCR2, and 
Vav1. Also, Fn1 and Col3a1 are involved in the integrin signalling pathway.  
Table 4.7: Grouping of the upregulated genes according to different pathways. Upregulated 
genes in mouse glomeruli and mouse tubules and the upregulated genes common to both mouse and 
rat glomeruli were divided into their different biological pathways.  
Pathway Diseased mouse vs. control 
(glomeruli) 
Common to both mouse and 
rat (glomeruli) 
Inflammation 
mediated by 
chemokine and 
cytokine signalling 
pathways 
Cx3cr1,  
Cxcr4,  
Prostaglandin G/H synthase 2 
(ptgs2), Col6a1,  
C3ar1,  
Arachidonate 5-lipoxygenase-
activating protein (Alox5ap),  
Ccr2 
Col6a1 
Integrin signalling 
pathway 
Collagen alpha-1(III) chain (Col3a1), 
Collagen alpha-1(I) chain (Col1a1), 
Fibronectin (fn1), Collagen alpha-
1(VI) chain (Col6a1), Collagen alpha-
2(I) chain (Col1a2) 
Collagen alpha-1(III) chain 
(Col3a1), Collagen alpha-1(I) 
chain (Col1a1), Fibronectin (fn1), 
Collagen alpha-1(VI) chain 
(Col6a1) 
T-cell activation H-2 class II histocompatibility antigen 
gamma chain (CD74),  
H-2 class II histocompatibility 
antigen,  
A-B alpha chain (H2-Aa),  
Leucocyte common antigen (Ptprc) 
H-2 class II histocompatibility 
antigen gamma chain (CD74),  
H-2 class II histocompatibility 
antigen,  
A-B alpha chain (H2-Aa),  
Leucocyte common antigen 
(Ptprc) 
Blood coagulation Plasminogen activator inhibitor 1 
(Serpine1), Fibrinogen gamma chain 
(Fgg) 
Plasminogen activator inhibitor 1 
(Serpine1) 
Apoptosis signalling 
pathway 
Allograft inflammatory factor 1 (Aif1),  
Bcl-2-related protein A1 (Bcl2a1a) 
Allograft inflammatory factor 1 
(Aif1),  
Bcl-2-related protein A1 (Bcl2a1a) 
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Figure 4.13: Pathway analysis. Upregulated genes in mouse glomeruli (B), mouse tubules (D), and 
upregulated genes common to both mouse and rat glomeruli (C) were sorted according to their 
different biological pathways. (A) The whole mouse genome divided into different pathways.  
Genes associated with macrophage activation and recruitment 
I found several upregulated genes that were associated with the trafficking and activation 
of macrophages. One of these genes was CCR2, which encodes the monocyte 
chemoattractant protein 1 (MCP-1) receptor. In addition, CX3CR1, a receptor of fractalkine, 
was upregulated in the mouse glomeruli and is known to be involved in macrophage 
recruitment. Furthermore, genes that are associated with macrophage activation such as 
CXCL2, which is also known as macrophage inflammatory protein 2-alpha, were 
upregulated. Some of these genes were associated with classically activated macrophages 
such as calprotectin (S100a8 and S100a9) and CxCl2. Furthermore, genes known to be 
macrophage markers, such as CD68 and EGF-like module-containing mucin-like hormone 
receptor-like 1(Emr1), which is also known as F4/80 in the mouse, were also upregulated.  
Genes common to the mouse, rat and humans 
I compared the upregulated genes in mouse and rat glomeruli to those found in human 
glomeruli (human results obtained from ERCB, Dr. Clemens Cohen) (table 4.8). Again, 
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genes associated with macrophage accumulation in the kidney, such as CD68 (a 
macrophage marker) and EMR1 (also known as F4/80), were upregulated. Some of the 
other genes that were upregulated are part of the complement pathway, such as C1qa and 
C1qc.  
Table 4.8: Upregulated genes common to mouse, rat and human glomeruli compared to the 
control glomeruli in each species. 
Mouse gene 
symbol 
Mouse gene title Mouse 
P value 
Mouse  
fold 
change 
Rat gene 
symbol 
Rat 
P 
value 
Rat 
fold 
chang
e 
Human 
gene 
symbol 
Lcn2 lipocalin 2 8.779E-
05 
8.705 Lcn2 5.49E-
05 
3.708 LCN2 
Col3a1 collagen, type III, 
alpha 1 
1.513E-
04 
4.898 Col3a1 3.81E-
05 
6.278 COL3A1 
Fn1 fibronectin 1 1.143E-
04 
3.852 Fn1 1.37E-
04 
3.484 FN1 
Cd44 CD44 antigen 1.078E-
03 
3.344 Cd44 6.97E-
03 
2.052 CD44 
C1qa complement 
component 1, q 
subcomponent, 
alpha polypeptide 
2.666E-
04 
3.273 C1qa 1.01E-
04 
2.904 C1QA 
C1qc complement 
component 1, q 
subcomponent, C 
chain 
2.253E-
04 
3.005 C1qc 6.92E-
04 
2.243 C1QC 
Col3a1 collagen, type III, 
alpha 1 
5.355E-
05 
2.963 Col3a1 3.81E-
05 
6.278 COL3A1 
Egr2 early growth 
response 2 
2.666E-
03 
2.880 Egr2 1.22E-
03 
2.499 EGR2 
Clec7a C-type lectin 
domain family 7, 
member a 
1.350E-
03 
2.844 Clec7a 2.10E-
04 
3.415 CLEC7A 
Il33 interleukin 33 2.391E-
03 
2.777 Il33 1.18E-
03 
2.269 IL33 
Bcl2a1a /// 
Bcl2a1b /// 
Bcl2a1d 
B-cell 
leukaemia/lymph
oma 2-related 
protein A1a /// B-
cell 
leukaemia/lymph
oma 2-related 
protein A1b /// B-
cell 
leukaemia/lymph
oma 2-related 
protein A1d 
3.244E-
04 
2.670 Bcl2a1d 3.20E-
04 
2.025 BCL2A1 
Col1a1 collagen, type I, 
alpha 1 
2.238E-
03 
2.662 Col1a1 5.23E-
03 
2.472 COL1A1 
Col1a1 collagen, type I, 
alpha 1 
2.238E-
03 
2.662 Col1a1 1.05E-
02 
2.160 COL1A1 
H2-Aa histocompatibility 3.425E- 2.636 RT1-Ba 2.89E- 2.651 HLA-
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2, class II antigen 
A, alpha 
04 05 DQA1 
Ms4a6d membrane-
spanning 4-
domains, 
subfamily A, 
member 6D 
6.743E-
04 
2.614 Ms4a11 4.79E-
04 
3.613 MS4A6A 
H2-Ab1 histocompatibility 
2, class II antigen 
A, beta 1 
2.247E-
03 
2.585 RT1-Bb 3.61E-
05 
2.565 HLA-
DQB1 
Laptm5 lysosomal-
associated 
protein 
transmembrane 5 
1.543E-
03 
2.582 Laptm5 2.68E-
04 
2.304 LAPTM5 
Egr2 early growth 
response 2 
4.321E-
03 
2.557 Egr2 1.22E-
03 
2.499 EGR2 
Ms4a6b membrane-
spanning 4-
domains, 
subfamily A, 
member 6B 
6.256E-
05 
2.495 Ms4a6b 2.84E-
03 
2.210 MS4A6A 
H2-Ab1 histocompatibility 
2, class II antigen 
A, beta 1 
2.871E-
04 
2.475 RT1-Bb 3.61E-
05 
2.565 HLA-
DQB1 
H2-Eb1 histocompatibility 
2, class II antigen 
E beta 
9.155E-
05 
2.422 RT1-Db1 4.20E-
04 
2.580 HLA-
DRB1 
H2-Eb1 histocompatibility 
2, class II antigen 
E beta 
9.155E-
05 
2.422 RT1-Db1 3.60E-
05 
2.477 HLA-
DRB1 
Lgals3 lectin, galactose 
binding, soluble 3 
2.540E-
03 
2.388 Lgals3 1.86E-
04 
3.623 LGALS3 
Serpine1 serine (or 
cysteine) 
peptidase 
inhibitor, clade E, 
member 1 
2.585E-
03 
2.323 Serpine1 1.07E-
03 
3.979 SERPIN
E1 
Serpine1 serine (or 
cysteine) 
peptidase 
inhibitor, clade E, 
member 1 
2.585E-
03 
2.323 Serpine1 5.91E-
03 
2.396 SERPIN
E1 
Cd74 CD74 antigen 
(invariant 
polypeptide of 
major 
histocompatibility 
complex, class II 
antigen-
associated) 
2.342E-
04 
2.305 Cd74 7.14E-
05 
2.720 CD74 
Lyz2 lysozyme 2 8.180E-
04 
2.272 Lyz2 8.90E-
05 
2.425 LYZ 
Cd68 CD68 antigen 2.657E-
02 
2.247 Cd68 1.89E-
02 
2.080 CD68 
H2-Ab1 histocompatibility 
2, class II antigen 
A, beta 1 
1.296E-
04 
2.243 RT1-Bb 3.61E-
05 
2.565 HLA-
DQB1 
Ctss cathepsin S 1.415E-
04 
2.242 Ctss 1.36E-
03 
2.174 CTSS 
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Aif1 allograft 
inflammatory 
factor 1 
8.242E-
04 
2.178 Aif1 2.41E-
04 
3.002 AIF1 
Rgs10 regulator of G-
protein signalling 
10 
3.649E-
03 
2.172 Rgs10 1.03E-
05 
2.933 RGS10 
Spp1 secreted 
phosphoprotein 1 
3.153E-
03 
2.129 Spp1 1.83E-
06 
5.812 SPP1 
H2-Aa histocompatibility 
2, class II antigen 
A, alpha 
1.585E-
04 
2.128 RT1-Ba 2.89E-
05 
2.651 HLA-
DQA1 
Lyz1 lysozyme 1 1.527E-
03 
2.096 Lyz2 8.90E-
05 
2.425 LYZ 
Havcr1 hepatitis A virus 
cellular receptor 1 
1.498E-
02 
2.087 Havcr1 7.88E-
06 
2.928 HAVCR1 
Col6a1 collagen, type VI, 
alpha 1 
6.592E-
03 
2.080 Col6a1 4.29E-
05 
2.537 no 
human 
homolog 
Emr1 EGF-like module 
containing, 
mucin-like, 
hormone 
receptor-like 
sequence 1 
3.499E-
03 
2.065 Emr1 2.86E-
04 
2.254 EMR1 
Coro1a coronin, actin 
binding protein 
1A 
2.929E-
03 
2.031 Coro1a 2.45E-
04 
2.186 CORO1
A 
Coro1a coronin, actin 
binding protein 
1A 
4.238E-
03 
2.030 Coro1a 2.45E-
04 
2.186 CORO1
A 
Evi2a ecotropic viral 
integration site 2a 
2.183E-
03 
2.028 Evi2a 4.02E-
03 
2.102 EVI2A 
Ptprc protein tyrosine 
phosphatase, 
receptor type, C 
2.157E-
02 
2.006 Ptprc 9.26E-
04 
2.132 PTPRC 
Ptprc protein tyrosine 
phosphatase, 
receptor type, C 
2.157E-
02 
2.006 Ptprc 4.39E-
03 
2.039 PTPRC 
 
4.3.4. The effect of liposomal clodronate on passively transferred antibodies 
When I first started, I planned to use liposomal clodronate to deplete macrophages. 
However, we observed an effect on the level of passively transferred antibodies in 
clodronate-treated mice in the first pilot experiment. Clodronate and saline-treated mice 
received equal amounts of anti-MPO antibodies (100 µg/g) but the level of anti-MPO 
antibodies detected in clodronate-treated mice was significantly less than in saline-treated 
mice (Figure 4.14, A). This meant that, for some reason, some of the antibodies that were 
injected into the clodronate-treated mice were lost.   
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Figure 4.14: Anti-MPO antibodies in clodronate and saline-treated mice. A: A significant 
difference was found in the level of anti-MPO antibodies between clodronate and saline-treated mice 
(unpaired t-test). B: Dilution curve to calculate the anti-MPO antibody titre, which was EC50=71-92 in 
saline-treated mice and EC50=31-50 in clodronate-treated mice.  
4.3.5. CD68 immunohistochemistry on mouse paraffin sections 
Immunohistochemical staining for CD68 was used to check for the presence of 
macrophages in the liver, lung, kidney, and spleen in all of the mice that were used in the 
pilot MEV experiment. Macrophages were not seen in the kidney sections from either saline 
or clodronate-treated groups, which is consistent with the mild histological phenotype 
described above (Figure 4.15, C and D). In addition, the liver and lung sections from both 
groups were similar when analysed under the microscope after CD68 staining. On the other 
hand, there was a marked decrease in macrophages in spleen sections from clodronate-
treated mice (Figure 4.15, B) compared to spleen sections from saline-treated mice (Figure 
4.15, A). There were more stained cells in the control spleen sections.   
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Figure 4.15: CD68 staining in mouse paraffin sections. The stained cells in these sections are 
macrophages. Some of these sections were treated with clodronate to deplete macrophages and 
staining was performed to see how effective clodronate was in depleting them. Staining was also 
performed to determine whether or not macrophages were present in the kidney after treating these 
mice with the anti-MPO antibody. A: spleen section from saline-treated mouse; B: spleen section from 
clodronate-treated mouse; C: kidney section from saline-treated mouse; D: kidney section from 
clodronate-treated mouse. 
4.3.6. Depletion of macrophages using anti-mouse CCR2 
Although clodronate was effective in depleting macrophages (as shown by IHC staining in 
the spleen), it had a negative effect on passively transferred antibodies for reasons that were 
not clear. As a result, I decided to use another method to deplete the macrophages: an anti-
mouse CCR2 (MC-21) antibody. It was very effective in depleting blood monocytes that 
expressed CCR2. These cells were also Gr1+CD11b+ monocytes, as shown by flow 
cytometry. These blood monocytes differentiate into classically activated macrophages in the 
tissue and also into Tip-DCs (TNF/iNOS-producing cells), as mentioned above. The CCR2 
marker was upregulated in mouse glomeruli, as shown by the Affymetrix array. Monocyte 
depletion was monitored throughout the experiment to make sure that the number of these 
cells stayed low (Figure 4.16, B). As a result, the number of Gr1+CD11b+ monocytes was 
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kept low throughout the experiment compared to mice from the control group (IgG2b treated) 
and untreated mice.  
 
Figure 4.16: Monocyte depletion. The GR1+CD11b+ monocytes were depleted using 20 µg of anti-
mouse CCR2. There was big reduction in the number of GR1+ monocytes on day 0 in the MC-21-
treated mouse compared to the IgG2b-treated mouse, as shown by FACS analysis (A). Monocytes 
were monitored throughout the experiment and the number of these cells remained low in MC-21-
treated mice (n=4) compared to IgG2b (n=4)-treated and untreated mice (B).  
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Induction of AAV in MC-21 and IgG2b-treated mice 
These mice were injected with 75 µg/g of anti-MPO antibodies and urine was collected to 
assess the disease status. Urine was collected on days 1 and 6. All mice had haematuria on 
day 6, which was between +1 and +4 (Figure 4.17, A). In addition, no significant difference 
was found between the MC-21 and IgG2b-treated mice in terms of the albumin/creatinine 
ratio (Figure 4.17, B).  
 
Figure 4.17: Urine analysis in the monocyte depletion experiment. The mice were negative for 
haematuria on day 1 and they had all developed urine haematuria by day 6 (A). The urine was 
collected from three MC-21-treated mice for technical reasons. No significant difference was found in 
the albumin/creatinine ratio (B); t-test (Mann-Whitney test).  
Histological analysis 
Histological sections were prepared in order to assess the disease in these mice. Kidney 
sections were used for the analysis and were stained with H&E or PAS. Mice from both 
groups (MC-21(figure 4.18 A and C) and IgG2b (figure 4.18 B) treated) had crescents, 
indicating a severe form of disease. However, no significant difference was found between 
MC-21 and IgG2b-treated mice in terms of the percentage of crescents (figure 4.18 D).  
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Figure 4.18: Histological analysis of the monocyte depletion experiment. Mice from both groups 
(MC-21 and IgG2b treated) developed crescents and necrosis (A and C). The arrows show crescents 
and necrosis in the glomeruli. No significant difference was found in the severity of the disease 
(estimated by the number of crescents), P=0.68 (D) using a t-test (Mann-Whitney test) analysis.  
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Figure 4.19: Histological sections from the anti-mouse CCR2 antibody experiment. Mice 
received 75 µg/g anti-MPO antibodies and 1,500 EU/g of LPS. They were treated with MC-21(F) or 
IgG2b (A, B, C, D, E). Mice from both groups developed crescents and necrosis. The arrows 
represent crescents and necrosis.  
Immunohistochemical staining 
The GR1+CD11b+ monocytes were depleted from the blood using anti-mouse CCR2, but 
CD68 staining in the frozen mouse sections showed the presence of some macrophages in 
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the kidney on day 6. Macrophages were detected in both IgG2b-treated (Figure 4.20, A and 
B) and MC-21-treated mice (Figure 4.20, D), and no significant difference was found in the 
total number of CD68-stained macrophages in the kidney between the two groups (Figure 
4.20, D). This means that these macrophages could be resident macrophages or that some 
monocytes were still able to infiltrate to the kidney after anti-mouse CCR2 antibody 
treatment.  
 
Figure 4.20: CD68 staining in the macrophage depletion experiment. Kidney sections from mice 
treated with MC-21 or IgG2b were stained for CD68. Macrophages were found in both MC-21 (D) and 
IgG2b (A and B)-treated mice. The number of macrophages is very low compared to the previous 
experiment. No significant difference in the total number of CD68-positive cells was found between 
the two groups (C); t-test (Mann-Whitney test) analysis.  
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4.4. Discussion 
 
In this chapter, I studied different methods of depleting macrophages and the effect of this 
depletion on the development of vasculitis in mice. Although clodronate was effective in 
depleting macrophages, it also had a negative effect on the passively transferred antibodies. 
As a result, we used anti-mouse CCR2 to deplete the blood monocytes and we found no 
significant differences between MC-21 and IgG2b-treated mice in the percentage of 
crescents. We investigated the macrophage phenotype in anti-MPO and anti-BSA-treated 
mice. The staining of serial sections from the kidney showed different staining patterns for 
CD206 (M2 macrophage marker) and CD68. I concluded that the macrophages found in the 
crescents were M1 macrophages. In addition, I studied gene expression in the glomeruli and 
tubules from anti-MPO-treated mice compared to gene expression in anti-BSA-treated mice 
(in rats and mice). I found 146 genes that were upregulated in mouse glomeruli and 139 
genes upregulated in rat glomeruli. I found 42 genes common to both rats and mice, 
including lipocalin-2 and hepatitis A virus cellular receptor 1, among others.  
In order to understand the role of macrophages in the development of AAV, I investigated 
the phenotype of macrophages in anti-MPO-treated mice and compared it to those from anti-
BSA treated-mice in both glomeruli and tubules. I found macrophages in the crescent areas 
of the glomeruli, as shown by CD68 staining. These cells did not express the mannose 
receptor, as shown by CD206 staining on serial kidney sections, although Chavele et al. 
(Chavele, Martinez-Pomares et al. 2010) showed the importance of the mannose receptor in 
the induction of crescentic glomerulonephritis in mice. They showed that animals were 
protected from the development of glomerulonephritis in mannose receptor-knockout mice 
(nephrotoxic nephritis model). They concluded that, through the mannose receptor (MR), 
mesangial cells underwent increased apoptosis and macrophages had diminished Fc-
mediated function. They also concluded that FcR and MR could interact through binding to 
nephrotoxic globulin. In addition, macrophages from Mr-/- mice showed an anti-inflammatory 
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phenotype after ingesting apoptotic mesangial cells. I discovered that CD206 macrophages 
were either not found in the crescents or were found in small numbers, but I also found that 
CD206 is expressed by mesangial cells. I showed that most of the CD68-positive cells in the 
ANCA-associated vasculitis model did not express the mannose receptor and we concluded 
that these were M1 macrophages. We think that M1 macrophages are more involved in the 
development of vasculitis in mice than M2 macrophages. Macrophages show a variety of 
phenotypes (Gordon 2003), and it could be that these alternatively activated macrophages 
were different in our model to those in their model (Chavele, Martinez-Pomares et al. 2010). 
Another explanation could be that these M2 macrophages are important and are involved in 
the development of the disease by switching from M2 to M1-type macrophages. Another 
explanation could be that other factors or cells are affected by the absence of the mannose 
receptor and these could be involved in the development of the disease.   
We know that the innate immune system is important for the initiation and amplification of 
inflammatory responses. This led me to further investigate the role of the innate immune 
system in ANCA-associated vasculitis by looking at the gene expression in animal models of 
vasculitis. We found genes that were upregulated in mouse and rat glomeruli compared to 
glomeruli from control animals. I found that some these genes are involved in complement 
activation. The importance of complement in renal disease has been reported in different 
studies. Brooimans et al reported the ability of proximal tubular epithelial cells from human 
kidny to synthesis complement (Brooimans, Stegmann et al. 1991). Xiao et al. showed the 
involvement of complement in the development of ANCA-associated vasculitis in mice (Xiao, 
Schreiber et al. 2007). They showed that the alternative complement pathway, rather than 
the classical pathway, was involved in development of the disease. In our study, 
complement components such as C1qa and C1qc were highly upregulated in both mice and 
rats, which suggests the involvement of a classical complement pathway. However, 
complement factor I (Cfi) was also upregulated in mice, and this complement component 
inhibits and regulates the formation of C3 convertase in all complement pathways. This 
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suggests the absence of complement involvement in our model. It could be that complement 
is only involved in the early stages of the disease, which is why C5 and factor B-knockout 
mice were protected.    
 
Figure 4.21: Complement pathways. There were some upregulated genes in the mouse glomeruli 
that were involved in complement activation, such as C1q, which is part of the classical complement 
pathway. However, there was an upregulation of complement factor I, which inhibits and regulates the 
formation of C3 convertase. The red arrows show the upregulated genes in mouse glomeruli.  
In addition, I found that some of these upregulated genes were involved in macrophage 
activation. As a result, I wanted to investigate whether these genes would confirm my work 
on macrophage phenotyping. The upregulated genes in mouse glomeruli that were involved 
in macrophage activation included protein S100-A8 and protein S100-A9. These two 
proteins formed a complex called calprotectin. Fujiu et al. showed the ability of kruppel-like 
factor-5 (KLF5) to induce the expression of S100a8 and S100a9 in a unilateral ureteral 
obstruction model (Fujiu, Manabe et al. 2011). They showed the involvement of these 
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proteins in the recruitment of Ly6C+ inflammatory monocytes and then triggered the 
differentiation of these cells to M1-type macrophages. These cells were shown to 
accumulate in the kidney on days 1-4, at time when S100a8 and S100a9 expression 
peaked. This confirms the involvement of M1 macrophages in kidney injury and supports my 
macrophage phenotype work and the decision to deplete Ly6C+ monocytes to halt the 
disease. Fujiu et al. were able to recruit adaptively transferred Ly6C+ monocytes to the 
kidney following S100a8/a9 injection. Furthermore, there was an upregulation of chemokine 
receptors involved in monocyte and macrophage infiltration and accumulation. One of these 
receptors was CCR2, which is found on GR1+ monocytes that mature into inflammatory 
macrophages and dendritic cells in tissue (Auffray, Sieweke et al. 2009). This supports my 
hypothesis, which suggests that blocking CCR2 could be beneficial in preventing disease 
development.       
I believe that macrophages are involved in renal vasculitis and that they are an important 
part of the development of this disease because large numbers of macrophages infiltrating 
the kidney have been reported in ANCA-associated vasculitis (Weidner, Carl et al. 2004; 
Xiao, Heeringa et al. 2005). In addition, macrophage depletion in other types of crescentic 
glomerulonephritis have provided protection against the disease. Over the years, many 
studies have been performed to investigate the cells involved in ANCA-associated vasculitis. 
I performed a pilot experiment to deplete macrophages from WT mice that were injected with 
anti-MPO antibody in order to assess the utility of liposomal clodronate in this approach. 
Clodronate has previously been used as a strategy to deplete macrophages and to study the 
function of macrophages in vivo (Van Rooijen and Sanders 1994). My results did not provide 
sufficient evidence to show that macrophages were important in the development of 
vasculitis because the disease was mild. Then, CD68 staining was performed on paraffin-
fixed sections to investigate the presence of macrophages in the kidney and, specifically, in 
glomeruli. A few macrophages were detected by immunohistochemical staining in a saline-
treated kidney, but they were only seen in tubules; this could have been because the 
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disease was very mild. Only one mouse showed crescents, in <1% of the glomeruli. 
However, my results showed that clodronate was very effective in depleting macrophages in 
the spleen. Claassen et al. showed that liposome-encapsulated clodronate was effective in 
depleting macrophages both in vivo and in vitro (Claassen I, Van Rooijen N et al. 1990). My 
results and the results of previous studies show that liposomal clodronate is effective in 
depleting macrophages, and I believe it is an important tool for studying the function of 
macrophages in glomerulonephritis in mice.  
However, fewer anti-MPO antibodies were detected in the serum of mice that received 
clodronate compared to mice in the control group. All of these mice received similar amounts 
of anti-MPO antibodies, which suggests that they should have had the same level of anti-
MPO antibodies in their serum. According to these results, I suggested that clodronate may 
have had an effect on the passively transferred antibodies. This effect could have been 
caused by macrophages engulfing clodronate and the antibodies as well. For this reason, I 
decided to investigate different methods of depleting macrophages and to determine 
whether previous studies performed using clodronate on antibody-induced disease were 
affected by this finding, or whether it was just specific to ANCA IgG. Huang et al. used 
liposomal clodronate to deplete macrophages in anti-GBM glomerulonephritis in rats (Huang, 
Tipping et al. 1997). They also used anti-T-cell antibodies and found that they reduced 
macrophage infiltration. They showed that the level of the anti-GBM antibody was not 
affected in rats when anti-T-cell antibodies were used, but they did not show the level of anti-
GBM when the mice were treated with clodronate. There are other examples in the literature 
where clodronate was used. Cittera et al. showed a beneficial effect of the inhibition of 
rituximab on tumours following clodronate treatment. They suggested an important role of 
macrophages in rituximab treatment, but they were not able to observe any increase in the 
number of macrophages following treatment with rituximab (Cittera, Leidi et al. 2007). One 
would expect to see an increase in the number of macrophages following rituximab 
treatment if they were important. What I wanted to demonstrate by listing these studies on 
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clodronate is that it is very important to measure the level of passively transferred antibodies 
following clodronate treatment. We believe that this effect of clodronate on passively 
transferred antibodies should be investigated further.  
Because clodronate had a negative effect on passively transferred antibodies, I decided 
to use anti-mouse CCR2 (MC-21) to deplete macrophages. The expression of CCR2 was 
upregulated in microdissected glomeruli from anti-MPO-treated mice. It was found that MC-
21 depleted Gr1+CD11b+ blood monocytes and that this depletion was maintained 
throughout the experiment by injecting mice with 20 µg of MC-21 daily. GR1+ blood 
monocytes differentiate into tissue inflammatory macrophages, so these experiments should 
help answer the question as to the role of macrophages recruited from the circulation in 
acute vasculitic glomerulonephritis. I found that both MC-21 and IgG2b-treated mice 
developed crescents and that there was no significant difference between the two groups in 
terms of the percentage of crescents. All the mice had haematuria by day 6. Our results 
showed the development of crescents in mice even though we also showed a complete 
depletion of blood monocytes. One explanation is that tissue macrophages, rather than 
infiltrating monocytes, were involved in the pathogenesis of vasculitis. On the other hand, 
Furuichi et al. showed a reduction in acute tubular necrosis and interstitial cell infiltration in 
ischaemia-reperfusion injury following anti-mouse CCR2 treatment and also in CCR2-
deficient mice (Furuichi, Wada et al. 2003). The difference between these two sets of results 
could be due to the macrophage phenotype that was still present in the kidney after 
depletion. In addition, these were different diseases induced by different methods. I could 
investigate this further by depleting resident macrophages in mice that express the 
diphtheria toxin receptor. This would allow me to determine the role of macrophages in 
ANCA-associated vasculitis. Finally, the form of disease in this experiment was mild, which 
limited my ability to draw definitive conclusions. Unfortunately, a sufficient amount of MC-21 
was not available to repeat the experiment, and insufficient amounts of anti-MPO antibodies 
were available.  
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Chapter 5 
 
Studying neutrophil degranulation in response to ANCA as another 
way of understanding the pathogenesis of ANCA and inhibition of 
degranulation by statins 
 
5.1. Introduction 
The mechanism of ANCA-induced injury is still unclear. The aim of these studies was to 
learn more about the disease and investigate the different factors involved in causing the 
disease. We looked at the role of macrophages in our previous work and wanted to 
investigate the response of neutrophils to ANCA in vitro because both of these cell types are 
part of the innate immune system, which is the focus of my work. I wanted to understand 
why some individuals develop vasculitis when they are ANCA negative. On the other hand, 
other individuals have ANCA IgG, but they do not develop the disease. This could mean that 
there are genetic and environmental factors involved in the development of the disease. It is 
important to understand what is happening on the cellular level. In this chapter, I focused on 
studying the variability in ANCA-induced neutrophil degranulation and neutrophil 
metabolomics following ANCA stimulation.  
Small vessel systemic vasculitis is characterised by the presence of anti-neutrophil 
cytoplasm antibodies (ANCA), which are capable of disrupting normal neutrophil function 
(Falk, Terrell et al. 1990). These diseases have a wide spectrum of presentation with 
different disease kinetics and severity of inflammation ranging from upper respiratory 
disease to life-threatening renal failure and pulmonary haemorrhage. There is no obvious 
correlation between these phenotypes and either genetic or other factors. ANCA are usually 
directed against the neutrophil granule components myeloperoxidase (MPO) (Falk and 
Jennette 1988) and proteinase-3 (PR3) (Niles, McCluskey et al. 1989). The capacity of 
ANCA to dysregulate neutrophil function can be assessed using various assays. The most 
common assays use the ability of the purified antibody to induce superoxide release and 
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degranulation from purified TNF-α-primed neutrophils. This neutrophil activating capacity of 
ANCA lies at the heart of paradigms that propose mechanisms by which ANCA cause 
vascular injury in patients with vasculitis.  
Anecdotally, it has been noted that the neutrophil activating capacity of IgG preparations 
from different patients with vasculitis vary in their ability to activate neutrophils. This 
phenomenon has not yet been studied formally. We looked at the results from previous 
experiments performed in our lab, which established a degree of variability in ANCA-induced 
neutrophil degranulation and superoxide release; however, these results were not 
investigated further. In addition, previous work was done on different days and at different 
time points which could introduce variability in the overall results. We looked at different 
variables that might have contributed to the variability seen in previous experiments. Some 
of this variability may be derived from the ANCA source, from neutrophil donors, or from the 
time at which the assay was done. These are all factors that we think contribute to the 
variability seen in ANCA-induced neutrophil degranulation and superoxide release. We used 
a general linear model to identify the factors that most influence variability. This approach 
incorporated a number of different statistical methods and was able to accommodate an 
enormous amount of information. Neutrophil donors and the ANCA source were found to be 
the main determinants of variability seen in previous work.   
We sought to investigate the variability in the ability of ANCA to stimulate neutrophils from 
healthy donors and to assess whether this variability is primarily a function of the ANCA 
itself, or whether neutrophils from different individuals vary in their response to different 
ANCA samples. Furthermore, we aimed to investigate whether this variability was correlated 
with the clinical phenotype of the individuals from whom the samples were taken.  
We also wanted to study neutrophil metabolomics after ANCA-induced neutrophil 
degranulation. The aim of this experiment was to investigate the variability in neutrophil 
degranulation from healthy donors in response to ANCA samples. Metabolomics could 
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provide some information regarding the variations seen here. This has not been done 
before, so the focus of this work was to see if this could be a viable approach. This can be 
done by studying neutrophil metabolomics following ANCA-induced neutrophil degranulation. 
We know that any biological process results in the generation or formation of specific 
metabolites that are considered to be the biological fingerprint of a cellular process. 
Metabolomics is the study of these metabolites and can be used to define changes in 
metabolites that are related to environmental, genetic and biological perturbation. 
Metabolomics has been used in human studies to define biomarkers related to human 
disease and also to study human responses to drug treatment and provide greater 
pathophysiological insight. The collection of all metabolites at the end of a cellular process in 
cells, tissues, or organs is called the metabolome. Unlike proteomic and RNA expression 
analyses, study of the metabolomic profile provides more details about the physiology of the 
cell. Different methods or technologies are used to identify and quantify these metabolites, 
including mass spectrometry (MS) and nuclear magnetic resonance (NMR). This can be 
achieved by transforming molecules in a sample into ionised fragments. These ions are then 
sorted by mass using electric and magnetic fields. The velocity of these charged molecules 
depends on their mass. Thus, the chemical composition of each molecule determines the 
mass-to-charge ratio and hence specifies different compounds.   
This technology has been used in different applications such as toxicity assessments, 
functional genomics, and others. A metabolomic approach could help in understanding why 
neutrophils from healthy donors respond differently to the same ANCA sample. In addition, 
this could help clarify why some individuals develop severe vasculitis while the disease in 
some is mild. In addition, some individuals do not develop vasculitis, even though they are 
ANCA positive, which could be explained by our work. However, the aim of this approach 
was to see if it can be done as it has not been done before.  
We hypothesised that ANCA-induced neutrophil degranulation can be blocked or reduced 
following anti-inflammatory treatment. Simvastatin is member of the statin family, which 
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includes inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase. These compounds are 
widely used as cholesterol lowering agents. In addition to their role in blocking 3-hydroxy-3-
methylglutaryl CoA reductase, their function is also mediated through blockage of the 
mevalonate pathway and the synthesis of isoprenoids (farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate) (Henneman, van Cruchten et al. 2011). Isoprenoids are 
essential for the post-translational modification of several proteins involved in important 
signalling pathways. This in turn will affect different cellular functions, which explains the 
multifunctional aspect of statins, such as their anti-inflammatory, antioxidant, and endothelial 
cell protective effects, among others (Mason 2003; Mason 2005). In addition, simvastatin 
has been shown to play an anti-inflammatory role in arthritis (Leung, Sattar et al. 2003). In 
this study, we also investigated the effect of simvastatin on ANCA-induced neutrophil 
degranulation.   
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5.2. Methods 
I have to mention here that the parallel superoxide experiments were done by Dr. Julie 
Williams but I prepared all IgG samples used in these experiments.  
5.2.1. ANCA IgG isolation  
Plasma exchange fluids were used as a source of human IgG; these were obtained from 
patients as a part of clinical patient care at University Hospital Birmingham. Plasma was 
stored at -20°C until use. Plasma samples were chosen from patients with ANCA-associated 
vasculitis (MPO or PR3), myeloma, Goodpasture’s disease (anti-GBM), renal transplant, 
vasculitis with negative ANCA, and from healthy controls. These disease controls were 
chosen because the kidney is affected; additionally, the morphology of kidney injury is 
somewhat similar to that seen in AAV but without ANCA. 
ANCA IgG was isolated from 5 ml of plasma. Plasma was filtered and then diluted 1:1 in 
loading buffer prior to protein G affinity purification as described in Chapter 2. Disease 
control and ANCA positive plasma samples were treated in the same manner in terms of 
storage and IgG isolation. IgG was then stored at 4ºC for no more than two weeks.  
5.2.2. Neutrophil isolation and degranulation experiment  
Neutrophils were isolated from human blood as previously described in Chapter 2. 
Healthy donors were used as the neutrophil source; all donors were Caucasians, from 
different age groups, and included both males and females. Neutrophil isolation from these 
donors was done on different days, which meant recruiting only two donors per day. In some 
cases, we isolated neutrophils from all individual donors in one day to eliminate this source 
of variability as shown below. 
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Neutrophil Donors Time experiment was done ANCA samples 
110024 
110025 
110026 
110046 
110057 
110068 
Done on different days, using 
two donors each day. I used 
12 ANCA each day + 
disease control + normal 
control. 
26 ANCA IgG (MPO and 
PR3) 
110024 
110057 
110016 
110068 
110025 
110046 
Done on the same day 8 ANCA IgG (MPO and PR3) 
 
The aim of isolating these neutrophils was to test the variability in neutrophil 
degranulation from different donors to the same ANCA IgG samples. Neutrophil 
degranulation was measured as previously described in Chapter 2 using MPO ANCA, PR3 
ANCA, disease control, and normal IgG.  
ANCA IgG vs. Disease control IgG 
We wanted to be sure that the response observed after treating neutrophils with ANCA 
was not mediated by endotoxin or other factors that might result from plasma handling, 
storage, and IgG preparation. As result, I compared neutrophil degranulation following 
stimulation with ANCA IgG and IgG from a disease control that was handled in the same 
manner as the ANCA sample. I used 20 ANCA IgG samples (10 MPO and 10 PR3) and 10 
disease IgG control samples. IgG isolation and neutrophil degranulation was performed as 
described in Chapter 2.   
General linear modelling of ANCA responses 
In order to identify the factors involved in the variability of ANCA-induced neutrophil 
degranulation, we looked at various research projects that were done in the past. We 
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excluded some assays where the source of ANCA IgG and neutrophil donors could not be 
identified. We only included those healthy neutrophil donors that had been tested on at least 
25 separate occasions (n=10 and 9 for superoxide and degranulation respectively), and only 
those ANCA IgG samples that had been tested on at least eight separate occasions (n=28 
and 32 for superoxide and degranulation, respectively). To investigate the independent 
contribution of different factors to the observed variability, we then generated four linear 
models for each assay using the following parameters: 
Model 1: ANCA source 
Model 2: Neutrophil donor 
Model 3: ANCA source + Neutrophil donor 
Model 4: ANCA source + Neutrophil donor + Assay month (to control for variation in the 
assay over time) 
Prospective assessment of variability in neutrophil responses resulting from variation 
in the ANCA source 
One of the factors affecting variability in ANCA-induced neutrophil degranulation and 
superoxide release is the ANCA source. Based upon the observed variability in assay results 
in the general linear model, we estimated that testing ANCA IgG from 26 separate patients 
with vasculitis using the same neutrophil donors would provide a significant response for 
understanding superoxide release. Fewer samples would be required to demonstrate a 
significant difference in the degranulation assay, but we elected to use the same ANCA 
samples for both assays to aid in comparison. Therefore, plasma exchange samples from 26 
patients with vasculitis were randomly selected from a pool of 143 samples, with stratification 
to ensure a roughly equal number of anti-PR3 and anti-MPO. We performed superoxide and 
degranulation assays in these 26 samples using the same six neutrophil donors. Assays 
were performed at different times. The anti-MPO and anti-PR3 levels in these 26 plasma 
exchange samples were measured by ELISA. 
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Prospective assessment of variability in neutrophil responses resulting from variation 
in the neutrophil donor 
Another factor involved in assay variability is the source of neutrophils, so in some 
experiments we decided to fix the ANCA source. We selected eight ANCA samples (three 
high responder samples, three low responders and two intermediate) for testing with cells 
from seven different neutrophil donors. In order to minimise the effect of using different 
neutrophil preparations under variable atmospheric conditions, we sought to prepare 
neutrophils from the seven donors at the same time and to split them for testing into the 
superoxide and degranulation assays using the same IgG preparations in each. One of the 
degranulation assays was lost for technical reasons, so for the analysis of the degranulation 
assay, six of the seven donors were used. 
5.2.3. Neutrophil metabolomics  
This experiment was done at the Bioscience Department at the University of Birmingham 
in collaboration with Dr. Jennifer Kirwan. This occurred after testing the possibility of 
obtaining a clear signal from neutrophils isolated by me from human blood using the same 
approach.  
I wanted to investigate why different healthy neutrophil donors vary in their response to 
the same ANCA IgG using a metabolomic approach. I used cells from six neutrophil donors, 
which were each treated with two ANCA IgG and disease control IgG samples. Neutrophils 
were isolated from six healthy donors as previously described. Neutrophils from each donor 
were divided into five tubes for five different treatments. First, 10 million cells were washed 
and snap frozen in liquid nitrogen (treatment 1). The remaining cells were treated with TNF-α 
and cytochalasin B for 15 minutes at 37ºC to stimulate the neutrophils and trigger the 
migration of antigens to the surface of neutrophils. The cells were then divided into four 
tubes from each donor (10 million cells per tube) as follows: 
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Table 5.1: Neutrophil donors and treatment groups in metabolomic experiment. Each sample 
was giving two numbers (e.g 1-1, 1-2, etc.), where the first number represents the donor and the 
second number represents treatment.  
Neutrophil Donors Treatment 
1. 110016 
2. 110024 
3. 110057 
4. 110025 
5. 110068 
1. Untreated (no stimulation with TNF-α 
and cytochalasin B) 
2. PR3 ANCA treatment          
3. MPO-ANCA treatment 
4. Anti-GBM IgG treatment 
5. No treatment 
 
The cells were incubated with IgG for 15 minutes at 37ºC, then cells were centrifuged and 
the supernatant was taken to measure MPO release. Cells were washed with PBS and snap 
frozen in liquid nitrogen. Then, I transferred the samples to the Bioscience Department at the 
University of Birmingham to for metabolomics analysis. This was done by setting clean 
Precellys tubes on ice for each sample. These tubes contained beads that were used later 
for grinding the tissue. Then, 8 μl/mg of sample of MeOH and 2.5 μl/mg of H2O were added 
to each tube. Next, frozen neutrophils were added to each tube and these tubes were put on 
the Precellys 24 homogeniser for 2 × 10 s bursts at 6,400 rpm. Next, the homogenised 
mixture was moved into clean 1.8 ml clean glass vials. Then, the glass vial was kept on ice 
and 8 μl/mg CHCl3 and 4 μl/mg H2O were added to each vial; each vial was vortexed for 30 
s and placed on ice for 10 minutes. Glass vials were centrifuged at 3,000 rpm for 10 minutes 
at 4ºC and the samples were then left for 5 minutes at room temperature. Samples were 
biphasic at this point, with protein debris separating the upper (polar) and lower (non-polar) 
layers. 50 μl aliquots were taken from the upper and lower layers and transferred into 1.8 ml 
glass vials. All aliquots were dried using a Speed Vac concentrator for 1 hour with no heat. 
Samples were then stored at -80°C until needed.    
 
 
Stimulation 
with TNF-α and 
cytochalasin B 
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Metabolite analysis using FT-ICR mass spectrometry:  
Samples were run on a mass spectrometer (MS) at the Biosciences Department at the 
University of Birmingham. Metabolites were analysed using Fourier transform ion cyclotron 
resonance mass spectrometry (FT-ICR/MS). This was done by re-suspending the dried polar 
extracts (in five times their original volume) in a 80:20 methanol/water solution containing 
0.25% formic acid. Samples were analysed in positive ion mode using a hybrid 7-T FT-
ICR/MS (LTQ, Thermo Fisher Scientific, Bremen, Germany) with a chip-based direct infusion 
nanoelectrospray ionisation assembly (Triversa, Advion Biosciences, Ithaca, NY). The 
conditions of nanoelectrospray was controlled by ChipSoft software (version 8.1.0) and 
consisted of 0.3 psi backing pressure, 1.7 kV electrospray voltage, and a 200 nl/min flow 
rate. An automatic gain control setting of 1 x 106 and a mass resolution of 100,000 were 
used for mass spectrometry. Xcalibur software (version 2.0, Thermo Fisher Scientific) was 
used for analysis with 2.25 minutes of analysis time per technical replicate. Data were 
collected using the SIM-stitching FT-ICR metho detailed by Southam et al. (Southam, Payne 
et al. 2007) and Weber et al. (Weber, Southam et al. 2011) over a mass range of m/z 70-
590. Each sample was analysed in triplicate; nine QC samples were analysed prior to 
analysis and a QC sample was analysed in triplicate every sixth sample.  
Using custom written code in Matlab (version 7.9.0, The MathWorks), transient data (in 
the time domain) were collected and processed as described previously (Southam, Payne et 
al. 2007). Specifically, all the SIM windows were joined together using SIM stitching code 
(Southam, Payne et al. 2007) (version 1.16). This was done to reject peaks with a signal to 
noise ratio <3.5, and also to internally calibrate the mass spectra using a list of 13 pre-
defined metabolites. Subsequently, only peaks that occurred in two or more of the three 
replicate measurements per sample were retained by applying a noise filtering algorithm 
(Payne, Southam et al. 2009). As a result, only peaks that were present in 50% or more of 
the samples were retained. Finally, data were normalised using the probabilistic quotient 
approach (Dieterle, Ross et al. 2006) after missing values were substituted as described by 
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Payne et al. This was followed by a generalised log transformation according to the 
approach reported by Persons et al (Parsons, Ludwig et al. 2007). This produced a final 
peak matrix that included a list of m/z values and their intensities across the samples.   
Principle component analysis (PCA) and partial least square discriminate analysis 
(PLSDA)  
Different factors could affect the analysis of metabolomics results; one of these is spray 
stability. Basically, the electrospray ionisation approach is used to transfer the sample into 
the mass spectrometer. Essentially, a liquid sample is passed into a charged needle which 
ionises the sample so that it comes out the other end as a very fine spray of ions. This spray 
can be measured in terms of its intensity by measuring the flow of ions. The intensity of this 
spray can change according to many factors, including the sample nature. The consistency 
of this spray is what is known as spray stability. This is measured by the relative standard 
deviation of the sample.    
Principle component analysis (PCA) is an unsupervised multi-variant technique. PCA is a 
powerful tool for reducing a number of observed variables into a smaller number of artificial 
variables that account for most of variance in the data set. It works by reducing the 
dimensionality of the data while retaining most of the variation in the data set. This can be 
achieved by identifying directions called principle components along which variations in data 
are maximised. As a result, samples can be represented by relatively small numbers instead 
of thousands of variables by using a few components. This allowed us to plot the samples in 
a way that made it possible to assess the similarity and differences between samples.  
On the other hand, partial least square discriminate analysis (PLSDA) is a supervised 
analysis which looks for maximum discrimination between groups. We used this approach 
because only partial separation was achieved on the PCA plot.   
Finally, we used forward selection to improve the prediction capability of the model. In this 
approach, variables were added to the model one at a time and these variables were tested 
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for inclusion in the model. Finally, the most significant of these variables was added to the 
model. This resulted in a reduction in the number of final variables because the peaks that 
were most representative of the sample class were selected.   
5.2.4. The effect of simvastatin on ANCA-induced neutrophil degranulation 
We investigated the possibility of using simvastatin as a treatment for ANCA-associated 
vasculitis. We studied the effect of simvastatin on ANCA-induced neutrophil degranulation in 
vitro. Neutrophils were isolated from healthy donors and pre-incubated with 10 μM of the 
active form of simvastatin (Calbiochem, UK) for 20 min at 37ºC. Then, the neutrophil 
degranulation assay was performed as previously described using MPO and PR3 ANCA 
samples. Neutrophil survival was confirmed by trypan blue staining.   
5.2.5. Confirming the survival of neutrophils following treatment with simvastatin 
Neutrophils were treated with simvastatin, which was dissolved in DMSO. We wanted to 
be sure that this treatment did not cause neutrophil death. Stock simvastatin was dissolved 
in 100% DMSO to a final concentration of 10 mM. This was then diluted 1:1,000 in HBH 
buffer to 10 μM which was then used to treat neutrophils. We checked the viability of 
neutrophils following incubation with different concentrations of simvastatin (5, 10, 20, 50, 
and 100 μM). Cell viability was checked every 30 minutes using trypan blue for a period of 
150 minutes.  
Statistical analysis 
The degree of the effect of different variables in the general linear models was assessed 
using the partial η2. The goodness of fit of the model as a whole was assessed by 
calculating the r2. Both of these parameters ranged from 0 to 1. The analysis result is in the 
appendix 7.5. 
When comparing the responses from different ANCA samples (fixed donor) and from 
different neutrophil donors (fixed ANCA source), we used a matched two-way ANOVA. We 
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calculated the Spearman correlation coefficient to assess the correlation between 
superoxide and degranulation responses, and between assay results and clinical phenotype. 
The assay results for the 26 samples were compared across various dichotomous clinical 
variables using the Mann-Whitney test. To investigate the independent association of 
various clinical variables with the assay result for a given ANCA sample, we used 
multivariate logistic regression with forced variable entry.  
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5.3. Results 
 
5.3.1. ANCA IgG vs. disease control 
Plasma samples were stored at -20°C and were not tested for the presence of endotoxin 
prior to IgG purification. We wanted to confirm that the differences seen in neutrophil 
degranulation were due to the effect of ANCA and not to endotoxin or some other 
unmeasured factor. We used disease control IgG samples which were prepared from 
patients with different diseases such as anti-GBM, myeloma, and others; these included 20 
ANCA IgG (MPO or PR3) and 10 disease control IgG samples. ANCA IgG and disease 
control IgG samples were purified from plasma exchange samples and were stored in the 
same way prior to IgG extraction. Neutrophils were isolated from healthy donors. There was 
a significant difference in neutrophil degranulation in response to ANCA IgG compared to 
disease control IgG (figure 5.1).  
 
Figure 5.1: Neutrophil degranulation in response to ANCA IgG and disease control IgG. There 
was a significant difference in neutrophil degranulation between ANCA IgG and disease control (A). 
Both MPO and PR3 ANCA induced a significant increase in neutrophil degranulation compared to IgG 
from disease control samples (B). Mann-Whitney test. 
5.3.2. ANCA IgG from different individuals with vasculitis vary in their ability to induce 
neutrophil superoxide release and degranulation 
We observed marked variability in both the superoxide and degranulation neutrophil 
responses across ANCA samples from 26 different patients with vasculitis (Figure 5.2). It 
was not possible to comment specifically on the relative contribution of the ANCA source 
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and neutrophil donor in these experiments as the neutrophil donors were not randomly 
selected. However, the ANCA source appeared to contribute more to the variability in the 
degranulation assay (72.2%) than in the superoxide assay (40.4%). This was done by 
comparing all the results using a two-way ANOVA and assuming that donors had the same 
effect (if any) at all levels of ANCA. 
 
Figure 5.2: Variability in neutrophil responses to stimulation with ANCA IgG preparations from 
different patients. (A) IgG was purified from the plasma exchange fluid of 26 randomly selected 
patients and their ability to induce neutrophil superoxide release from the same nine donors was 
measured. (B) The neutrophil degranulation response to the same 26 IgG preparations was also 
measured in six of these neutrophil donors. The lines and bars depict the median and interquartile 
range, respectively. The p value represents the variation of the results as an effect of ANCA treatment 
using two-way ANOVA. 
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5.3.3. Neutrophils from different healthy donors vary in their response to ANCA 
stimulation 
We went on to select eight ANCA samples from the previous experiments and measured 
responses in the same six or seven neutrophil donors. All assays were performed at the 
same time with the same neutrophil preparations. We again observed marked variability in 
both the superoxide and degranulation neutrophil responses across these donors, when 
tested using neutrophils from the same donors (Figure 5.3). Although I again cannot 
comment specifically on the relative contribution of the ANCA source and neutrophil donor in 
these experiments, it did appear that greater variability was derived from the donor in the 
superoxide assay (29.9% of the variability) than in the degranulation assay (8.1% of the 
variability). 
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Figure 5.3: Variability in neutrophil responses to stimulation with ANCA IgG preparations 
using different neutrophil donors. (A) Eight IgG samples were selected from the previous pool of 
26 samples and their ability to induce the release of superoxide from neutrophils from the same seven 
donors was measured. (B) The neutrophil degranulation response to the same eight IgG preparations 
was measured in six of the same seven neutrophil donors. Both assays were performed on the same 
day using the same neutrophil preparations. The p value calculated using two-way ANOVA. 
5.3.4. Correlation between the degranulation and superoxide neutrophil responses to 
ANCA stimulation 
As the experiments examining the contribution of the neutrophil donor to variability were 
all performed at the same time using the same neutrophil preparation for both the 
superoxide and degranulation assays, it was possible to assess the correlation between 
superoxide and degranulation responses for each ANCA-neutrophil pair. I observed that, in 
approximately two thirds of cases, both assays were concordant (i.e. either positive in both 
or negative in both, Figure 5.4). In the remaining one third, the assays were discordant 
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(either positive for superoxide or negative for degranulation in 25%, or vice versa in 8%). 
Overall, the two assays were moderately correlated (r=0.48), with the relationship best 
described by an exponential equation (r2=0.55, Figure 5.4). Any measurement above two 
standard deviations (2SD) was considered positive in relation to measurements following 
incubation with a range of normal IgG preparations.  
 
Figure 5.4: Concordance between neutrophil degranulation and superoxide release in paired 
samples. Each data point represents a paired degranulation/superoxide release assay performed 
using the same IgG preparation and donor, performed at the same time. The dashed line (----) depicts 
the best fit line described by the data and the dotted lines ( ---------) depict the mean+2SD following 
incubation with a range of control normal IgG preparations. The shaded areas describe values that 
are positive in one assay, but negative in another (“discordant”) and the % values reflect the fraction 
of assays that lie within each quadrant. One third of the assays were discordant. 
5.3.5. Confirming survival of neutrophils after treatment with a statin  
Simvastatin was dissolved in dimethyl sulphoxide (DMSO), which could affect the survival 
of cells. The final concentration of DMSO was 10μM. We investigated the survival of 
neutrophils after treatment with the statin for 20 minutes using trypan blue. Cells were 
incubated with different concentrations of simvastatin for 150 minutes, which is much longer 
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than the time used in the experiment, but the total time required for the experiments, 
including treatment with ANCA IgG, takes about 150 minutes. There was little or no 
reduction in the percentage of viable cells after 150 minutes when the concentration was 
increased to 20μM. The number of viable cells started to decrease when the concentration 
was increased to 50 or 100μM, which is much higher than the concentration used in the 
experiment (10μM) (figure 5.5).  
 
Figure 5.5: The effect of a statin (dissolved in DMSO) on cell survival. The number of viable cells 
was monitored for 150 minutes after treating the cells with different concentrations of the statin (5, 10, 
20, 50, and 100 μm). There was no reduction in cell survival at concentrations up to 20 μM. 
5.3.6. The effect of ANCA-induced neutrophil degranulation following treatment with 
simvastatin  
We observed a significant difference in neutrophil degranulation following treatment with 
simvastatin. Simvastatin reduced ANCA induced neutrophil degranulation (Figure 5.6, A). 
The effect of simvastatin was also seen on fMLP (positive control) induced neutrophil 
degranulation. There was a reduction in both ANCA-PR3 and ANCA-MPO induced 
neutrophil degranulation in response to treatment with the statin (Figure 5.6, B), but this was 
only significant for ANCA-PR3.  
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Figure 5.6: The effect of statin on ANCA-induced neutrophil degranulation. Treatment with a 
statin significantly induced a reduction in ANCA-induced neutrophil degranulation (A). This reduction 
was seen in both ANCA-PR3 and ANCA-MPO induced degranulation (B). Mann-Whitney test.  
5.3.7. Neutrophil metabolomic analysis  
Spray stability of sample  
Spray stability, as measured by the relative standard deviation (RSD) of replicates, was 
higher than expected. 5_5 was especially high at 47%. This may have been due to the 
nature of the biological sample or the concentration of the sample. 
Multivariate analysis 
The RSD of the quality control (QC) samples had a median of 31%. Generally, the QCs 
did not cluster as well as was anticipated. This was probably linked to the poor spray stability 
noted previously. Additionally, despite the QCs being a combination of several samples, the 
QCs did not cluster at the centre of the PCA plot. Only treatment 1 clustered well, although 
treatment 4 appeared to cluster in PC1 with the exception of 5_4 (figure 5.7). This means 
that there was technical variation in this experiment of 31%; this was high compared to the 
expected value of <20%.  
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Figure 5.7: Unsupervised multivariate technique. Principle component analysis was the first 
approach used to separate the samples into related groups or clusters. Each point in the graph 
represents an individual donor and treatment (the first number is the donor number and the second 
number is the treatment number). For example 2_1 is donor 2 and treatment 1 (untreated 
neutrophils). Only treatment 1 clustered relatively well. Using this method, 33.12% of the variation in 
the data can be explained by PC1 and 18.25% can be explained by PC2.  
PLSDA 
Since there was only partial separation on the PCA scores plot, a supervised technique, 
PLSDA, was used to analyse the data. This technique is used to sharpen the separation 
between groups and works by rotating PCA components to allow maximum separation 
between classes. Again, only untreated neutrophils (treatment group 1) were well-
differentiated from the other groups (Figure 5.8). On the other hand, none of the treated 
neutrophils clustered, even those neutrophils that only received TNF-α and cytochalasin B 
(no IgG treatment) (treatment 5).  
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Figure 5.8: Partial least square discriminate analysis. This supervised technique is used to look 
for maximum discrimination between groups. Only untreated neutrophils (treatment 1) clustered well. 
Treated neutrophils, on the other hand, did not cluster.  
In order to improve the prediction capability of the model, a forward selection procedure 
was carried out to select the peaks that were most predictive of sample class. Prior to 
forward selection, the classification errors were as follows: 
Treatment group Classification error (%) 
1 8.5 
2 44.0 
3 42.4 
4 44.1 
5 57.1 
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Of these, only treatment group 1 (untreated neutrophils) was significant after permutation 
testing (p<0.01). Classification error represents the proportion of cases that are incorrectly 
predicted.  
Following forward selection, which determined that 82 of the variables were more 
discriminatory, the classification errors improved as follows: 
Treatment group Classification error (%) 
1 1.85 
2 16.4 
3 32.3 
4 39.4 
5 46.1 
 
Of these, treatments 1, 2 and 3 were deemed significant after permutation testing 
(p=<0.001, p=<0.001 and p=0.04, respectively) 
 
195 
 
 
Figure 5.9: PLSDA of all treatment groups following forward selection. The classification errors 
improved following forward selection and it was relatively possible to see some clustering of treatment 
groups 1, 2, and 3; these had the lowest classification errors. 
Metabolites detected following ANCA treatment 
I identified some metabolites that were downregulated in ANCA-PR3 and ANCA-MPO 
compared to the control group (HBH buffer treated). These metabolites were slightly 
upregulated in relation to treatment 1 (untreated neutrophils), but when compared to 
treatment 5 (TNF-α, cytochalasin B, and HBH treated), these metabolites seemed to be 
downregulated in ANCA-PR3 treated cells. One of these metabolites was taurine, which has 
many biological roles such as antioxidation, osmoregulation, and modulation of calcium 
signalling. Aucubin was another metabolite that was downregulated following treatment with 
ANCA-PR3. It has various biological activities, including anti-inflammatory activities, blood 
pressure reduction, antimicrobial activity, and liver protection.  
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 Fold change (in relation to treatment 1)  
Metabolite ANCA-PR3 ANCA-
MPO 
TNF-α and cytochalasin B p-value 
Taurine 0.155 0.215 0.232 0.0075 
Aucubin 0.151 0.246 0.225 0.0063 
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5.4. Discussion  
I found variability in neutrophil degranulation in response to the same ANCA IgG. This 
was seen when the degranulation assay was done on different days using two donors each 
time and also when the assay was done on the same day using six donors and eight ANCA 
IgG. There was some variation in the release of superoxide between different donors when 
they were treated with the same ANCA IgG. I found that 2/3 of the cases were either positive 
for both assays (degranulation and superoxide) or negative for both. The effect of ANCA-
induced neutrophil degranulation was specific to ANCA IgG because there was no or little 
neutrophil degranulation in response to IgG from disease control samples. In addition, 
simvastatin treatment significantly reduced ANCA-induced neutrophil degranulation.  
Neutrophils are part of the innate immune system and they have been reported to have 
an important role in ANCA-associated vasculitis and necrotising crescentic 
glomerulonephritis (NCGN), causing tissue damage. Several studies have shown the ability 
of ANCA to activate TNF-α primed neutrophils, which results in the release of reactive 
oxygen radicals (Falk, Terrell et al. 1990; Charles, Caldas et al. 1991; Keogan, Esnault et al. 
1992; Brouwer, Huitema et al. 1994; Mulder, Heeringa et al. 1994). The mechanisms that 
are involved in ANCA-induced neutrophil degranulation are not fully clear. We have shown 
here the variability in ANCA-induced neutrophil degranulation from healthy donors. Franssen 
et al. have shown differences in ANCA-induced neutrophil degranulation when they 
compared c-ANCA and p-ANCA (Franssen, Huitema et al. 1999). The variability that was 
found in our experiment could be caused by different factors. One reason could be the 
availability of the antigens (PR3 and MPO) on the surface of the neutrophils that were 
purified from healthy donors. This could explain the variability that we saw in ANCA-induced 
neutrophil degranulation from healthy donors when they were treated with the same ANCA 
IgG. We also noticed that some ANCA-IgG samples had the ability to induce greater 
neutrophil degranulation (as measured by ELISA) compared to other ANCA samples. 
198 
 
Different studies have shown the importance of the binding of ANCA to FcγRIIa in neutrophil 
activation (Mulder, Heeringa et al. 1994). It is possible that the binding of ANCA to the Fc 
receptor on the surface of neutrophils might be the reason why we observed differences in 
ANCA-induced neutrophil degranulation. This means that there might be more ANCA-IgG in 
a specific sample which would result in more receptor binding to induce a stronger response. 
The amount of ANCA in each sample was not known, and we only assessed the IgG 
concentration. This quantitative difference could result from the IgG preparation method. The 
use of a PR3 or MPO affinity column could be used to standardise the amount of ANCA in 
the preparations. Another explanation could be that there are differences in IgG subclass 
distributions in these ANCA samples. Pankhurst et al. have shown that IgG3 is the most 
effective subclass for inducing neutrophil adhesion and altered behaviour (Pankhurst, Nash 
et al. 2011).  
 
In future experiments, I would like to study ANCA-induced neutrophil degranulation on 
cells from vasculitis patients. It would be interesting to see how neutrophils from these 
patients respond when treated with ANCA IgG from the same patient or different individuals.   
 
We investigated the effect of simvastatin on ANCA-induced neutrophil degranulation and 
we found that it attenuated neutrophil degranulation in vitro. Statins are used as cholesterol 
lowering agents and recently have been proposed to have LDL cholesterol-independent anti-
inflammatory properties. For example, pravastatin has been found to inhibit superoxide 
generation following neutrophil treatment with formyl-methionyl-leucyl-phenylalanine (fMLP) 
(Kanno, Abe et al. 1999). We know that the binding of ANCA to antigens on the surface of 
neutrophils is required to induce neutrophil degranulation and release reactive oxygen 
radicals. Choi et al. have shown that treatment with simvastatin or cerivastatin reduces the 
translocation of PR3 and MPO following TNF-α stimulation (Choi, Rolle et al. 2003). This 
could explain the reduction in neutrophil degranulation that we observed following treatment 
with simvastatin. This could be tested by performing immunofluorescence staining on these 
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neutrophils following treatment with simvastatin compared to untreated cells to check for 
antigens on the surface of neutrophils. In addition, a reduction has been shown in ANCA-
induced respiratory burst activity in TNF-α primed neutrophils. It has been suggested that 
this inhibition could be explained in part by the ability of statins to inhibit the ERK pathway 
since previous experiments showed the involvement of p38 MAPK and ERK in the ANCA-
induced neutrophil respiratory burst (Kettritz, Schreiber et al. 2001). These findings support 
previous work on statins suggesting that they could play an anti-inflammatory role. On the 
other hand, Al-Ani et al. were not able to find any effect of statins on ANCA-associated 
vasculitis in a rat model of vasculitis (Al-Ani, Al Nuaimi et al. 2011).    
 
I also looked at the possibility of studying metabolites following ANCA-induced neutrophil 
degranulation. We used six healthy donors, and each donor sample underwent five different 
treatments (untreated, PR3-ANCA (ANCA1), MPO-ANCA (ANCA 28), disease control IgG, 
and TNF-α, and cytochalasin B). We were not able to observe clustering of the different 
donors with specific treatments, except for untreated samples. This could be due to technical 
variability or experimental design. We estimated the technical error to be 31%, which was 
much higher than anticipated. Another reason that these results did not cluster could be that 
they are biologically different. In other words, these healthy donors respond differently to the 
same ANCA IgG in terms of neutrophil degranulation. So, the experimental design could be 
incorrect. If I was to repeat this experiment, I would use only one healthy donor and treat 
these neutrophils with different ANCA samples (PR3 and MPO) to study the effect of ANCA 
on neutrophil degranulation and compare PR3-ANCA to MPO-ANCA. I think that we 
included too many variations in this experiment, including donor variation and treatment 
variation. I conclude that this approach was difficult to assess and interpret because of the 
variation in these biological samples. I would suggest repeating the experiment using only 
one ANCA IgG sample and one donor neutrophil. The aim of this experiment would be to 
only look at the differences in metabolites following ANCA IgG treatment.   
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Chapter 6 
 
Overview Discussion 
 
6.1. Project summary and application of results 
The innate immune system is the first line of defence and it is crucial for initiating the 
inflammatory response. I wanted to investigate different components of the innate immune 
system and their involvement in ANCA-associated vasculitis (AAV). I was interested in 
studying the role of macrophages in AAV as this has not been investigated previously; 
specifically, I wished to determine if macrophage depletion could result in protection from the 
development of vasculitis. In addition, neutrophils are an important factor in AAV and 
studying the variability of ANCA-induced neutrophil degranulation was another one of my 
aims. I used a mouse model of vasculitis to study the role of macrophages; I also tried to 
improve this model. Furthermore, I looked at gene expression in animal models of AAV by 
comparing tissues from animals with vasculitis to those from control animals to find 
upregulated genes in the glomerulus. 
Establishing and working to improve the mouse model 
I started by establishing the animal model and establishing a MPO-/- mouse colony to 
raise anti-MPO antibodies. I cultured WEHI cells as a source of murine MPO and then tried 
using different methods such as MPO peptides, recombinant MPO, and MPO heavy chain to 
raise anti-MPO antibodies. These approaches resulted in the production of anti-MPO 
antibodies, but these antibodies showed a low affinity for murine MPO compared to the MPO 
used for immunisation. This was investigated by anti-MPO ELISA. In addition, I was not able 
to induce disease in WT mice using antibodies generated following immunisation with the 
antigens previously mentioned. 
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I tried inducing vasculitis in mice using anti-murine MPO antibodies, but I found that the 
form of the disease was very mild. I was able to induce a relatively severe form of the 
disease when I used LPS with anti-MPO antibodies. The mice developed crescentic 
glomerulonephritis with around 13% crescents.   
Macrophages in AAV 
I investigated macrophage infiltration into the kidney in mice treated with anti-MPO 
antibodies and LPS. I was able to show macrophage recruitment to the kidney following 
disease induction. Macrophages are mainly found in the crescent region of the kidney and 
there was also positive interstitial macrophage staining. I also investigated the type of 
macrophage infiltrating the kidney to determine whether these were M1 or M2-type 
macrophages. I found that the macrophages recruited into the crescent were mainly CD206 
negative, which suggests that these cells are classically activated macrophages. In addition, 
I found strongly positive MHCII staining in the kidney.  
Microarray and gene expression in AAV 
I investigated gene expression in the glomerulus following disease induction, which is a 
novel approach. I found 42 upregulated genes common to both mouse and rat glomeruli. 
These genes are involved in macrophage activation, complement activation, cell adhesion, 
as well as antigen processing and presentation. In addition, there were some highly 
upregulated genes in mouse glomeruli such as lipocalin 2, also known as NGAL and the 
kidney injury molecule 1 (Kim 1). These genes are considered to be acute kidney injury 
biomarkers. Furthermore, there was an upregulation of collagen genes, especially collagen I, 
and these were found to be involved in most of the biological processes mentioned in 
Chapter 4. In addition, fibronectin 2 was upregulated in both mouse and rat glomeruli. There 
were other genes involved in cell adhesion and recruitment, such as CX3CR1 and CCR2, 
which are also involved in macrophage recruitment.  
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Macrophage depletion 
I investigated the effect of macrophage depletion on disease development in mice 
following treatment with anti-MPO antibodies. I started by depleting macrophages using 
liposomal clodronate, which was effective in depleting macrophages. However, there was a 
significant reduction in the level of passively transferred antibodies in clodronate-treated 
mice compared to the control group. As a result, I used an anti-CCR2 antibody to prevent 
GR1+ monocytes from infiltrating the kidney. These are inflammatory monocytes which 
differentiate into inflammatory macrophages in the tissue. GR1+ cells were almost 
completely depleted in the blood, as shown by FACS throughout the experiment. However, 
no significant differences were found in crescent formation or in the percentage of CD68-
positive cells in the kidney between the IgG2b and anti-CCR2-treated mice. The disease in 
this experiment was mild and I was not able to exclude the effect of macrophages in disease 
development.  
The variability in neutrophil degranulation 
I studied the variability in neutrophil degranulation in response to ANCA-IgG. Variability 
was shown in ANCA-induced neutrophil degranulation resulting from neutrophil donors and 
also in the source of ANCA. This was seen in both neutrophil degranulation and superoxide 
release. The effect seen on neutrophil degranulation was specific to ANCA-IgG, as IgG from 
control patients with diseases such as myeloma failed to induce neutrophil degranulation. I 
tried to investigate this variability using a metabolomics approach in order to study the 
metabolites following the degranulation experiment. This is a novel approach and the aim 
was to investigate whether using this approach was possible.  
The effect of simvastatin on ANCA-induced neutrophil degranulation 
Simvastatin is cholesterol-lowering agent known to have anti-inflammatory effect. There 
was a significant reduction in ANCA-induced neutrophil degranulation following treatment 
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with 10 μM simvastatin. This effect of simvastatin was seen on both PR3 and MPO-ANCA, 
but it was only significant on PR3-ANCA.  
6.2. Different approaches for improving the mouse model of vasculitis 
The mouse model of ANCA-associated vasculitis confirmed the pathogenicity of Anti-
MPO antibodies and was also used to study the disease. The disease was induced by the 
i.v. administration of anti-murine MPO antibodies. There are some limitations of this model, 
which I will discuss here. 
One of the limitations of this model is the source of murine MPO. The WEHI 3 cells are 
one source of murine MPO, but a large number of cells are required to generate a sufficient 
amount. This approach is not practical in most cases and it is also expensive. I tried different 
methods to find a reliable source of murine MPO. I used recombinant mouse MPO, MPO 
multi-antigenic peptides, and MPO heavy chain to immunise MPO-/- mice and investigated 
the possibility of producing antibodies that could induce vasculitis. These mice responded to 
immunisation and produced anti-MPO antibodies. However, these antibodies were antigen 
specific, as shown by ELISA, which means that they produced high titres when the plate was 
coated with the antigen used for immunisation but they produced relatively low titres when 
the plate was coated with murine MPO. This suggests that the antibodies produced following 
immunisation reacted poorly with murine MPO. This could explain the absence of disease 
when WT mice were injected with IgG from purified from the immunised animals. 
Apostolopoulos et al. used recombinant MPO to immunise MPO-/- mice; they detected the 
production of antibodies to native murine MPO (Apostolopoulos, Ooi et al. 2006). However, 
they did not report the antibody titre and they did not demonstrate the ability of these 
antibodies to induce disease in WT mice. 
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6.2.1. Why did the immunisation with non-native MPO not work? 
There are several reasons that could explain why the use of recombinant MPO, MPO 
peptides, and MPO heavy chain was not as effect as native MPO in generating MPO 
antibodies. One explanation could be that whole MPO is required to generate an immune 
response in MPO-/- mice, which results in the production of anti-MPO antibodies. 
Furthermore, Erdbrugger et al. investigated the MPO epitopes recognised by ANCA and 
they identified what could be a target epitope on MPO heavy chain (Erdbrugger, Hellmark et 
al. 2006). However, they suggested that MPO-ANCAs target a number of regions of MPO 
rather than a single epitope. Another explanation could be that the native MPO differs from 
recombinant MPO as a result of post-translational modification and changes in protein 
folding, which affect the exposure of immunogenic epitopes. For example, different studies 
have shown that ANCA only binds to the MPO holoenzyme and not denatured MPO, which 
suggests a conformational nature of the target MPO epitopes (Falk, Becker et al. 1992; 
Tadros, Pozzi et al. 1993). As a result, antibodies generated following immunisation with 
MPO peptides or recombinant MPO are not necessarily as pathogenic as anti-murine MPO 
antibodies. 
6.2.2. What was the idea behind the maternal transfer experiment?  
The current model of vasculitis requires the immunisation of a large number of MPO-/- 
mice with murine MPO in order to raise anti-MPO antibodies, which can then be used to 
induce disease in WT mice. We thought that it would be possible to reduce the number of 
mice needed for immunisation if we could develop vasculitis in newborn mice from mothers 
immunised with MPO. One of the well-known pieces of clinical evidence of ANCA 
pathogenicity came when a neonate developed pulmonary-renal syndrome following 
transplacental transfer of MPO-ANCA from the mother (Bansal and Tobin 2004). I 
immunised MPO-/- females with MPO peptides and then mated them with WT males to 
produce heterozygous offspring. Although the newborn mice did not develop vasculitis, they 
showed detectable levels of anti-MPO peptides antibodies in ELISA. This is an encouraging 
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finding which shows that anti-MPO antibodies were transferred from the mother to offspring. 
The reason why these offspring did not develop vasculitis could be because MPO peptides 
and not native MPO was used to immunise the mothers. As I explained earlier, MPO 
peptides may not be sufficient to induce anti-murine MPO antibodies. The only way to 
confirm this is to use murine MPO for immunisation and then investigate if newborn mice 
develop vasculitis. 
6.3. Macrophage phenotype 
I investigated macrophage accumulation in the mouse kidney following disease induction. 
In addition, I studied the macrophage phenotype and whether they were classically or 
alternatively activated.  
6.3.1. Macrophage infiltration into the kidney 
I found strong positive staining of a macrophage marker (CD68) in the kidney following 
disease induction. There was a positive correlation between the number of macrophages 
and the percentage of crescents, which suggests the involvement of macrophages in the 
development of vasculitis. In addition, I found that most CD68+ macrophages were observed 
in the crescents. These results are in agreement with previous work performed by Xiao et al. 
(Xiao, Heeringa et al. 2005), where they showed an accumulation of neutrophils and 
macrophages as a result of anti-MPO-induced NGCN.  
6.3.2. What are the phenotypes of accumulating macrophages?  
I investigated the type of accumulated macrophage in the kidney using different markers 
that should identify M1 and M2 macrophages. The mannose receptor is a well-known M2 
marker and I used it to identify alternatively activated macrophages. My results showed that 
most CD68+ macrophages in the crescents did not express the mannose receptor, which 
suggests that they were classically activated macrophages. Macrophages include different 
subsets of cells that differ in their functions and phenotypic plasticity. Their functions in renal 
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diseases are very diverse as they can be involved in both renal inflammation and fibrosis. 
On the other hand, they could have an anti-inflammatory role that involves tissue 
remodelling and wound healing (Wang and Harris 2011). The M2 macrophages secrete anti-
inflammatory cytokines and are reported to reduce organ injury (Herbert, Holscher et al. 
2004). The macrophages in our mouse model were most likely to be pro-inflammatory M1 
macrophages as they lacked expression of the mannose receptor, which is an M2 marker. It 
would be more convincing if double staining was done to study macrophage phenotype. 
However, I was not able to do double staining because of the antibodies available as 
explained in Chapter 4. Nevertheless, serial sections that were used in my experiment can 
be used successfully to identify the same areas on the tissue and used to compare two 
different markers and whether they are on the same cells or different cells.   
6.3.3. What genes are associated with macrophage activation in the glomeruli?   
I wanted to investigate the characteristics of macrophages in the glomeruli by studying 
gene expression and whether or not there were any genes associated with macrophage 
activation. I found several genes that were associated with macrophage activation, such as 
calprotectin (S100a9 and S100a8), F4/80, CXCL2 and other genes. In addition, I found an 
upregulation of chemokine and cytokine receptors involved in macrophage infiltration, such 
as CCR2 and CX3CR1. In addition, Furuichi et al. demonstrated the involvement of CCR2 in 
ischaemia-reperfusion injury in the kidney (Furuichi, Wada et al. 2003). They also showed a 
reduction in the amount of macrophage infiltration in CCR2-deficient mice. Another 
chemokine receptor that could be involved in macrophage infiltration is CX3CR1, which was 
upregulated in mouse glomeruli. Auffray et al. showed an association between the 
commitment of myeloid progenitors to the monocyte/macrophage/DC lineage and CX3CR1 
(Auffray, Fogg et al. 2009). Furthermore, Li et al. demonstrated the involvement of CCR2 
and CX3CR1 in monocyte/macrophage infiltration during kidney ischaemia-reperfusion injury 
(Li, Huang et al. 2008). They found that CCR2 and CX3CR1 play an important role in 
inflamed monocyte recruitment in the kidney and they also showed that CX3CR1-deficient 
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mice are protected from ischaemia-reperfusion injury. I believe that CCR2 and CX3CR1 are 
involved in macrophage infiltration in ANCA-associated vasculitis. In my model, I think that 
macrophages are recruited to the kidney at an early stage of the disease via chemotactic 
gradient. Lipopolysaccharide stimulate macrophages to secrete TNF-α which results in the 
activation of macrophages and the expression of ANCA-antigens on the surface of 
neutrophils. This allows ANCA to bind to these antigens causing neutrophil degranulation 
and release of ROS and chemokines which results in the recruitment of CCR2+ monocytes. 
These monocytes differentiate in to classically activate macrophages and release pro-
inflammatory cytokines such as TNF-α, IL-1, and TGF-β. I have observed 1.8 fold increases 
in the glomeruli for VCAM-1 which is an adhesion molecule critical for monocyte recruitment. 
In addition, macrophage adhesion to endothelium could be CD44-dependent as this antigen 
was upregulated in mouse glomeruli and shown previously to be involved in macrophage 
recruitment and adhesion (Hollingsworth, Li et al. 2007). 
6.4. What function could macrophages have in ANCA-associated 
vasculitis? 
Macrophages can be pro-inflammatory or anti-inflammatory depending on the type of 
activation. Classically activated macrophages (M1) secrete pro-inflammatory cytokines and 
are involved in tissue injury. On the other hand, alternatively activated macrophages secrete 
anti-inflammatory cytokines and could be involved in tissue repair. However, the function of 
macrophages is more complicated than that and there is evidence to suggest that 
macrophages do not stay committed to the same activation state. For example, M1 
macrophages can change to M2-type macrophages following phagocytosis of apoptotic cells 
(Duffield 2003). Macrophage accumulation is a characteristic of most glomerular and 
interstitial kidney diseases. It is thought that macrophages initially accumulate to modulate 
the immune response and clear apoptotic cells. However, this function could later transform 
into an inflammatory role resulting in tissue destruction (Ricardo, van Goor et al. 2008).  
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I have shown some evidence via immunohistochemistry staining which indicates that 
classically activated macrophages were the dominant type in glomeruli (crescent). One of 
the genes upregulated in the glomeruli was collagen (Col1a1, Col1a2, Col3a1, Col5a1 and 
Col6a1) and the deposition of collagen can lead to fibrosis. Collagens and fibronectin are 
some of the extracellular matrix (ECM) proteins. Different factors could be responsible for 
collagen and fibronectin upregulation. One of these factors involves the action of 
transforming growth factor-beta 2 (TGF-β2) in the SMAD pathway (Zode, Sethi et al. 2011). 
Chaussepied et al. showed the ability of disease macrophages from Holstein-Friesian cattle 
to produce a high level of TGF-β2 (Chaussepied, Janski et al. 2010). It could be that 
macrophages accumulating in glomeruli produce TGF-β2, which then acts on the SMAD 
pathway to up-regulate the expression of collagens and fibronectin 1 by glomerular epithelial 
cells. Zode et al. demonstrated that TGF-β2 acts through SMAD2 and SMAD3 (Zode, Sethi 
et al. 2011). However, mice treated with anti-MPO antibodies did not develop fibrosis, which 
was opposite to what we expected. This could have been because the model represents the 
acute form of disease and only lasted 6 days; fibrosis may develop at a later stage of the 
disease. However, my results indicate that the fibrosis pathways are activated at a very early 
stage of disease, which may have therapeutic implications. 
In addition, macrophages are thought to have a role in matrix destruction through the 
production of matrix metalloproteinases (MMPs) (Duffield 2003). There was slight 
upregulation (less than a two-fold increase) of MMP2, MMP12, MMP11 and MMP14 in 
mouse glomeruli. On the other hand, tissue inhibitor of metalloproteinase 1 (TIMP1), which 
has an inhibitory role against most of the known MMPs, was upregulated in mouse glomeruli 
by more than a 2-fold increase. Previous studies reported that the expression of TIMP-1 is 
predominant in the early stage of the disease (liver fibrosis) but that its expression 
decreases in later stages of liver fibrosis (Iredale, Benyon et al. 1998). In addition, Lin et al. 
showed the ability of TIMP-1 to inhibit rat mesangial cell apoptosis (Lin, Chen et al. 2002). It 
could be that we saw a high expression of TIMP-1 in mouse glomeruli because the 
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experiment was relatively short and the disease was still in its early stages. I observed a 
greater reduction in TIMP-1 expression in rat glomeruli while MMPs were still present. This 
could have been because the rat model has a relatively longer duration and this finding 
resembles what has been found in liver fibrosis explained earlier. The presence of TIMP-1 
could inhibit the proteolytic activity of tissue macrophages, which could explain the absence 
of kidney fibrosis in our model.  
 
 
Figure 6.1: Proposed action of macrophages in crescentic glomerulonephritis. Neutrophils are 
stimulated by cytokines such as TNF-α which result in the migration of ANCA antigens to the surface 
allowing ANCA to bind to neutrophil. This results in neutrophil degranulation and release of ROS and 
also migration of neutrophils through the endothelium. Then, CCR2+ monocytes are recruited into the 
glomeruli following chemotactic gradient by CCL2. These monocytes are then differentiate in to 
macrophages in the tissue and secrete inflammatory cytokines such as TGF-β which result in 
formation of collagen and extracellular matrix (ECM) and matrix metalloproteinases (MMPs). 
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6.5. What are the effects of macrophage depletion on disease 
development? 
I expected macrophages to be involved in the development of AAV in the mice as all of 
the evidence shown here suggests the presence of classically activated macrophages in the 
crescents. The logical approach of studying macrophage involvement in the disease was by 
either depleting them or preventing their accumulation in the kidney. The non-selective 
depletion of macrophages using clodronate was previously used to study the role of 
macrophages in different disease models (Jo, Sung et al. 2006). However, I found that 
clodronate had an effect on the passively transferred anti-MPO antibodies, as explained 
previously. I think it is very important to investigate this further as it could have affected the 
findings of previous work where clodronate was used in disease induced via the passive 
transfer of antibodies.  
I have tried different approaches of studying macrophage involvement in AAV, for 
example, by blocking macrophage recruitment to the site of injury using anti-CCR2. 
However, the disease was mild and no difference was found in the percentage of crescents 
between anti-CCR2 treated mice and the control group. In addition, macrophages were 
detected in kidney sections from both the anti-CCR2 and control groups. This could mean 
that resident kidney macrophages were involved in the initiation of inflammation. Cailhier et 
al. demonstrated the importance of resident macrophages in initiating peritoneal 
inflammation in a peritonitis model (Cailhier, Partolina et al. 2005). However, the disease 
was mild in my experiment and it was difficult to reach any robust conclusions about the role 
of macrophages. I would suggest repeating the experiment and performing macrophage 
depletion using the diphtheria toxin approach, which was described in the introduction, or 
repeating the same experiment with anti-mouse CCR2.  
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6.6. What are the sources of variation in ANCA-induced neutrophil 
degranulation?    
The severity of the disease and risk of relapse vary in patients with vasculitis (Jayne 
2005). In addition, Little et al. showed that some rats are resistant to induced vasculitis, 
which suggests that genetic factors are involved in the development of this disease (Little, 
Smyth et al. 2009). Also, I found that the severity of this disease in mice varied after anti-
MPO antibody injections. Furthermore, previous work in our laboratory showed a variation in 
ANCA-induced neutrophil degranulation and superoxide release. In addition, the severity of 
the disease, as measured by the level of serum creatinine, correlates with the number of 
activated intraglomerular neutrophils (Brouwer, Huitema et al. 1994). I wanted to investigate 
this further in order to understand more about the role of the innate immune system in 
vasculitis. I found variations in ANCA-induced neutrophil degranulation and that the sources 
of these variations mainly depended on the source of neutrophils and the ANCA source. 
Different factors can affect the variability of ANCA-induced neutrophil degranulation in 
healthy donors. One of these factors could be the availability of antigens on the surface of 
neutrophils. Muller Kobold et al. showed a correlation between disease activity and the 
expression of PR3 by neutrophils in Wegener’s Granulomatosis (WG) (Muller Kobold, 
Kallenberg et al. 1998). I wanted to understand the mechanism behind the variability 
observed in our assays by studying the metabolomic profile of neutrophils following 
treatment with ANCA IgG. This is a novel approach and the aim was to investigate whether 
or not it was feasible in our samples. The advantage of this approach is that it is unbiased 
and looked at the effect in the whole cell. However, we found technical variations, as 
previously described in Chapter 5.  
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Figure 6.2: potential factors in the variability of ANCA-induced neutrophil degranulation. There 
are different factors that could contribute to the variations seen on my degranulation experiments. 
Different factors may have contributed to the variations observed in our experiments. One 
of these factors could have been the biological nature of our samples which includes the 
variation in the lifestyle of different donors such as smoking and also the health of each 
donor and if they had an infection on that day. In addition, we introduced multiple factors in 
our experiment, such as donors and treatment variations; this made it difficult to study and 
compare neutrophil metabolomics. I think it is important to minimise the number of variables, 
at least at the start of the project, in order to understand how the samples behave and to 
make it easier to analyse. For future experiments, the neutrophils should be isolated from 
one healthy donor only and then treated with ANCA or normal IgG, which will reduce the 
number of variables.  
6.7. What is the effect of simvastatin on ANCA-induced neutrophil 
degranulation?    
We investigated the effect of the active form of simvastatin on ANCA-induced neutrophil 
degranulation in vitro. The idea came from my colleague Bahjat Al-Ani who was interested to 
see the effect of simvastatin vasculitis. Simvastatin significantly reduced ANCA-induced 
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neutrophil degranulation. Statin is an anti-inflammatory agent that has been reported to 
inhibit the upregulation of pro-inflammatory cytokines such as TNF-α and IFN-γ in the anti-
GBM rat model (Fujita, Shimizu et al. 2010). Furthermore, it has been shown that neutrophil 
stimulation with TNF-α is necessary to cause ANCA-induced neutrophil degranulation in 
vitro. Tumor necrosis factor-α stimulates antigens to migrate to the surface of neutrophils, 
thus allowing ANCA to bind to them, triggering neutrophil degranulation. Simvastatin might 
act by blocking or inhibiting the action of TNF-α, which could result in the inhibition or a 
reduction in the level of antigen presentation on the surface of neutrophils. We hypothesised 
that simvastatin might result in the reduction of crescentic glomerulonephritis in rats. My 
colleague Bahjat Al-Ani treated rats that were immunised with human MPO with simvastatin. 
However, these rats developed crescentic glomerulonephritis and they were not protected 
following simvastatin treatment (Al-Ani, Al Nuaimi et al. 2011). A simvastatin suspension, 
which is used as a human drug, was used for this experiment; furthermore, it is known that 
simvastatin needs to be activated in the human liver. However, we do not know whether it 
became activated when given to the rats. On the other hand, the active form of simvastatin 
was used for the in vitro experiment. This could explain the absence of a simvastatin effect 
in vivo.  
6.8. Future work 
This thesis has led to some interesting findings and it would be useful to follow these 
further. First of all, I have shown that anti-recombinant MPO can be transferred from the 
mother to the newborn mice in maternal transfer experiment. It would be useful to investigate 
this further by using murine MPO instead of recombinant MPO to immunise MPO-/- female 
mice. I think that this experiment is worth repeating because it could help to reduce the 
number of mice needed for immunisation and it could also reduce the amount of MPO 
required.  
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In addition, it would be useful to increase the number of animals in macrophage depletion 
experiment to draw a final conclusion. However, I would use C57 mice if I was to repeat the 
experiment, as I have shown that we can induce a good disease in these mice. Anti-CCR2 
was very effective in depleting GR1+ monocytes and it can be used in future experiments.  
I would also like to further investigate the effect of clodronate on passively injected 
antibodies. We showed a significant reduction in the level of passively transferred antibodies 
following treatment with clodronate. This experiment could be repeated using either anti-
MPO antibodies or other antibodies such as the anti-GBM antibody and then measure the 
level of the antibody in the serum following clodronate treatment.  
Furthermore, it would be useful to further investigate the variability of ANCA-induced 
neutrophil degranulation. I would like to isolate neutrophils from patients with AAV and then 
stimulate the neutrophils with ANCA from the same patient or different vasculitis patients. 
This would help understand whether ANCA from certain patients is highly pathogenic or 
whether these patients are just more susceptible than others. I would also further investigate 
the possibility of studying neutrophil metabolomics, but I would consider minimising the 
number of variables in the experiment. I would start by isolating neutrophils from one healthy 
donor and then treating them with MPO-ANCA, PR3-ANCA or normal IgG. This would allow 
us to investigate the variability in neutrophil degranulation due to ANCA treatment only and 
not due to donor variations. 
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7. Appendix 
 
7.1. Buffers for MPO isolation 
 
Stock solutions 
Stock solutions g/mol Weight (g) Volume (ml) Mol/L 
CaCl2.2H2O 147 5.373 36.55 1.0 
MgCl2.6H2O 203.3 8.444 41.6 1.0 
CETAB  20 200 10% 
MnCl2.4H2O 197.9 8.09 40.86 1.0 
α-Methyl D-
mannopyranoside 
194.18 38.8 200 1.0 
PMSF 174.2 0.871 50 0.1 
Sodium acetate 
pH 6.0 
136.1 68.05 500 1.0 
Sodium acetate 
pH 6.3 
136.1 68.05 500 1.0 
NaCl 58.44 58.5 500 2.0 
 
Buffer A (100 ml) 
solutions Stock (M) End Concentration Volume (ml) 
Sodium acetate pH 
6.0 
1.0 0.0067 0.67 
MgCl2.6H2O 1.0 0.003 0.30 
NaCl 2.0 0.003 0.15 
CETAB   10.00 
PMSF   0.5 
 Total: 11.62 + 88.38 
H2O 
 
Buffer B (1 L) 
solutions Stock (M) End Conc. (M) Volume (ml) 
Sodium acetate pH 
6.3 
1.0 0.1 100 
NaCl 2.0 0.1 50 
 Total: 150 + 850 H2O 
 
Buffer B Con A (100 ml) 
Solutions Stock (M) End Conc. (M) Volume (ml) 
Sodium acetate pH 
6.3 
1.0 0.1 10.0 
NaCl 2.0 0.1 5.0 
CaCl2.2H2O 1.0 0.001 0.1 
MgCl2.6H2O 1.0 0.001 0.1 
MnCl2.4H2O 1.0 0.001 0.1 
 Total: 15.3 + 84.7 H2O 
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Buffer B Elution (100 ml) 
Solutions Stock Conc. (M) End Conc. (M) Volume (ml) 
Sodium acetate pH 6.3 1.0 0.1 10.0 
NaCl 2.0 0.1 5.0 
CaCl2.2H2O 1.0 0.001 0.1 
MgCl2.6H2O 1.0 0.001 0.1 
MnCl2.4H2O 1.0 0.001 0.1 
α-Methyl D-
mannopyranoside 
1.0 0.75 75.0 
 Total: 90.3 + 9.7 H2O 
 
Buffer D 
Solutions Stock (M) End Conc. (M) Volume (ml) 
Sodium Acetate PH 
8.9 
1.0 0.05 50 
NaCl 2.0 0.1 50 
 Total: 100 + 900 H2O 
 
Buffer E 
Solutions Stock (M) End Conc. (M) Volume (ml) 
Sodium Acetate PH 
8.9 
1.0 0.05 50 
NaCl 2.0 1.0 500 
 Total: 550 + 450 H2O 
 
7.2. SDS-Page 
 
10 % gel 
% Gel 10% 
Acrylamide 2.5 ml 
Bis-acrylamide 650 μl 
Tris PH 8.8 3.73 ml 
10% SDS 100 μl 
10% APS 100.5 μl 
TEMED 7.5 μl 
H2O 2.948 ml 
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Stacking gel 
% Gel 5 % 
Acrylamide 500 μl 
Bis-acrylamide 260 μl 
Tris PH 6.8 500 μl 
10% SDS 40 μl 
10% APS 40 μl 
TEMED 4 μl 
H2O 2.656 ml 
 
7.3. Buffers for neutrophil isolation 
 
7.3.1. ACD 
 
4.2 g Disodium hydrogen citrate 
5.0 g D-glucose 
200 ml pyrogen-free water 
 
7.3.2. Dextran 2 %  
 
9.0 g NaCl 
20 g Dextran T500 
1 L pyrogen-free water 
 
7.3.3. HBH 
 
500 ml Hanks buffered salt solution 
5 ml 1M HEPES 
7.4. Buffers for anti-MPO ELISA 
 
7.4.1. Carbonate buffer (0.015 M) 
 
0.795 g Na2CO3 
1.465 g sodium hydrogen carbonate 
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500 ml H2O 
7.5. General linear modelling results of chapter 5 
 
Table 7.1: General linear modelling of the factors contributing to variability in superoxide (n=345) and 
degranulation (n=343) assays. The R2 value reflects how well the model accounts for the observed 
variability in the data (maximum=1) and the Partial η2 value reflects how much each factor contributes 
to the observed variability (maximum=1). 
   Model R2 Partial η2                                              Model R2 Partial η2 
Superoxide release   Degranulation   
Model 1  0.18  Model 1  0.46  
 ANCA source  0.18  ANCA source  0.46 
Model 2  0.40  Model 2  0.18  
 Neutrophil donor  0.40  Neutrophil donor  0.18 
Model 3  0.77  Model 3  0.91  
 ANCA source  0.38  ANCA source  0.66 
 Neutrophil donor  0.64  Neutrophil donor  0.83 
Model 4  0.99  Model 4  0.97  
 ANCA source  0.95  ANCA source  0.91 
 Neutrophil donor  0.92  Neutrophil donor  0.83 
 Assay month  0.95  Assay month  0.04 
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